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About GSK  
Our mission
GSK’s mission is to improve the 
quality of human life by enabling 
people to do more, feel better, 
live longer. We are doing this by 
developing innovative products  
and improving access to healthcare 
for patients around the world. 
Cover image
Nahya Salim, a paediatrician and research scientist in Tanzania, Africa, has 
been working on GSK’s RTS,S malaria vaccine trials at the Ifakara Health 
Institute since 2007. She is currently overseeing trials of the new vaccine, 
as well as researching how malaria interacts with other diseases, such as 
intestinal worms, TB and HIV. 
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Our people
Began the roll out of preventive 
healthcare benefits through our 
Partnership for Prevention programme, 
which will be available to employees and 
their families worldwide by 2018.
 See page 52
As part of our commitment to transparency we report our performance each year 
across the four areas of our responsible business approach.
At a glance  
2013
Health for all
Achieved a major milestone with our 
malaria vaccine candidate, RTS,S, which 
demonstrated that over 18 months of 
follow-up it almost halved the number of 
malaria cases in young children (aged 
5-17 months at first vaccination) and 
reduced by around a quarter the malaria 
cases in infants (aged 6-12 weeks at first 
vaccination).
 See page 27
Health for all
Formed an innovative new partnership 
with Save the Children to help save the 
lives of one million children over five years.
 See page 15
Health for all
Donated our four billionth albendazole 
tablet to fight lymphatic filariasis and 
intestinal worms, as part of our commitment 
to work with partners to control or eliminate 
ten of the 17 neglected tropical diseases.
 See page 26 4bn
Our planet
Our Scope 1 and 2 carbon emissions  
from our operations grew slightly in 2013, 
although they remain 7% lower than our 
2010 benchmark. 
Our Scope 3 emissions (excluding raw 
materials) increased by 1.5% in 2013 
across the value chain due to strong sales 
of HFA propellant-based inhalers, and have 
increased by 11% since 2010.
 See page 64
Our behaviour 
Became the first pharmaceutical 
company to enable external 
researchers to access detailed 
anonymised patient-level  
data from clinical trials  
through a new online system.
 See page 40
Our behaviour
Announced plans to evolve the way 
we sell and market products to 
healthcare professionals to further 
align the company’s activities with the 
interests of patients. 
 See page 44
Our people
Launched a new performance 
management system to  
better link employee  
reward with our values.
 See page 59
External recognition
Topped the biannual 
Access to Medicines Index 
since it began in 2008 (the 
next index is in 2014).
The only healthcare 
company to be included  
in the CDP Performance 
Leadership Index and the 
CDP Disclosure Leadership 
Index in 2013.
Became first company to be 
awarded global certification 
to the Carbon Trust’s Water 
Standard in recognition  
of our year-on-year 
reductions in operational 
water use globally.
Achieved Bronze ranking  
in RobecoSAM’s 2014 
Sustainability Yearbook 
(based on 2013 submission), 
putting us in the top 10%  
of our industry.
Member of FTSE4Good 
since 2004.
Narrowly missed inclusion of the  
Dow Jones Sustainability Ranking  
in 2013 with a score of 81.
Our planet
Used 2% less water in our  
operations during 2013, and  
are using 16% less than  
in 2010. 
 See page 65
2%
REDUCING WATER
YEAR ON YEAR
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Vaccines
Our vaccines business is one of the largest in 
the world, producing more than 30 vaccines 
for children and adults against a range of 
infectious diseases. In 2013, we delivered 
860 million vaccine doses, over 80% of them 
for use in developing countries.
£3.4bn
Turnover
13%
of Group
Consumer healthcare
We develop and market a range of 
consumer health products based on 
scientific innovation. We have brands in four 
main categories: Total wellness, Oral care, 
Nutrition and Skin health.
£5.2bn
Turnover
20%
of Group
£26.5bn
2013 Group turnover
Our values are 
transparency, respect 
for people, integrity and 
patient focus.
As a global healthcare company, our 
commercial success depends on creating 
innovative new medicines, vaccines and 
healthcare products, and making these 
accessible to as many people who need 
them as possible. 
By doing this, we will be able to grow our 
business and provide benefits to patients, 
consumers, society, our employees and our 
shareholders. 
We put our values at the heart of every 
decision we make, and we commit to help 
people do more, feel better, live longer.
Who we are 
Where we are
We have a significant global commercial 
presence in more than 150 markets, with a 
network of 86 manufacturing sites 
worldwide, and R&D centres in the UK, USA, 
Spain, Belgium and China.
GSK is a science-led global healthcare company that researches and manufactures 
a range of products to help people do more, feel better and live longer.
Pharmaceuticals
We develop and make medicines to treat a 
broad range of conditions including: 
respiratory disease, cancer, heart disease, 
bacterial and viral infections such as HIV, 
lupus and skin conditions. 
£17.9bn
Turnover
67%
of Group 
Employees by region 2013 (%)
  USA
  Europe
  EMAP
  Japan
  Other
17
39
38
33
33
28
25
7
7
Turnover by region 2013 (%)
  USA
  Europe
  EMAP
  Japan
  Other
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Chairman’s statement
Message from our Chairman
The company continues to deliver strong 
operational and financial performance,  
and I have no doubt that commercial 
success is directly linked to operating in  
a responsible way and which meets the 
changing expectations of society. 
In this respect, the company continues  
to adopt industry-leading positions on  
a range of issues. 
The announcement of plans during 2013  
to evolve the way the business interacts 
with healthcare professionals and pays 
sales staff are developments I was 
particularly pleased to see.
In the same way the Board strongly 
supports the commitments the company 
has made to advance transparency around 
clinical trial data. Over time, it is to be 
hoped these steps will advance medical 
science and improve patient care.
The importance of strong ethical behaviour 
and operating according to the company’s 
values is something myself and Board 
colleagues pay continued attention to. 
The allegations of fraudulent behaviour by 
certain employees within our business in 
China are wholly contrary to the company’s 
values and we take this matter extremely 
seriously. In addition to the Chinese 
Government investigation, we have 
commissioned an independent review  
of our Chinese operations by the law firm 
Ropes and Gray, and we will implement  
all appropriate actions as necessary  
on conclusion of these investigations. 
The role of the CR Committee is to provide 
high-level guidance and oversight on 
matters related to responsible business. 
In 2013, we have reviewed progress against 
the ambitious CR commitments, first set out 
in last year’s Report. After just one year, 
while few of these long-term goals  
are close to completion (indeed, if they 
were, I would question whether they were 
challenging enough), it is the Committee’s 
view that GSK is on track and there is 
tangible evidence of steps being taken  
that will help the company achieve them  
(see page 9).
The Committee continues to recognise the 
value that external perspectives can bring, 
and in May, Sophia Tickell was reappointed 
as an external advisor. As a respected CR 
expert with specific expertise in healthcare 
and climate change, she brings valuable 
external insight. I would also like to welcome 
Non-Executive Director, Hans Wijers, who 
joined the Committee in October.
The CR Committee and the Board will 
continue to support – and constructively 
challenge – the company’s actions to 
operate a responsible values-based 
business. I look forward to seeing further 
progress in 2014.
Sir Christopher Gent
Chairman
As Chairman of the Board and the Board-level Corporate Responsibility Committee, 
I see first-hand that, for GSK, being a responsible business is not just about 
demonstrating robust governance; it is central to the company’s strategy. 
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As a global healthcare company, GSK can play an important role in meeting 
societal challenges. In 2013, we continued to develop innovative life-saving drugs 
and work with partners to get medicines to the people that need them most.
CEO’s statement
Message from our CEO
Over the past six years we have been 
making fundamental changes to deliver 
innovation and access to our products  
for patients and customers, and improved 
sustainable financial performance for  
our shareholders.
2013 was the most productive period of 
R&D output in the company’s history. Of the 
six major new medicine files we profiled at 
the start of 2013, five were approved and 
we are expecting regulatory decisions for 
the remaining asset in this group in the first 
half of 2014. In addition, we launched our 
new injectable quadrivalent flu vaccine in 
the USA. Together, these new drugs offer 
patients a range of new treatment options 
and represent substantial opportunities for 
business growth. 
We continue to take action to reform our 
business model to meet the expectations of 
society and deliver our mission, in line with 
our values. 
In 2013, we made new commitments to 
increase transparency of our clinical 
research by announcing our support for the 
AllTrials campaign and becoming the first 
pharmaceutical company to commit to 
publishing the detailed clinical study reports 
for all of our medicines. In May, we were the 
first in our industry to launch an online 
system enabling researchers to request 
access to anonymised patient-level data 
from our clinical trials. I am pleased that 
some other companies have now also 
adopted this approach.
We also announced plans to evolve the way 
we sell and market products to healthcare 
professionals, to further align our activities 
with the interests of patients and remove 
even the perception of conflict of interest. 
Specifically, we plan to stop direct 
payments to healthcare professionals for 
speaking engagements and for attendance 
at medical conferences, and extend our US 
‘Patient First’ programme globally, to 
decouple sales team remuneration from 
scrip generation.
We continue to expand access to our 
medicines to people living in the  
developing world. 
During 2013, we signed a ground-breaking 
five-year partnership with Save the Children, 
to combine the resources and capabilities 
of our two organisations to help save the 
lives of one million children living in the 
poorest countries in Africa. 
In 2013, we donated our four billionth tablet 
of albendazole to treat intestinal worms and 
lymphatic filariasis – part of our long-term 
commitment to tackle neglected tropical 
diseases – and delivered 862 million vaccine 
doses worldwide. We also strengthened our 
global initiatives to tackle non-communicable 
diseases such as cancer, diabetes, 
respiratory and heart disease. 
I am also delighted we achieved a 
significant milestone for our malaria vaccine 
candidate which demonstrated that it could 
potentially halve the number of malaria 
cases in young children. This vaccine has 
the potential to save hundreds of thousands 
of childrens’ lives and we plan to file for 
approval during 2014. We are committed to 
making it available at a not-for-profit price. 
There is no higher priority for me than the 
values-based conduct of our employees.  
In the past few years, we have focused  
on bringing to life our values and being 
thoughtful about what they really mean  
at a human level.
It is because of my strong belief in our 
company’s values that the allegations made 
in China about the behaviour of some 
individuals were so disappointing. The 
investigation into this matter by the 
authorities in China continues and we are 
cooperating fully. As a company, we are 
committed to learning the lessons and 
taking all necessary action in relation to  
the outcome of this investigation.
Our continued commitment to transparency 
was also evident in our efforts to disclose 
and address our environmental impacts.  
We are the only healthcare company listed  
in both the CDP’s Disclosure Leadership 
Index and its Performance Leadership Index 
in 2013, for our clear reporting and 
performance on climate impacts.
My job as CEO is to deliver a healthy 
company, and that is only possible with 
healthy employees. Our ground breaking 
Partnership for Prevention initiative will give 
benefits-eligible employees and their 
families equal access to preventive and 
basic healthcare benefits wherever they are 
based. 
In 2014, we will continue to challenge our 
business model at every level, to ensure we 
are responding to the needs of patients and 
meeting the wider expectations of society.
Sir Andrew Witty
Chief Executive Officer
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We are adapting our business model and pursuing a strategy that delivers 
sustainable performance through innovation and expanding access,  
driven by our values. 
How we create value
Our mission
We have a challenging and inspiring 
mission: to improve the quality of human life 
by enabling people to do more, feel better, 
live longer. This mission gives us the 
purpose to develop innovative medicines 
and products, and make them available to as 
many people who need them as possible. 
Our mission is underpinned by a number  
of key factors.
To achieve our mission, we rely on our 
people – their knowledge, their expertise 
and their enthusiasm – and put our values  
at the heart of every decision we make. 
Our business model
We have a broadly-based and balanced 
business across pharmaceuticals, vaccines 
and consumer healthcare. At the core of our 
business model are the concepts of innovation 
and access. We create value by researching 
and manufacturing innovative and high 
quality products, and making these 
accessible to as many people who need 
them as possible.
Improving healthcare and making it 
affordable and accessible to more people  
is a huge challenge, and one that requires  
a combined effort.
To meet this challenge, everyone involved in 
providing healthcare – industry, healthcare 
professionals, universities, healthcare 
funders including governments, charities 
and regulators – need to work together. 
With this in mind, partnership and 
collaboration is a key principle of our 
business approach. 
We continue to reform our business model. 
For example, we have taken industry-leading 
positions to improve global public health 
through our pricing and access strategies, 
increase transparency of our clinical trial 
data and modernise our commercial 
practices and interactions with customers.
Outputs
Delivering innovation and maximising 
access to our products generates value  
for patients, and society more widely.
Our primary contribution is to make 
products that provide benefits to patients 
and consumers. 
Successful delivery of this generates 
profitable and sustainable performance.  
In turn, this allows us to generate value  
and returns for our shareholders, and 
enables us to reinvest in the business.
We also create value by making direct  
and indirect economic and social 
contributions in the countries where we 
operate. These wider benefits to society 
include contributions through tax, 
employment and enhancing the well-being 
of local communities through our global 
community initiatives. 
Our strategic priorities – grow, deliver, 
simplify – help us work towards our vision, 
while enhancing business performance and 
delivering sustainable growth. 
We focus on understanding the needs of 
patients, consumers and individual markets 
so we can channel our research into 
developing appropriate products.  
These insights also enable us to adapt  
our business model to improve availability 
and affordability.
Our mission
Reinvestment
OutputsOur business model
Benefits to patients  
and customers
Cash and profit  
generation
Shareholder value  
and returns
Wider benefits  
to society
To improve the quality  
of human life by enabling 
people to do more,  
feel better, live longer.
Underpinned by 
Our values
Our strategic priorities
Our people
Our insights
Manufacturing
Making and shipping 
high standard products 
around the world
Commercialisation  
and distribution
Increasing access  
to our products
R&D
Discovering and 
developing innovative 
medicines
GSK Corporate Responsibility Report 2013  8
Note to SB. Please keep coloured gradient on the 
buttons for both normal and rollover actions please.
Our aim Our progress Highlights Our priorities
Grow  
a diversified 
business
We have been creating a more 
balanced business and product 
portfolio, capable of delivering 
sustainable sales growth. This is 
centred on our three business  
areas of Pharmaceuticals,  
Vaccines and Consumer Healthcare.
Total sales grew 1% to £26.5 billion in 2013  
(3% excluding divestments).
Performance was generated from multiple  
businesses and geographies reflecting  
successful implementation of the strategy.
•	Successful	launch	and	commercialisation	
of new products from our pipeline
•	Continue	to	invest	in	key	growth	
businesses including Emerging Markets, 
Vaccines and Consumer Healthcare
•	Look	for	further	opportunities	to	 
increase focus and optimise value  
of our product portfolio
Deliver  
more products  
of value
We have changed our R&D 
organisation so that it is better  
able to sustain a pipeline of products 
that offer valuable improvements  
in treatment for patients and 
healthcare providers.
This is underpinned by a focus  
on improving productivity and  
rates of return in R&D.
During 2013, we received approvals for six major  
new products and several new indications for existing 
medicines and vaccines. 
We also generated a high volume of phase III  
data on key assets in our pipeline. 
Our estimated return on R&D investment  
increased to 13%.
•	Delivery	of	phase	III	data	for	six	 
potential new medicines and vaccines,  
and around ten NME phase III starts  
across 2014/2015
•	Continued	focus	on	increasing	R&D	 
rate of return
Simplify  
the operating  
model
As our business continues to change 
shape, we are transforming how  
we operate so that we can  
reduce complexity and become  
more efficient.
This frees up resources to reinvest 
elsewhere in the business.
We have several restructuring programmes  
which are on track to deliver total annual savings  
of £4.3 billion by 2016, compared with 2007.  
During 2013 we delivered incremental savings  
of £400 million.
We are also making good progress transforming  
our manufacturing network, supply chain and  
enterprise-wide processes.
•	Further	cost	savings	delivery	from	 
our restructuring programmes
•	Further	roll-out	of	standardised	enterprise	
platforms and delivery of an integrated 
supply chain
Responsible 
business
Being a responsible business is 
central to our strategy, and how we 
deliver success is just as important  
as what we achieve. Ensuring our 
values are embedded in our culture 
and decision-making helps us better 
meet the expectations of society. 
In 2013, we have made considerable further progress  
on our agenda to operate responsibly.
Specifically, we took action to increase transparency  
of clinical research data, and modernise our commercial 
operations and interactions with customers.
We also made progress on driving access to medicines  
in the poorest countries and passed a key milestone in  
the development of a potential vaccine against malaria.
•	File	our	RTS,S	malaria	vaccine	candidate	 
for approval in 2014 and, if approved,  
offer at a not-for-profit price 
•	 Implement	changes	on	how	we	 
incentivise our sales teams and  
work with healthcare professionals 
Our business  
strategy
Our business strategy aims to help us deliver sustainable growth, reduce risk, 
and enhance the long-term value we deliver to our shareholders and society.
£26.5bn
Group turnover
39%
Group turnover outside USA and Europe
6
Significant new product approvals 
in 2013
40
Medicines in phase II/III development
£400m
Incremental savings in 2013
10
Days reduction in working capital
60%
Increase in the volume of medicines supplied  
to Least Developed Countries since 2010
1st
Pharmaceutical company to sign AllTrials 
campaign for research transparency
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Commitments 
Progress overview
In 2012, we developed forward-looking commitments across the four areas of our 
responsible business approach. They aim to address unmet global health needs  
and are aligned with our strategic priorities and our values.
This year we are reporting on our progress against these commitments and here 
we provide a summary.
 Commitments  Progress tracker  Find out more
H
ea
lth
 fo
r 
al
l Innovation for unmet 
medical needs
Adapt the open innovation R&D model, currently used for Diseases of the Developing 
World, to apply to other areas of great unmet medical need and scientific challenge, 
including infectious disease and Alzheimer’s disease, by 2015.
On track Worked to promote R&D of new antibiotics and accelerate development 
of treatments for Alzheimer’s disease through the Innovative Medicines 
Initiative, and continued to research multi-drug-resistant tuberculosis. 
Page 18
Developing vaccines  
that don’t need to be 
kept cold
Invest in the development of vaccines that don’t require continuous refrigeration, 
making distribution easier and less expensive.
On track Partnered with the Bill & Melinda Gates Foundation to accelerate 
advances in vaccine research, including making them less vulnerable  
to heat.
Page 17
Building products to 
better meet needs
Continue to build a core range of products and formats to better meet the needs of 
people across the globe, including those less able to access and afford our products.
On track Our ‘catch-up’ programme in developing countries received approvals 
for a further 26 products in 2013; and we reached 16,000 villages in 
India with low cost nutritional formulation of Horlicks. 
Page 22
Better access  
to medicines  
and vaccines
Further embed our flexible pricing strategy and innovative business models for our 
prescription medicines and vaccines, to increase usage among those less able to 
access and afford our products.
Progressing well Updated our approach to tiered pricing for vaccines. 
Page 20
Reducing child mortality Continue to invest in innovative cross-sector partnerships to reduce child mortality. On track Formed a ground-breaking partnership with Save the Children to help 
save one million children’s lives. Page 15
 Strengthening healthcare 
infrastructure
Continue to work with partners to support the development and strengthening of 
healthcare infrastructure. We anticipate this could improve access to healthcare for 
20 million under-served people by 2020 (vs 2012).
Progressing well Launched innovative partnerships with Barclays and Vodafone, and 
invested £5.1 million in strengthening healthcare infrastructures through 
our 20% reinvestment programme in Least Developed Countries.
Page 23
Access to antiretroviral 
treatment for HIV
Through ViiV Healthcare, continue to increase access to our medicines and care 
for adults and children living with HIV around the world. We will help World Health 
Organization (WHO) and UNAIDS achieve their goal of reaching 15 million people 
globally with antiretroviral treatment by 2015.
On track Committed to grant the UN-supported Medicines Patent Pool, a 
voluntary licence to develop paediatric formulations of the antiretroviral 
medicine abacavir, to treat HIV in the 118 countries where 98% of HIV 
positive children live globally.
Page 29
Fighting malaria Build on our 30 year commitment to contribute to the fight against malaria through 
continued R&D investment and partnerships on the ground.
Progressing well Announced large scale phase III trial data for our malaria vaccine RTS,S 
and are developing a medicine, Tafenoquine, in partnership with MMV for 
the treatment and relapse prevention of vivax malaria.
Page 27
Eliminating and 
controlling neglected 
tropical diseases
Help to eliminate and control ten neglected tropical diseases that affect 1.4 billion 
people, by 2020 – including the elimination of lymphatic filariasis, through our 
continued investment in R&D, ongoing product donations and our contribution to the 
London Declaration on Neglected Tropical Diseases.
On track Donated 763 million albendazole tablets to eliminate Lymphatic Filariasis 
and control soil-transmitted helminths, and screened our compound 
library for promising treatments for parasites that cause sleeping 
sickness, Chagas Disease and Visceral Leishmaniasis.
Page 26
Eradicating polio Continue to support the WHO objective of eradicating polio by 2018 by providing 
vaccines to UNICEF until this is achieved.
Progressing well Provided a further 412 million doses of Oral Polio Vaccine to the Global 
Polio Eradication Initiative. Page 27
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 Commitments  Progress tracker  Find out more
O
ur
 b
eh
av
io
ur
Promoting values in sales  
and marketing practices
Continue to drive a values-based approach to sales and marketing practices across 
the world, with the interests of consumers and patients at its core.
On track Announced changes to our global sales and marketing practices 
to further ensure patient interests come first, and introduced a new 
performance management system focused on values.
Page 43
Rigorous patient and 
consumer safety
Continue to ensure the interests and safety of patients and consumers are of 
paramount importance in the way we design and undertake our clinical trials, our 
product quality assurance and our monitoring and reporting of adverse events in 
ongoing product usage.
Progressing well Strengthened resources to enhance our pharmocovigilance operating 
model, expanded dedicated product quality teams and maintained our 
robust policies and governance framework on patient safety. Page 41 and 45
Minimising animal testing Rigorously challenge the need for animal studies and work to minimise the impact 
on animal welfare, by investing in the development of alternative studies and sharing 
animal-based data.
On track Reduced number of animals used in our research by 10% in 2013.
Page 41
Promoting Human Rights Address the UN Guiding Principles on Business and Human Rights across our own 
operations and our supplier relationships.
On track Conducted a human rights impact assessment and prioritised seven 
areas for further analysis, and updated our human rights statement 
accordingly.
Page 39
Transparency in clinical 
trial data
Be as transparent as possible with our clinical trial data, including publishing 
clinical study reports (without patient-level data) for all outcome trials of medicines 
conducted by GSK and, within an appropriate process, making available to 
researchers access to anonymised patient level data to further scientific enquiry.
Progressing well Launched online system enabling researchers to request access to 
the detailed anonymised patient-level data from our clinical trials and 
became first pharmaceutical company to publish clinical study reports. Page 40
Ensuring ethical 
stakeholder interactions
Demonstrate that all GSK interactions with patient advocacy groups and political 
stakeholders are conducted appropriately, ethically and transparently.
On track Embedded new criteria to ensure public policy groups we work with 
are aligned with our values and agreed relevant Standard Operating 
Procedures.
Page 47
O
ur
 p
eo
pl
e Promoting inclusion  
and diversity
Continue to promote inclusion and diversity globally at GSK. On track Agreed to establish Global Disability Council and introduced gender 
targeted coaching and sponsorship. Page 55
Creating inspiring and 
healthy workplaces
Continue to create a working environment that inspires people to grow and perform 
in a healthy and resilient way.
On track Interim employee survey results showed improvements in team leader 
effectiveness; continued to roll out preventive healthcare for employees; 
reduced injury and illness rates by 12% from 2012.
Page 57
Community volunteering 
to create change
Extend volunteering opportunities to bring about positive change to communities and 
global health while providing individual development.
On track Increased the number of employees taking part in PULSE volunteer 
partnership programme to 99 (from 58 in 2010). Page 54
O
ur
 p
la
ne
t Aiming to be  
carbon neutral
Reduce our overall carbon footprint by 25% by 2020 (vs. 2010) and have a carbon 
neutral value chain by 2050.
Work to do Scope 1 and 2 carbon emissions from our operations up 2% in 2013, 
but down 7% since 2010; Scope 3 emissions (excluding raw materials) 
up 1.5% in 2013 and up 11% since 2010, due to strong sales of HFA 
propellant-based inhalers.
Page 64
Reducing our  
water impact
By 2020, reduce our water impact across the value chain by 20% (vs. 2010). On track Used 16% less water in our operations (vs. 2010); mapped water use 
across our value chain; became first company to be awarded global 
certification to the Carbon Trust’s Water Standard.
Page 65
Reducing our  
waste
By 2020, reduce our operational waste by 50% (vs. 2010). On track Cut total waste by 6% and sent 39% less to landfill (vs.2010); achieved 
zero waste to landfill at 37 sites. Page 66
Building sustainability  
in our supply chain
Build sustainable supply lines for our Nutrition portfolio and work with local farmers 
to improve their agricultural practices, improve their yields, their competitiveness and 
their livelihoods.
On track Began working with a dairy supplier in India to develop a secure supply 
of locally produced whey protein (from milk) to make Horlicks, and now 
source 60% of whey protein from the local supplier in India for Horlicks. 
Page 67
Commitments 
Progress overview continued
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Driven by our steadfast focus on the 
patient, we are bringing health benefits 
to more people around the world 
through our open, flexible and 
collaborative approach to innovation 
and access to healthcare.
Health 
for all
In this section
Health for all overview 12
Improving healthcare:  
a global challenge 14 
Ground-breaking partnership  
with Save the children 15
Innovative science to create  
value for all  16 
Access to healthcare  20
Diseases of the  
developing world  26 
HIV/AIDS 29
Health and well-being  
in our communities  31
In focus
Philomene is being treated for breast 
cancer at the Butaro Cancer Centre 
of Excellence, Rwanda. As part of our 
work to address non-communicable 
diseases in the developing world, we 
are funding the training of cancer 
healthcare professionals in Rwanda in 
partnership with charities and the 
government. This will increase access 
to trained cancer specialists for 
patients like Philomene. 
 Read more on page 25
GSK Corporate Responsibility Report 2013  12
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External perspective
“ Given the scale of the disease 
burden in developing countries,  
we look forward to our continued 
work with GSK to develop essential 
lifesaving health interventions. 
We’re particularly excited about 
GSK’s long-term commitment to 
global health R&D and innovation 
in malaria.” 
Dr. Trevor Mundel
President, Global Health Programme,  
Bill & Melinda Gates Foundation
Health for all
Overview
To bring new vaccines and medicines to 
patients faster, we are accelerating our 
innovation processes, opening up our 
research findings and resources to others, 
and bringing together partners to explore 
new delivery models and flexible pricing 
strategies to increase access to our existing 
range of products. 
We have been at the forefront of the 
transformation in our industry’s approach  
to global healthcare over the past decade, 
but we know there is still much more to  
be done to meet major health challenges. 
We want to play a leading role in this effort, 
while generating the returns we need to 
invest and grow our business. 
We remain committed to improving 
treatment options and life-saving vaccines 
and medicines through our strategies to 
extend access and foster innovation, and  
our continued focus on diseases of the 
developing world. The ways in which we 
have evolved our business model enable us  
to make a significant contribution to the UN’s 
Millennium Development Goals for 2015.
Through our own work and collaboration 
with others in our sector and beyond, we 
are creating sustainable solutions that will 
improve quality of life by enabling people  
to do more, feel better and live longer.
Internal perspective
“ Scientific and technological 
innovation will enable us to make 
the advances necessary to bring 
new medicines, in new ways, to 
patients everywhere. At GSK, we are 
working with many partners and 
across many areas – such as gene 
therapy and biopharmaceuticals – 
to develop medicines for diseases 
where effective treatments do not 
currently exist. We’re also playing 
our part in exploring new ways to 
stimulate innovation in areas where 
the commercial incentive is weaker 
– for example on TB, antibiotic 
resistance or Alzheimer’s.” 
Patrick Vallance
President, Pharmaceuticals R&D, GSK
External perspective
“ Community health workers provide 
vital services to rural communities 
and GSK has been a pioneer and 
trail-blazer in supporting the 
deployment of CHWs across Africa. 
The One Million Community Health 
Workers Campaign will save lives  
and help rural communities in  
sub-Saharan Africa to break free of 
extreme poverty. By promoting the 
systematic deployment of a million 
CHWs, roughly 1 per 100 
households in rural areas, the 
Campaign will support sub-Saharan 
Africa to make major strides 
towards the Millennium 
Development Goals and beyond.” 
Jeffrey Sachs
Director of the Earth Institute and the 
Sustainable Development Solutions Network
GSK Corporate Responsibility Report 2013  13
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Health for all
2013 at a glance
6
£3.4bn
Innovative science to create value for all
Of the six major new medicines we profiled 
at the start of 2013, five were approved.  
We are expecting regulatory decisions  
for the remaining asset in the first half of 
2014. We also launched a new injectable 
quadrivalent flu vaccine in the USA.
GSK accounted for 19% of FDA  
new drug approvals.
 See page 16
412m
Diseases of the developing world
Provided 412 million doses of oral polio 
vaccine as part of our continued support for 
global efforts to eliminate the disease – we 
have contributed over 15.8 billion doses 
since 1988.
 See page 27
Diseases of the developing world
Achieved a major milestone in our malaria 
vaccine candidate, which demonstrated that 
over 18 months of follow-up, RTS,S almost 
halved the number of malaria cases in young 
children (aged 5-17 months at first 
vaccination) and reduced by around a 
quarter the malaria cases in infants (aged 
6-12 weeks at first vaccination).
 See page 27
Diseases of the developing world
Donated our four billionth albendazole tablet 
to fight lymphatic filariasis and intestinal 
worms as part of our commitment to work 
with partners to control or eliminate 10  
of the 17 neglected tropical diseases.
 See page 26
Invested £3.4bn in global research and 
development for innovative medicines, 
vaccines and consumer products.
We have 40 new molecular entities in  
phase II/III clinical development.
 See page 16
Innovative science to create value for all
Access to healthcare
Partnered with Save the Children to help 
save the lives of one million children.
 See page 15
Access to healthcare
Increased our focus on non-communicable 
diseases such as diabetes and cancer in 
developing countries through research and 
training for healthcare providers.
 See page 25
46.8m
Access to healthcare
Delivered 46.8 million vaccine doses to  
GAVI Alliance at affordable prices to protect 
children from pneumococcal diseases, 
rotavirus gastroenteritis and cervical cancer. 
 See page 20
£221m
Health and well-being in our communities
Donated £221 million to promote the health 
and well-being of communities through 
funding, product donations and employee 
volunteering.
 See page 31
HIV/AIDS
Obtained regulatory approval in the USA, 
Canada and Chile for Tivicay (dolutegravir),  
a new treatment option for people living  
with HIV.
 See page 29
HIV/AIDS
Agreed to grant the UNITAID-backed 
Medicines Patent Pool, a voluntary  
licence for paediatric formulations  
of the antiretroviral medicine,  
abacavir, in 118 countries,  
where 98% of HIV positive  
children live.
 See page 30
Access to healthcare
Reinvested 20% of the 
profits we made in Least 
Developed Countries 
– £5.1 million – to train 
community health workers 
and strengthen healthcare 
infrastructure in those 
countries.
 See page 23
Access to healthcare
Updated our tiered pricing model for 
vaccines to increase support for countries 
committed to long-term immunisation 
programmes that reflects their ability to pay.
 See page 20
4bn
Save the Children partnership
Through our ground-breaking partnership 
we are bringing much needed medicines 
and vaccines to some of the world’s 
poorest children, training thousands of 
healthcare workers, and seeking to 
alleviate child malnutrition.
See page 15
ViiV Healthcare
The specialist HIV company GSK jointly 
established in 2009 with Pfizer, 
researches new treatments, improves 
access to medicines and works with 
communities to combat stigma and 
discrimination surrounding HIV/AIDS.
See page 29
Malaria and antibiotic resistance
We are committed to tackling malaria 
through vaccine research, developing 
new treatments, promoting the use of 
preventive measures and increasing 
access to anti-malarials in least 
developed countries.
See pages 18 and 27
BarriersDiseases of the Developing World
Working with the Gates Foundation, 
World Health Organization, other 
pharmaceutical companies and donors, 
we are helping to control or eliminate 10 
of the 17 Neglected Tropical Diseases 
that affect 1.4 billion people.
See page 25
Pricing
We cap the prices of our patented 
medicines and vaccines in least 
developed countries, offer flexible and 
tiered pricing in middle income countries 
and take a responsible approach  
to pricing in high income countries. 
See page 20
20% reinvestment 
Since 2009, we have reinvested 20% of 
the profits we generate in least 
developed countries into programmes 
that strengthen community healthcare 
and improve access to healthcare in 
these countries.
See page 23
Resistance to existing 
treatments
Resistance to antimicrobials  
is a problem for many diseases 
affecting developing countries, 
including malaria. 
Stigma and discrimination
Discrimination and stigma can 
prevent patients suffering 
from diseases such as HIV, 
and even asthma, from 
accessing treatment. 
Poverty
Poverty has a huge effect on 
people’s health and 
well-being. Factors such as 
lack of resources, 
malnourishment, unsafe water 
and poor sanitation all 
contribute to poor health.
Treatments don’t exist
More effective treatments are 
needed for diseases including 
tuberculosis and hepatitis C, 
but developing them can take 
years and cost hundreds of 
millions of pounds, with low 
returns.
Affordability
High prices can prevent 
governments and people, 
especially the 2.8 billion living on 
less than $2 a day, from buying 
the medicines they need. 
Healthcare infrastructure
Many developing countries lack 
adequate healthcare facilities 
and staff. Africa suffers most, 
with 24% of the global burden  
of disease but just 3% of  
health workers. 
Malaria
Each year there are around 
215 million cases of 
malaria globally and more 
than 660,000 malaria 
deaths, 80% of which 
occur in just 14 countries.
HIV/AIDS
Of the 35 million people 
living with HIV in 2012, 
only 9.7 million people 
received anti-retroviral 
therapy in low and middle 
income countries.
Non communicable 
diseases (NCDs)
NCDs account for 
two-thirds of global 
deaths, with developing 
countries carrying  
over half of the world’s 
NCD burden.
Tuberculosis
Despite a 45% drop in  
TB mortality from 1990, 
TB still killed 1.3 million 
people in 2012,  
a quarter of whom were  
HIV-positive. 
Maternal health
Only 50% of pregnant 
women in developing 
countries receive the 
recommended healthcare 
during pregnancy.
Child mortality
Six million children a year 
still die before their fifth 
birthday (despite a 47% 
drop in child mortality 
since 1990).
Global health burden
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GSK’s response
Improving healthcare: 
a global challenge
As a global healthcare company, GSK works within the context of the global 
health burden, exemplified by the UN Millennium Development Goals. We 
recognise the complex barriers to health and are responding in innovative ways.
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Ground-breaking partnership 
with Save the Children  
to help save one million lives 
 Commitment
Continue to invest in innovative cross-sector  
partnerships to reduce child mortality.
Our ground-breaking 
partnership with international 
children’s charity, Save the 
Children, will help save the 
lives of one million children. 
By combining our expertise, 
resources and capabilities, 
we will bring much-needed 
medicines and vaccines to 
some of the world’s poorest 
children, train thousands of 
healthcare workers, and seek 
to alleviate child malnutrition. 
GSK is investing at least 
£15 million in grants and we 
are encouraging employees 
to raise £1 million a year 
through volunteering and 
fund raising (see page 56). 
Globally, over six million 
children die every year due  
to a lack of basic healthcare, 
vaccines or nutritious food. 
We are establishing 
signature programmes in the 
Democratic Republic of 
Congo (DRC) and Kenya to 
test the impact of a series of 
comprehensive interventions. 
A joint R&D board will 
explore the development of 
new or repurposed products 
to tackle the causes of 
newborn and infant death. 
One of our first life-saving 
projects is the reformulation 
of chlorhexidine, an antiseptic 
found in our Corsodyl 
mouthwash, for umbilical 
cord cleansing to prevent 
infection in newborns. If 
applied for the first few days 
of their life, this gel could play 
a vital role in preventing 
infection and saving babies’ 
lives. This is one of the 13 
interventions recommended 
by the UN Commission on 
Life Saving Commodities.1 
We are also registering a 
child-friendly, powder-based 
antibiotic into the DRC to 
help fight pneumonia, one of 
the biggest killers of children 
under five, as well as 
developing a low-cost 
nutritional product to help 
combat child under-nutrition.
This new partnership builds 
on our collaboration with 
Save the Children over the 
past eight years, which 
includes work on our 20% 
reinvestment programme in 
Least Developed Countries 
(see page 23) and the Africa 
Malaria Partnership (see 
page 28). Together we 
awarded US$1 million in 
2013 for healthcare 
innovations originating in the 
developing world. The award 
was split between five 
organisations, with the 
largest portion going to 
Friends of Sick Children in 
Malawi, for their development 
of a low-cost device to help 
newborn infants breathe. 
1 Source: http://www.
everywomaneverychild.org/
resources/un-commission-on-life-
saving-commodities
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We are committed to creating innovative 
products that deliver value for all – 
healthcare payers and providers, and most 
of all, patients. We are accelerating the 
delivery of new products by streamlining our 
research and development (R&D), focusing 
on products that bring most value, and 
forging strong partnerships with others in 
our industry and in academia. 
We also aim to stimulate innovation by 
opening up access to our expertise, our 
facilities and, in some cases, our intellectual 
property to support external research in 
areas of great medical need. 
Developing medicines and vaccines for 
diseases that disproportionately affect 
developing countries and poorer 
populations in middle-income countries 
remains a key focus for GSK. 
Unprecedented approvals and  
strong pipeline 
Our approach is helping us accelerate R&D, 
yielding impressive results. Of the six major 
new medicine files we profiled at the start of 
2013, five were approved: Breo and Anoro for 
respiratory disease, Tafinlar and Mekinist for 
melanoma (skin cancer) and Tivicay for HIV. 
We are expecting regulatory decisions for 
albiglutide, the remaining asset in this group,  
in the first half of 2014. In addition, we launched 
our new injectable quadrivalent flu vaccine in 
the USA. Overall, GSK accounted for 19%  
of FDA new drug approvals during 2013.  
We have achieved this feat while spending 
less on R&D than we did five years ago. 
Our approach to innovation is helping us strengthen our portfolio of medicines, 
vaccines and consumer healthcare products to bring benefits to patients around 
the world.
Our six major new medicines are: 
 • Breo/Relvar Ellipta approved in the USA 
to treat Chronic Obstructive Pulmonary 
Disease (COPD), the fifth leading cause 
of death globally, in Europe to treat 
asthma and COPD, and in Japan to treat 
asthma.
 • Anoro Ellipta also approved for COPD  
in the USA.
 • Tafinlar, an oral metastatic melanoma 
therapy, approved in the USA and Europe.
 • Mekinist, a treatment for melanoma, 
approved in the USA.
 • Tivicay, ViiV Healthcare’s new treatment 
option for people living with HIV, approved 
in the USA and Europe.
 • Fluarix/Flulaval, quadrivalent flu vaccines 
that protect against four different strains 
of the virus, approved in the USA 
(Flulaval) and Europe (Fluarix).
Our pipeline remains extensive and we  
aim to have a continued flow of product 
launches which will bring benefits to 
patients and continue to diversify our 
portfolio. We have around 40 new molecular 
entities (NMEs) in phase II/III clinical 
development. In 2014 and 2015 we expect 
phase III read-outs for six NMEs and are 
planning ten NME phase III starts in key 
areas such as respiratory, oncology and 
immuno-inflammation.
Our Discovery Performance Unit (DPU) 
based discovery research strategy is also 
continuing to progress very well. They have 
shown sustained improvement in both quality 
of compounds and more especially the 
research areas being prospected, such as 
immuno-inflammation, antibody platforms, 
epigenetics and heart failure. 
We are committing resources to stimulate 
innovation into the development of promising 
new technologies that could treat the 
diseases of tomorrow. For example, in 2013, 
we established a new bioelectronics R&D 
unit to catalyse research into approaches 
that modulate signalling patterns in the 
nerves to specific organs, which offer new 
ways to treat chronic diseases. 
We also encourage entrepreneurship  
and innovation in the biotech sector.  
For example, we joined forces with Johnson 
& Johnson to launch the Index Ventures’  
first fund which is dedicated to making 
investments in the life sciences sector and 
our own independent corporate venture 
firm, SR One. GSK is also a founding 
investor in the new Global Health 
Investment Fund (see case study below). 
Innovative science to 
create value for all
Saving millions of lives: How’s that for a return on investment?
We have committed US$10 million to a new 
investment fund structured by JPMorgan 
Chase & Co. and the Bill & Melinda Gates 
Foundation to help tackle health challenges 
that are particularly prevalent in low-income 
countries by advancing the most promising 
innovations. The Global Health Investment 
Fund, or GHIF, will finance the development  
of new drugs, vaccines, diagnostic tools  
and other interventions that target malaria, 
tuberculosis, HIV/AIDS, and maternal and 
infant mortality. 
To mitigate the risk of investing in the clinical 
development of new technologies, the Gates 
Foundation and the Swedish International 
Development Cooperation Agency will partially 
offset potential losses in the Fund. GSK will 
also contribute valuable advice on scientific 
and product development, manufacturing,  
and regulatory issues through our participation 
on the Fund’s Scientific Advisory Board. 
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Making vaccines more immune to heat
 
Vaccines are notoriously susceptible  
to heat, making transport a challenge, 
especially in hot, remote regions where 
people often need them most.
In 2013, GSK and the Bill & Melinda Gates 
Foundation (BMGF) partnered in a new joint 
initiative that aims to accelerate advances  
in vaccine research and development that 
have the potential to transform global health. 
GSK and BMGF will invest a combined 
US$1.8 million in early stage research into 
vaccine thermostability.
One of the first projects is exploring how to 
make adjuvants – a critical component of 
some vaccines – more heat stable. The 
project will initially focus on GSK’s RTS,S 
malaria vaccine candidate (see page 27), 
which has been designed for use in infants 
and children in sub-Saharan Africa, where 
maintaining vaccines at an optimum 
temperature can be challenging.
 Commitment
Invest in the development of vaccines that don’t 
require continuous refrigeration, making distribution 
easier and less expensive.
How we innovate
To foster innovation, we empower our scientists 
and researchers to think creatively while 
maintaining a focus on scientific discipline.  
To help us do this more effectively, we: 
 • Research only those treatments that offer 
significant improvements over existing 
options, based on our understanding of 
patient needs.
 • Create smaller specialist research teams, 
such as our specialist multidisciplinary 
Discovery Performance Units. 
 • Simplify processes, improve team 
efficiency and enable people to focus  
on higher value activities.
 • Access and catalyse innovation through 
collaborations with public and private 
organisations.
 • Identify and terminate projects that are 
unlikely to be successful early to free up 
resources to pursue more promising leads.
 • Focus on progressing the development of 
pipeline projects by optimising resources 
through innovative and smarter clinical  
trial design.
Through our Focus on the Patient 
programme, we connect our researchers 
with the patients they are ultimately 
developing medicines for. This provides our 
researchers with important insights into the 
challenges of living with a disease, and 
enables us to incorporate patient feedback 
directly into the R&D process. In 2013, more 
than 5,000 employees participated in seven 
patient seminars on topics such as neglected 
tropical diseases, type 2 diabetes, gene 
therapy, HIV, chronic hand eczema and 
Duchenne muscular dystrophy. 
Collaborating with others
The world’s biggest public health challenges 
can only be solved if researchers from 
different scientific organisations and 
institutions work together, sharing their 
knowledge and expertise. To this end, we are 
involved in a number of innovative 
collaborations with a broad range of both 
public and private bodies. These include 
initiatives with governments, scientific 
institutions and other companies to address 
some key public health problems, including 
antibiotic resistance and dementia.
Innovative science to 
create value for all
continued
“ Having had my world turned upside 
down in 1997, due to my systemic 
sclerosis diagnosis, the Focus on the 
Patient programme has given me hope 
that a cure will be discovered, 
consigning this debilitating disease  
to the history books. The programme 
has provided a perfect platform for me  
to share the day-to-day challenges of 
living with this condition, and highlight 
potential areas for future treatments 
which are currently absent.” 
Nicola Whitehill
Focus on the Patient participant
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Addressing the urgent need to tackle antibiotic resistance
No one would like to go back to a time 
before penicillin revolutionised the 
treatment of bacterial infections. But the 
alarming growth in antibiotic resistance is 
making this once impossible scenario 
more probable. 
Antibiotic resistance, which is the ability  
of a microorganism to withstand the 
effects of an antibiotic, has coincided with 
declining antibacterial drug development. 
As a result, the world is seeing isolated 
infections of multi-resistant bacteria that 
are untreatable with existing drugs.
Despite the challenging scientific, 
regulatory and commercial environment, 
we are one of the few pharmaceutical 
companies committed to delivering new 
antibacterials to help address the  
growing threat of antibacterial resistance. 
This commitment includes:
 • A dedicated R&D team focused on 
antibiotics research that has resulted  
in three antibacterial compounds in the 
early stages of clinical trails.
 • Endorsing the appropriate use of 
antibacterials, aiming to reduce resistance 
by ensuring that the right medicine is 
prescribed at the right dose, for the right 
duration (antibacterial stewardship).
 • Ongoing efforts to engage with scientific 
and medical communities and share 
findings from our own R&D.
 • A commitment not to license our new 
antibacterials for agricultural use, 
recognising that high levels of 
antibacterial use in farming has the 
potential to increase resistance.
We are also participating in a range of 
collaborations to address the challenges  
of delivering new antibiotics to the market, 
including New Drugs for 4 Bad Bugs –  
the key programme of the Innovative 
Medicines Initiative. Through this 
unprecedented initiative, we have led the 
development of three new collaborative 
models on clinical trial, basic research and 
drug discovery, which has created a single 
vision, a comprehensive research plan, 
and a fully collaborative framework 
agreement that takes into account the 
interest of all partners involved.
With one of our investigational 
antibacterials due to enter phase III 
development in 2014/2015, we are already 
seeing evidence that our approach to 
antibiotics R&D is working. This potential 
new medicine was discovered by GSK 
scientists and is being developed in 
partnership with the USA’s Defense Threat 
Reduction Agency and Biomedical 
Advanced Research and Development 
Authority – highlighting the merits of 
collaboration in this area.
Innovative science to 
create value for all
continued
Targeting unmet medical needs
 Commitment
Adapt the open innovation R&D model, currently used 
for Diseases of the Developing World, to apply to 
other areas of great unmet medical need and scientific 
challenge, including infectious disease and Alzheimer’s 
disease, by 2015.
We adopt flexible business models that 
enable us to use our expertise to address 
areas of unmet medical need where there is 
not necessarily potential for commercial 
return. Central to this is our open innovation 
strategy, which has transformed our 
approach to intellectual property and 
external partnerships. 
While our current open innovation models 
focus on diseases of the developing world, 
we are also exploring ways to extend these 
models to solve other pressing health 
challenges, including anti-microbial 
resistance and non-communicable diseases 
such as Alzheimer’s.
For example, we are working with others to 
encourage research into new antibiotics 
through the Innovative Medicines Initiative (IMI), 
one of the largest public-private partnerships in 
global health research (see page 47). GSK is 
also leading IMI’s PharmaCog project, which 
aims to accelerate the development of new 
drugs for Alzheimer’s disease, and we are 
funding the UK Dementias Research 
Platform. Led by the Medical Research 
Council, the platform is a public-private 
partnership that seeks to improve the ability to 
detect signs of early-stage 
neurodegenerative disease and support the 
development of new treatments.
Our Discovery Partnerships with Academia 
programme brings together the insight and 
creativity of the academic world, and GSK’s 
drug discovery expertise and tools to 
translate innovative research into medicines 
that benefit patients. In 2013, we launched 
Discovery Fast Track in North America,  
a competition designed to identify promising 
academic research that could accelerate 
development of new therapies. The eight 
projects selected target important unmet 
medical needs, including antibiotics 
resistance, diseases of the developing world 
and certain types of cancer. The winners will 
be granted access to GSK’s screening 
technology, compound libraries and 
expertise in drug discovery.
Trust in Science, our partnership with 
government funding agencies, aims to build  
a sustainable, long-term scientific research 
base in Latin America and Africa. The 
initiative partners GSK teams with other 
scientists to develop medicines for diseases 
affecting the regions, focusing on infectious 
diseases as well as non-communicable 
diseases. Eleven new projects were selected 
for support in Brazil and Argentina in 2013, 
in addition to the 26 existing active projects 
in Latin America, and we also launched Trust 
in Science in Africa. We received 182 
proposals in Kenya, Tanzania and Uganda, 
eight of which were selected in the areas  
of malaria, HIV, nutrition, maternal health  
and COPD. 
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Innovative science to 
create value for all
continued
In early 2014, we joined the Accelerated 
Medicines Partnership (AMP), a new 
partnership between the National Institutes 
of Health (NIH), ten pharmaceutical 
companies, and three non-profit 
organisations. The goal of the AMP is to 
transform the current model for developing 
new diagnostics and treatments in 
challenging disease areas by jointly 
identifying and validating promising 
biological targets. Work will begin in three 
disease areas: Alzheimer’s disease, 
diabetes, and the autoimmune disorders, 
rheumatoid arthritis and lupus, with an initial 
investment of more than $188 million. GSK 
will be participating in, and providing 
funding for, the Alzheimer’s pilot. The data 
and analyses generated through this work 
will be made publicly available to the broad 
biomedical community. 
We are also working in collaboration with 
partners in industry and academia to 
enhance approaches to delivering new 
clinical candidates against multi-drug-
resistant tuberculosis (TB). 
Sharing our research 
The industry average time from discovery  
to approval of a new drug is more than  
13 years, with a failure rate of over 95%2.  
We believe that by sharing our research 
findings – on our successes and failures 
– we can accelerate the drug development 
process by helping others build on our 
existing research, and stimulate innovation 
to develop new therapies for patients. 
As part of this commitment, we have already 
screened GSK’s entire compound library of 
over two million compounds for any that may 
inhibit malaria or TB, identifying 13,500 and 
180 promising ‘hits’ respectively. By making 
information on these hits available, we hope 
to encourage other scientists to carry out 
additional research that will drive the 
discovery of new treatments against these 
diseases. Our malaria compound set is part 
of the ‘malaria box set’ that Medicines for 
Malaria Ventures has sent to more than  
160 groups around the world. We have also 
shared our TB compound set with more than 
ten research groups around the world. 
Through our Open Lab initiative, researchers 
are also screening our compound library for 
‘hits’ that could ultimately lead to new 
treatments for neglected tropical diseases 
(see page 26).
In 2013, we participated in an innovative pilot 
project led by the U.S. National Center for 
Advancing Translational Sciences, enabling 
academic researchers to evaluate compounds 
we released for new therapeutic uses. We also 
partnered with InnoCentive to utilise their 
global network of problem solvers to come up 
with solutions to key challenges through 
‘crowdsourcing’. For example, more than 675 
solvers from 57 countries responded to our 
challenge to explain an unusual toxicity profile, 
resulting in 33 credible proposals, from which 
two were ultimately pursued. 
We also enable independent researchers  
to examine the findings and conduct their 
own analyses to further medical research 
(see page 40).
Open Lab
Research at our Open Lab in Tres Cantos, 
Spain, is focused on discovering and 
developing new medicines for diseases of  
the developing world (see page 26). Here,  
we do not generate or direct projects;  
we simply support the ideas of others.  
By the end of 2013, 38 visiting scientists 
have made use of the open lab, working on 
early stage research alongside our 
scientists, and are utilising our facilities, 
resources and knowledge to advance their 
own research projects. Since the Open Lab 
was established in 2010, it has built up a 
portfolio of 35 research projects, one-third 
of which are now complete. 
In 2013, the Wellcome Trust awarded an 
additional £5 million to GSK that will take 
our open approach a step further. It will 
enable researchers at the Open Lab to 
tackle the next phase of drug development 
with the aim of turning promising active 
compounds into high quality experimental 
drugs. The funding will help progress the 
most promising projects underway by 
independent scientists at the Open Lab and 
from GSK’s own research portfolio.
2 U.S. National Institutes of Health, http://www.nih.gov/
news/health/jun2013/ncats-18.htm
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Access to healthcare
Lack of access to healthcare is most acute 
in the world’s poorest countries. Millions of 
people in regions and communities with 
limited resources still can’t access the 
healthcare they need, including vital 
vaccines, medicines and diagnostics. 
To improve access, we employ innovative 
funding mechanisms and use a flexible 
pricing approach that is based on a 
country’s wealth and ability to pay, as well 
as working to improve availability of our 
products for the people who need them. 
But even when vaccines and medicines are 
available, there aren’t always enough trained 
health workers to administer them. To help 
address this challenge, we are helping to 
strengthen healthcare infrastructure, with a 
particular focus on training health workers.
Affordability
 Commitment
Further embed our flexible pricing strategy and 
innovative business models for our prescription 
medicines and vaccines, to increase usage among 
those less able to access and afford our products.
Our innovative business models offer a 
range of options to improve affordability of 
our medicines and vaccines, including price 
caps for the poorest countries, flexible and 
tiered pricing in middle-income countries, 
and support for governments and low-
income patients in high-income countries. 
We have used a tiered pricing model for 
vaccines for over 20 years, enabling us to 
produce and reliably supply effective, 
high-quality vaccines and support the 
continuous development of new vaccines. 
We are committed to improving access to our products – irrespective of where 
people live or their ability to pay – by focusing on the affordability and 
availability of our products, and investing in strengthening health systems.
We also encourage governments to adopt 
public policies that support differential 
pricing through, for instance, our continued 
support for the EU’s Tiered Pricing 
Regulation and our work with the UK’s 
Industry Government Forum on Access  
to Medicines. 
Pricing in developing countries 
For millions of people in resource-poor 
settings, affordability is a significant barrier 
to getting the medicines they need. In 2013, 
GSK commissioned the first ever global 
study to identify healthcare innovations in 
developing countries that could be 
replicated to increase access to affordable 
medicine. The study, conducted by the 
International Centre for Social Franchising, 
assessed opportunities to scale up and 
replicate over 900 healthcare programmes 
and found that, for the most part, existing 
healthcare delivery models target the more 
affluent emerging middle class, rather than 
the poorest.
By increasing the overall volume of products 
we sell, we are able to sustain lower prices 
on our essential medicines and vaccines for 
those most in need. Our Developing 
Countries and Market Access (DCMA) 
operating unit has a clear objective to 
increase patient access to GSK medicines 
and vaccines for around 800 million people 
in Least Developed Countries (LDCs), while 
expanding our market presence and 
ensuring that our business continues  
to be sustainable. 
The DCMA unit adopts a lower price/higher 
volume approach in developing countries, 
and employees are incentivised to increase 
volumes of medicines delivered, rather than 
just focusing on the revenue they bring in. 
Since the unit was established in 2010, the 
volume of medicines we supply to LDCs has 
increased by 60% to 89 million packs of 
product in 2013.
Since 2009, we have capped the prices of 
our patented medicines in LDCs at no more 
than 25% of prices charged in developed 
countries – provided they cover our 
manufacturing costs so we can sustain 
these prices in the long term. 
Capped prices apply to brands that treat 
non-communicable diseases such as 
asthma and COPD, as well as infectious 
diseases such as malaria. We have also 
reduced the prices of our off-patent 
antibiotics, Augmentin and Zinnat, by up to 
50% in certain countries, and all vaccines 
are capped at 25% of the West European 
average price.
Our vaccines are included in immunisation 
campaigns in 170 countries worldwide. In 
2013, we delivered 862 million vaccine 
doses, over 80% of them for use in 
developing countries.
In 2013, we refined our approach to 
vaccines pricing by increasing the number 
of pricing tiers and basing price ranges on 
Gross National Income per capita. The 
lowest tier, tier 7, corresponds to GAVI 
eligible countries. GSK is a long-standing 
partner of the GAVI Alliance, which funds 
immunisation programmes for some of the 
world’s poorest countries. GAVI-eligible 
countries – those with a Gross National 
Income per capita of US$1,570 or below 
– always get our lowest prices, which can 
be as little as one-tenth of those for 
developed countries. Our approach is 
designed to support governments making  
a long-term investment in immunisation  
and reflects our desire to enable countries 
to expand upon their commitment to 
immunisation as their economies grow.
“ Giving countries prices for vaccines 
that reflect their ability to pay enables 
them to plan programmatically and 
financially, which should ultimately 
create better predictability. In return, 
vaccine companies will be able to 
access wider markets, increase their 
production volumes (which will reduce 
their manufacturing costs), and have 
the opportunity to do the right thing 
for people who need, but cannot afford, 
their vaccines today.”
Dr Seth Berkley
CEO, The GAVI Alliance
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In 2013, we committed to provide an 
additional 240 million doses of Synflorix to 
the GAVI Alliance for use in developing 
countries over the next ten years. This will 
help to protect up to 80 million more 
children from pneumococcal diseases, such 
as meningitis and pneumonia – the leading 
cause of death in children under five in 
developing countries. This is in addition to 
the 480 million doses of the vaccine that we 
have already committed to GAVI through the 
Advance Market Commitment framework 
that offers heavily discounted vaccines for 
children living in the world’s poorest 
countries. In 2013, we supplied 31 million 
doses of the vaccine for introductory 
vaccine programmes in four countries.
GSK has also committed 132 million doses 
of Rotarix to GAVI over the next five years, 
which will help protect 60 million children 
against rotavirus gastroenteritis – which kills 
half a million children a year worldwide. 
In addition to Synflorix and Rotarix, in 2013 
we announced a new commitment to the 
GAVI Alliance to supply our cervical cancer 
vaccine, Cervarix, as part of a long-term 
programme to help protect girls and women 
against cervical cancer in the world’s 
poorest countries (see case study). 
Flexible pricing in middle-income countries
Our approach to pricing in middle-income 
countries is based on a recognition of the 
economic and social diversity (and disparity) 
that exists within these countries. We have 
flexible pricing and innovative payment 
schemes that enable more people to access 
our products, while growing our business by 
increasing the volumes we sell. Our Market 
Access and Pricing team is responsible for 
developing innovative pricing strategies and 
establishing market access programmes to 
make GSK medicines available to as many 
patients as possible in these countries. 
Where affordability remains a barrier, we 
offer a range of payment schemes that 
makes it easier for more patients to afford 
the treatments they need, often by 
partnering with NGOs. These include: 
pricing according to patient income; 
monthly payment plans that help patients 
manage the cost of treatments; and 
discount cards that enable eligible patients 
to receive direct discounts when picking up 
their prescriptions in our partner 
pharmacies. For example, in 2013 we 
introduced a reimbursement programme in 
Turkey for Volibris (used to treat pulmonary 
arterial hypertension), and enabled 270 
metastatic breast cancer patients in India to 
access Tyverb through a scheme that offers 
patients who complete six months of 
treatment an additional month free of 
charge, where appropriate. 
Middle-income countries benefit from tiered 
pricing of our vaccines and we also supply 
vaccines to the Pan American Health 
Organization, which purchases on behalf of 
middle-income countries in Latin America 
and the Caribbean.
Access to healthcare
continued
Protecting girls and women against cervical cancer in Madagascar
In November 2013, 15,000 girls (aged 9-13 
years) living in Madagascar, Africa, were 
vaccinated against Human Papillomavirus 
(HPV) – the leading cause of cervical cancer 
– as part of a demonstration project 
supported by Ministry of Health, UNICEF, 
WHO and GAVI Alliance. 
Madagascar is one of seven sub-Saharan 
countries to collaborate with GAVI as part of 
a long-term programme to help protect girls 
against cervical cancer in the developing 
world – where more than 85% of cervical 
cancer deaths occur. 
GSK has committed to supply its cervical 
cancer vaccine, Cervarix, to the GAVI 
Alliance at a reduced price. Initially, the 
vaccine will be supplied to GAVI 
demonstration projects, allowing 
governments to gain practical knowledge, 
before scaling-up immunisation programmes 
nationally.
By 2020, GAVI expects more than 30 million 
girls in the world’s poorest countries to have 
been immunised with HPV vaccines. 
Managing healthcare costs in high-income 
countries
High-income countries also face challenges 
related to the affordability of healthcare. 
Public healthcare budgets in Europe are 
under immense pressure as a result of the 
economic environment and over 15% of 
Americans lacked health insurance 
coverage in 2012.3
In these markets we also take a responsible 
approach to prices. It is important that they 
reflect the value our medicines bring to 
patients. But we are also very mindful of the 
burden of healthcare costs. That’s why we 
have priced our newly launched products at 
or below the prices of those currently 
available, despite their positively 
differentiated profiles. 
In Europe, we tailor our approach to specific 
country needs and work with governments to 
demonstrate value for patients, payers, 
healthcare professionals, taxpayers and our 
industry. For example, we partner with the 
Italian government to enable earlier patient 
access to innovative medicines by sharing 
risk and responsibility through Managed 
Entry Schemes. These include cost sharing 
which discounts the price of Arzerra, our 
leukaemia drug; risk sharing, which discounts 
the price of initial therapies for non-
responder patients; and pay-for-performance 
for our Votrient and Tyverb drugs, which fully 
reimburses costs for non-responder patients.
3 Source: http://www.hsph.harvard.edu/news/hsph-in-the-
news/global-health-noncommunicable-diseases-bloom/
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Availability of our products
 Commitment
Continue to build a core range of products and formats 
to better meet the needs of people across the globe, 
including those less able to access and afford our 
products.
Increasing access requires making 
medicines not only more affordable, but also 
more available. For effective treatment, 
patients need the right medicines in the 
right place at the right time. To increase  
the availability of our products, we are 
expanding our portfolios and product 
registrations in developing countries, 
harnessing the combined capabilities of our 
Consumer Healthcare and Pharmaceutical 
divisions, and increasing local manufacturing 
and capacity building in the markets we serve.
Portfolio expansion and product registration
We are committed to expanding our portfolios 
by increasing the availability of our medicines 
for non-communicable diseases, such as 
cancer and diabetes, as well as infectious 
diseases in developing countries (see page 25). 
As part of this effort, we are working with 
regulators to increase the registration of 
medicines in our existing portfolio.
Through our ‘catch up’ programme, which 
aims to bring more of our established products 
to developing countries, we received approvals 
for a further 26 products treating non-
communicable diseases, respiratory, 
antibiotics and oncology in 2013. We are also 
offering affordable pricing options on new 
drugs when they first enter a market.
Joining forces to increase impact
In 2013, we expanded our global 
programmes to combine the strengths  
of our Pharmaceuticals and Consumer 
Healthcare businesses through 
collaborations to better meet patient needs.
For example, our businesses have joined 
forces to tackle COPD, a debilitating, 
incurable, and potentially fatal lung condition 
affecting more than 200 million people 
globally and chiefly caused by smoking – 
blamed for 90% of COPD deaths.  
As many as two-fifths of COPD patients 
continue to smoke. We are talking to doctors 
and pharmacists not only about treatment for 
appropriate patients with Seretide (Advair), 
our respiratory medicine, but also how our 
NiQuitin and other smoking cessation 
products can help those affected, or at risk, 
to quit tobacco. We are working with 
pharmacies too, to promote awareness and 
earlier diagnosis of this under-recognised 
condition. The programme is live in Brazil, 
Argentina, Australia, Turkey and Russia and 
is being further expanded.
In another collaboration, we are working 
with pharmacies to enhance how we help 
patients and consumers get the treatments 
and advice they need. For people in 
developing regions like Africa, pharmacies 
are a chief source for healthcare. In Africa, 
this programme will start in Nigeria, Kenya, 
Angola, and Côte d’Ivoire in 2014, with 
more countries to follow. By increasing our 
contacts with pharmacies, we can boost 
availability of healthcare and expert advice 
to those who need them.
New formulations to better meet  
patient needs
We are looking for ways to increase access to 
respiratory treatments in developing countries 
by reducing pack sizes and engineering 
low-cost formulations to reach greater 
numbers of patients. For example, we have 
re-engineered Ventolin Rotacaps using a 
version of our established GSK inhaler 
technology, but one that is five times less 
expensive to produce. The new inhaler is 
available in four markets – the Philippines, 
Indonesia, Kenya and Nigeria – and we have 
submitted it for regulatory approval in other 
markets. Ultimately we hope it will open up 
access to many more patients who are 
currently unable to afford inhaled respiratory 
medicines. 
Other new formulations have the potential  
to revolutionise paediatric healthcare.  
For example, we are working with Biological E., 
a leading Indian vaccines company,  
on a first-of-its-kind combination paediatric 
vaccine to protect children from polio and 
other infectious diseases. The new fully 
liquid formulation will enable fewer 
injections for children, to improve 
compliance in immunisation schedules. 
In the USA, GSK offers several patient-
assistance programmes to help eligible 
patients get the prescription medicines or 
treatments they need. Programmes include:
• Commitment to Access for cancer  
or specialty treatments. 
• Bridges to Access for non-cancer 
medicines.
• GSK Vaccines Access Program for 
providing vaccines to adult applicants.
• GSK Access for senior and disabled 
patients enrolled in Medicare Part D.
In 2013, 316,580 eligible patients enrolled 
in our U.S. Patient Assistance Programs, 
which provided prescribed GSK medicines 
and vaccines worth a total of US$176 
million (£112 million), up from $159 million 
(£100 million) in 2012.
We remain committed to improving 
productivity in R&D so we can develop more 
innovative new medicines with greater 
efficiency. The improved efficiencies that  
we are seeing within our R&D business 
organisation are also enabling us to be more 
flexible with the pricing of our medicines.
 
Access to healthcare
continued
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Preparing for pandemic
In 2013, we signed an agreement with the 
World Health Organization to donate 
7.5% of our ‘real time’ pandemic influenza 
vaccine production, and two million 
treatment courses of antiviral medicine for 
distribution to countries most in need in 
the event of a future pandemic. 
This agreement, known as a Standard 
Material Transfer Agreement 2, confirms 
that, in the event of a pandemic, vaccines 
will be available to the WHO as soon as 
the first production cycle is completed. In 
addition to the donation, GSK will also 
reserve further volumes of pandemic 
vaccine (2.5% of ‘real time’ production) 
and antiviral medicine (eight million 
treatment courses), should they be 
required.
Local manufacturing and capability building
GSK has 46 manufacturing sites outside 
Europe and North America. By operating 
local manufacturing sites, we develop the 
skills and technical expertise of the 
workforce in these countries and cut down 
the costs of production and transportation. 
Transferring the technology to produce drugs 
and vaccines is one of the most sustainable 
ways to bridge the access gap between the 
developed and developing world. We have a 
number of joint ventures and technology 
transfer arrangements that help build the 
capabilities of developing countries to 
research and manufacture vaccines, while 
increasing our access to markets. For 
example, our joint venture with Biological E. 
in India is working on the early stage 
research and development of a new 
paediatric vaccine (see page 22). We also 
have long-standing technology transfer and 
manufacturing agreements with the Oswaldo 
Cruz Foundation in Brazil in areas essential 
to Brazil’s universal immunisation 
programme. In 2013, we announced plans  
to develop a new £85 million manufacturing 
facility in India, where we have invested over 
£100 million in building our manufacturing 
network over the last decade.
Strengthening healthcare systems
 Commitment
Continue to work with partners to support the 
development and strengthening of healthcare 
infrastructure. We anticipate this could improve access 
to healthcare for 20 million under-served people by 
2020 (vs 2012).
GSK is committed to strengthening 
healthcare infrastructure in developing 
countries by working with partners to explore 
new healthcare delivery models and 
supporting projects in 34 of the world’s 
Least Developed Countries (LDCs). In doing 
so, we hope to improve access to healthcare 
for 20 million under-served people by 2020. 
We continued to work towards this goal in 
2013 by training more community health 
workers, scaling up our activities with 
non-profit partners, and collaborating with 
companies in other sectors to create innovative 
models to strengthen healthcare systems.
Reinvesting in the community
Since 2009, we have reinvested 20% of the 
profits we generate in LDCs into community 
programmes that strengthen healthcare 
systems and improve access to healthcare 
in these countries. 
Training frontline community health workers, 
who can reach millions of people in remote, 
rural areas with vaccines, medicines and 
advice, is central to our 20% programme. 
Working with AMREF in East and Southern 
Africa, Save the Children in West and 
Central Africa, and CARE International in 
Asia, we invested £5.1 million in 2013 
(based on 2012 profits) and a total of  
£15 million since 2009 to train and build 
capacity among health workers. 
Projects include training over 800 
community health workers in Angola to care 
for nearly 30,000 mothers and young 
children suffering from malaria, respiratory 
and diarrhoeal diseases; equipping 
community health volunteers with the skills 
needed to screen 7,862 children for 
malnutrition in Liberia; and reaching more 
than one million people and 31,000 
expectant mothers in Nepal by training 
health workers and providing operational 
support and equipment. Details of all our 
projects can be found on our website. 
Where possible, we conduct in-depth 
monitoring to track our progress. In 2013, 
we also committed US$750,000 to the  
One Million Community Health Workers 
campaign led by the United Nations 
Sustainable Development Solutions 
Network, which will fund a new online 
‘Operations Room’ to monitor the progress 
of the campaign’s efforts to train growing 
numbers of health workers in sub-Saharan 
Africa. The overall goal is to ensure one 
million health workers are operating in rural 
areas by 2015 and help meet the health-
related Millennium Development Goals. 
We also help to strengthen healthcare 
systems through our initiatives to tackle 
counterfeit medicines (see Our Behaviour, 
page 46).
Access to healthcare
continued
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Partnering to explore new healthcare 
delivery models
Lack of finance and poor access to 
essential medicines have been identified by 
the World Health Organization as major 
barriers to strengthening healthcare 
systems in Africa. In September 2013, we 
announced a new partnership with Barclays 
to increase access to affordable healthcare 
and medicines in Zambia while supporting 
small business development and job 
creation. Together, we will invest up to  
£7 million over three years in a project that 
will explore how to build a cost effective 
private sector medicine supply chain, 
establish small enterprise health outlets, 
test an affordable micro health insurance 
product and embed healthcare education in 
existing community finance networks. We 
aim to reach one million Zambians by 2016, 
and create a model that can be scaled up 
and replicated across Africa. 
Our partnership with Vodafone is 
harnessing the power of mobile technology 
to help increase vaccination rates for 
children in Africa against common infectious 
diseases. Mobile phones are used to create 
vaccine records, send text message 
reminders to mothers, and share stock data 
in real time to ensure vaccines are available 
when and where they are needed. In 2013, 
we set up an initial one-year pilot project 
with 90 clinics in Mozambique. 
We continue to work with One Family Health, 
an enterprise that uses a franchise system for 
nurses to own and operate local clinics, to 
extend access to basic healthcare in Kenya 
and Rwanda. In 2013, we committed  
£1.8 million over three years to help open  
180 nurse-owned Child and Family Wellness 
health posts in Rwanda, with the support of the 
Rwandan government. 
Access to healthcare
continued
Improving healthcare and delivering safe water in Senegal
Through our 20% reinvestment 
programme, we are helping to improve 
access to healthcare services for young 
children and mothers in Senegal, where 
many children under five die from 
preventable diseases such as diarrhoea, 
malaria and pneumonia. 
Building on an existing GSK health  
and sanitation project, our partner,  
Save the Children, has trained 101  
nurses, improving their knowledge of 
immunisation, conducting audits of 
maternal and neo-natal deaths and 
post-abortion care, and educating 49 
community health workers on home births 
and how to raise awareness of important 
health issues among the community. 
In addition, the project has also trained  
36 health workers and community leaders 
on community-led sanitation, taught  
12 bricklayers to build ventilated latrines, 
and cleaned up local water sources  
to ensure a safe water supply for over  
34,000 people.
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Focus on non-communicable diseases
When it comes to public health issues in 
the developing world, the focus has been 
predominantly on infectious diseases such 
as malaria. Yet chronic non-communicable 
diseases (NCDs) – such as diabetes, 
cancer, cardiovascular and chronic 
respiratory diseases – account for nearly 
half of deaths and disabilities in countries 
with the lowest incomes – and are  
growing fast.
The lack of focus on NCDs in developing 
countries is compounded by the 
misperception that diseases like cancer 
are a developed world disease. But 
changing lifestyles and demographics 
mean that the global burden of NCDs, is 
in fact, in the developing world: 80% of 
NCD-related deaths occur in low-and 
middle-income countries.4 Tackling this 
significant challenge is an important focus 
for GSK and, to do so, we have adopted a 
strategic approach on NCDs with a 
particular emphasis on developing 
countries. This includes:
Innovation and Research 
We have assets in clinical development 
for all four of the priority NCDs, and we 
are working to adapt our existing products 
to better meet the needs of patients in 
emerging markets. For example, we are 
conducting research on improving Flolan, 
our treatment for advanced stages of 
pulmonary arterial hypertension, to allow 
greater stability at higher temperatures.
Access and Affordability 
Our Developing Countries and Market 
Access unit is responsible for increasing 
patient access to our medicines and 
vaccines in developing countries (see 
page 20). We also focus on educating 
healthcare providers to recognise 
symptoms and treatment options. When 
our analysis revealed high levels of under 
treatment and under diagnosis of asthma 
in five urban centres (in Bangladesh, 
Cambodia, Kenya, Senegal and Zambia), 
we rolled out respiratory ‘masterclass’ 
awareness and education sessions in key 
regions, educating healthcare 
professionals on asthma diagnosis and 
treatment options. Similarly, we are 
supporting several training programmes 
for health care providers in Africa, ranging 
from basic oncology training for general 
doctors to formal pathology training for 
specialist doctors.
Prevention and Health Education
The four main risk factors that contribute 
to the onset of NCDs are smoking, 
alcohol, poor diet and lack of exercise. 
Our Consumer business has several 
initiatives that address these risk factors, 
focusing in particular on smoking 
cessation, better oral health and improved 
nutrition. For example, for patients with 
COPD, we are working to tackle the 
condition’s chief cause, smoking (see 
page 22).
Access to healthcare
continued
Partnership 
We partner with several organisations  
that focus on combating NCDs in the 
developing world. For example, we are 
working with Amgen, a biopharmaceutical 
company, to use our expertise in several 
Asian countries to support the launch of 
Vectibix for patients with metastatic 
colorectal cancer. In Bangladesh, we 
support an NGO seeking to establish 
breast cancer screening programmes  
that use mobile phones to increase 
adherence to treatment programmes  
for women with breast cancer. 
In December 2013, we announced the 
formation of the Oncology Clinical and 
Translational Consortium, a collaborative 
scientific research network comprised of 
six internationally renowned 
comprehensive cancer centres in North 
America and Europe. The consortium will 
foster scientific collaboration among the 
members and GSK in preclinical, 
translational and clinical development  
of novel anticancer therapeutics.
4 Source: http://www.hsph.harvard.edu/news/hsph-in-
the-news/global-health-noncommunicable-diseases-
bloom/
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Diseases of the  
developing world
Tackling diseases of the developing world 
not only improves health, but boosts 
economic development. We work with 
partners in the public and private sectors  
to research new vaccines, engage 
communities in adopting preventive 
measures, and make medicines and 
treatments available and affordable.  
In 2013, we achieved a major milestone  
in the development of the world’s first  
malaria vaccine and intend to file for 
approval in 2014. 
We also advocate the adoption of public 
policies that provide adequate financing for 
mechanisms such as the GAVI Alliance 
(funding immunisation in poor countries) 
and the Global Fund to Fight AIDS, TB and 
Malaria. We are on the Board of the Roll 
Back Malaria Partnership, and we are a 
founding member of the Global Alliance  
to Eliminate LF.
Neglected tropical diseases, polio and malaria affect billions of people in the 
world’s most vulnerable communities. We aim to help treat, prevent and 
ultimately eliminate these diseases.
Neglected tropical diseases
 Commitment
Help to eliminate and control ten neglected tropical 
diseases that affect 1.4 billion people, by 2020 
– including the elimination of lymphatic filariasis, 
through our continued investment in R&D, ongoing 
product donations and our contribution to the London 
Declaration on Neglected Tropical Diseases.
Neglected tropical diseases (NTDs) present 
significant health risks to the world’s 
poorest communities. More than one billion 
people, including 800 million children, are 
affected by NTDs. Symptoms can often 
prevent people from working and children 
from going to school, making it harder for 
them to escape poverty. 
As a leading partner of the London Declaration, 
GSK is working with the Bill & Melinda 
Gates Foundation, WHO, other 
pharmaceutical companies, donors and 
national governments to help control or 
eliminate 10 of the 17 NTDs that affect over 
1 billion people by 2020. Our most 
significant contribution to this collective 
commitment is in the elimination of 
lymphatic filariasis (LF) and control of 
soil-transmitted helminths (intestinal worms) 
through the donation of albendazole tablets, 
as well as collaborating with public and 
private partners to research new treatments 
for other NTDs.
Progress to date
Progress against the commitments made 
under the London Declaration is tracked 
through an annual public scorecard. In the 
first two years of the partnership, over 40 
endemic countries have developed multi-
year plans to fight NTDs. GSK and other 
pharmaceutical partners are meeting 
increased requests for drugs. 
GSK has now donated more than 4 billion 
albendazole tablets to support efforts to 
eliminate LF in 58 countries and de-worm 
school-age children in 46 countries.  
Our albendazole donation programme  
has reached over 600 million people –  
200 million of whom are children – since  
it began in 2000. In 2013, we donated  
648 million albendazole tablets for LF 
elimination and 115 million tablets to treat 
soil-transmitted helminths. These donations 
support the WHO’s 2020 goals to eliminate 
LF globally and deworm 75% of school age 
children in countries where intestinal worms 
are endemic. 
We are also working with logistics partners  
to improve the supply and delivery of NTD 
donations from manufactures to recipient 
countries. Donors and endemic country 
leaders have committed over US$785 million 
up to 2020, but more is needed. We are 
working with partners to close funding gaps, 
while supporting the development of new 
medicines and diagnostic tools to find, 
investigate, treat and prevent these diseases.
Researching new treatments
Existing treatments for Visceral 
Leishmaniasis – an NTD that is fatal if left 
untreated – can be both costly and 
challenging. We are investing in the 
development of a better, more affordable 
treatment at our specialist R&D unit in Tres 
Cantos (see page 19). We are screening 
our compound library for molecules that 
inhibit the growth of the leishmania parasite 
and are working with the University of 
Dundee in a project to identify a class of 
chemicals to combat this parasite. 
We are also researching new treatments for 
African trypanosomiasis (sleeping sickness) 
that can be administered orally. By 
eliminating the need for injections from 
trained healthcare workers, this aims to 
increase availability of treatment in 
communities and reduce strain on medical 
services. Through our Open Lab 
collaboration with Northeastern University 
and the Spanish Research Council, 32 
promising chemical hits were identified in 
2013, which are being investigated further. 
Open Lab collaborations with New York 
University and the University of Georgia also 
aim to develop more effective treatments  
for American trypanosomiasis (Chagas 
Disease) using GSK’s compound library.
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Polio 
 Commitment
Continue to support the WHO objective of eradicating 
polio by 2018 by providing vaccines to UNICEF until 
this is achieved.
Polio has been eradicated in many 
countries, but is still endemic in 
Afghanistan, Nigeria and Pakistan, and 
there have been recent outbreaks in Syria. 
We are committed to supporting the WHO 
objective to eradicate polio completely by 
2018, by providing vaccines to UNICEF 
until this is achieved. If this objective is not 
achieved, the WHO estimates that we could 
see 200,000 new cases each year 
worldwide within a decade. 
GSK has played a leading role in efforts to 
eradicate polio over the last 60 years, and 
we continue to collaborate and innovate to 
achieve this goal and prevent the disease 
resurfacing in countries already declared 
‘polio free’. 
As a global healthcare company, our role 
includes manufacturing vaccines and using 
our research expertise to explore new ways 
of tackling polio. We also price vaccines to 
help make sure those in need can access 
them, while investing in next-generation 
products. As part of our long-term 
commitment to fighting polio and preventing 
its resurgence, we have invested in building 
manufacturing facilities to ensure a long-
term supply of vaccines. For example, we 
are investing €320 million in building a new 
facility in Wavre, Belgium, which will begin 
production in 2018.
Immunisation programmes using the oral 
polio vaccine (OPV) are relatively 
inexpensive and because it is taken orally, 
the vaccine can be distributed by volunteers 
without the need for a trained healthcare 
worker or injection equipment. In 2013, we 
provided 412 million doses to the Global 
Polio Eradication Initiative (GPEI), a public-
private partnership led by national 
governments and the WHO. 
Since 1988, we have contributed over  
15.8 billion doses and we have committed 
to meeting at least 30% of the GPEI’s 
current polio vaccine requirements, 
procured through UNICEF, until 2017. We 
are systematically stockpiling OPV to meet  
this demand which is expected to require 
around 1.5 billion doses.
In countries where polio has been 
eradicated, OPV will be phased out and 
replaced with the inactivated polio vaccine 
(IPV) to prevent the (very low) risk of polio 
re-emerging from the live vaccine itself. We 
already produce and supply IPV to a variety 
of developed countries, and we are 
investing in developing lower cost 
combination vaccines (containing the 
vaccines for polio and other diseases in  
a single vaccine) for the developing world 
(see page 20).
Malaria
 Commitment
Build on our 30 year commitment to contribute to the 
fight against malaria through continued R&D investment 
and partnerships on the ground.
Malaria is one of the world’s deadliest 
diseases and affects many of the world’s 
poorest people. An estimated 3.4 billion 
people – more than half the world’s population 
– are at risk of contracting the disease. 
Approximately 627,000 malaria-related deaths 
are reported each year, mainly children under 
five living in sub-Saharan Africa. Malaria 
related illnesses and mortality cost Africa’s 
economy nearly $12 billion a year.
GSK is committed to tackling malaria by 
researching a vaccine, developing new 
treatments, promoting use of existing 
preventive measures and increasing access 
for anti-malarials in Least Developed Countries.
Achieving a milestone on a vaccine  
In 2013, we achieved a major milestone  
in the development of the world’s first 
malaria vaccine. RTS,S, the most clinically 
advanced malaria vaccine candidate to date, 
almost halved the number of malaria cases 
in young children (aged 5-17 months at first 
vaccination) and reduced by around a 
quarter the malaria cases in infants (aged 
6-12 weeks at first vaccination), as shown by 
the results of our large-scale phase III trial, 
published in October 2013.
The health impact of the RTS,S vaccine was 
evaluated in the context of existing malaria 
control measures, such as insecticide-
treated bed nets, in 11 research centres in 
seven African countries. The latest trial 
results found that the vaccine nearly halves 
the number of malaria cases in children 
between 5 and 17 months for at least 18 
months after the initial shot. 
Based on these findings, we plan to submit 
a regulatory application to the European 
Medicines Agency (EMA) in 2014. If 
approved, the WHO believes that a policy 
recommendation for the vaccine candidate 
could be possible by 2015. We will partner 
with multiple stakeholders, including African 
governments, to ensure that the delivery and 
implementation of the vaccine across Africa 
takes place as rapidly as possible.
This ground-breaking achievement builds 
on our 30-year commitment to combat 
malaria through continued R&D investment 
and partnerships on the ground. We have 
invested $350 million in the development of 
RTS,S through a public-private partnership 
with the PATH Malaria Vaccine Initiative 
(MVI) and support from the Bill & Melinda 
Gates Foundation. 
The price of RTS,S will cover the cost of 
manufacturing the vaccine together with  
a small return of around 5% that will be 
reinvested in R&D for second-generation 
malaria vaccines, or vaccines against other 
tropical diseases.
Diseases of the  
developing world
continued
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Developing new treatments
As resistance to current malaria treatments 
increase, we are supporting the 
development of new medicines at our 
research facility in Tres Cantos (see page 19). 
We are developing a medicine, Tafenoquine, 
in partnership with Medicines for Malaria 
Venture (MMV) for the treatment and 
relapse prevention of vivax malaria (a strain 
that affects millions of people in Asia and 
South America). Based on clinical trial 
results, we will further progress the 
development of this investigational medicine 
in the hope that this could offer a convenient 
single dose alternative to the current 14-day 
standard treatment. In 2013, the U.S. Food 
and Drug Administration granted 
Tafenoquine Breakthrough Therapy 
designation.
Promoting preventive measures 
GSK works to improve the prevention and 
treatment of malaria in sub-Saharan Africa 
through the Africa Malaria Partnership, 
which supports local NGO programmes. 
We have committed more than £4 million to 
community initiatives since 2001, and have 
partnered with organisations on the ground 
to promote the use of existing interventions, 
such as bed nets and indoor residual 
spraying. These projects focus on 
community health worker training and 
community empowerment, as well as 
reaching pregnant women and children 
under five years. In Ghana, we are working 
with human development organisation FHI 
360; in Nigeria with the Carter Center; in 
Kenya with Save the Children; and in 
Tanzania with AMREF. 
Diseases of the  
developing world
continued
Read more online
We publish more detail online on key  
issues including:
 • Clinical trials in the developing world 
 • Developing world vaccine production 
technology transfer
 • IP and access to medicines in  
developing countries
 • Pandemic preparedness and  
developing countries
 • Technology transfer, capacity building  
and developing countries
 • Working together for the health of mothers 
and children
 • GSK briefing on non-communicable 
diseases in the developing world 
 • GSK position statement on the post  
2015 development agenda
 • Pricing and reimbursement
 • Product donations
Partnering with Tony Blair Faith Foundation in Sierra Leone
As part of our commitment to expanding 
healthcare access in rural communities, 
we are partnering with the Tony Blair Faith 
Foundation (TBFF) in Sierra Leone to 
reach 4.8 million people – nearly 80% of 
the population – with vital malaria 
prevention education by 2015. 
Through a pioneering healthcare model, 
TBFF has trained more than 450 local 
religious leaders, who in turn educated 
11,000 ‘Malaria Faith Champions’ frontline 
messengers who engage with specific 
families. The programme has already 
reached around one million people, with 
nearly 80% of the 222,484 households 
contacted since September 2011, 
confirming they are acting on the advice 
provided.
We are investing £780,000 in the 
programme and, with GSK’s support, 
TBFF will continue to scale up its work in 
Sierra Leone to reach 600,000 more 
households. We plan to explore similar 
opportunities in other countries that have  
a high malaria burden and where this 
model could be effective.
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HIV/AIDS
Over 35 million people live with HIV. ViiV 
Healthcare is researching new treatments, 
improving access to medicines, and working 
with communities to combat stigma and 
discrimination.
Researching new treatments
ViiV Healthcare is focused on driving 
innovation in HIV research and discovery. 
The company’s goal is to find new ways to 
limit the impact of the virus, developing new 
medicines that are more effective and 
improve tolerance and treatment adherence 
over existing options. 
Launching Tivicay (dolutegravir)
In 2013 ViiV Healthcare reached an 
important milestone with the approval of 
Tivicay, their first new treatment to be 
delivered. In August 2013, the U.S. FDA 
approved Tivicay (dolutegravir), an 
investigational integrase inhibitor which 
blocks an HIV enzyme (integrase) and 
prevents HIV from replicating, for adults and 
children, 12 years and older, living with HIV. 
This was followed by approvals in other 
markets, including Argentina, Canada and 
Chile, and approval in Europe in January 
2014. Dolutegravir brings new treatment 
options to patients. In October 2013, ViiV 
Healthcare also submitted regulatory 
applications in Canada, the EU and the 
USA for the Single Tablet Regimen 
combining dolutegravir with abacavir and 
lamivudine (known as ‘dolutegravir-Trii’) to 
reduce the number of pills required for 
people living with HIV. 
Progress with the pipeline
There are currently four other clinical phase 
assets in the ViiV Healthcare portfolio and 
several pre-clinical discovery programmes 
in partnership with a range of partners, 
including GSK’s HIV Discovery 
Performance Unit, pharma/biotech and 
academic institutions engaged in the field of 
treating HIV.5 Examples of these 
partnerships are efforts to understand new 
modes of action, antibody therapy, new 
ways of delivering existing therapies (such 
as nanotechnology and long acting delivery) 
prevention of HIV and understanding the 
pathway to a functional cure of the disease. 
Work on our experimental integrase inhibitor 
GSK744 continues to progress. GSK744 is 
an investigational integrase inhibitor, from 
the same class as antiretroviral drugs as the 
recently approved Tivicay (dolutegravir). 
Each is a distinct new chemical entity. The 
two integrase inhibitors have similar 
structures and antiviral activities, but differ 
with respect to certain other attributes. 
GSK744 in particular has a longer 
elimination half life and slower absorption 
after injection, potentially permitting its use 
as a long-acting injectable formulation. A 
second study of the long-acting injectable 
form of this drug is set to begin in the 
second quarter of 2014.
ViiV Healthcare also supports collaborative 
research trials in resource-poor settings to 
understand public health issues such as 
prevention of mother-to-child HIV 
transmission and HIV-TB co-infection. In 
total, at the end of 2012, 31 such clinical 
trials were underway; 11 of the 31 trials are 
paediatric studies. African countries 
participating in the paediatric studies 
include Malawi, South Africa, Tanzania, 
Uganda, Zambia and Zimbabwe.
Addressing gaps in paediatric HIV 
treatment and care
Even as new HIV infections among children 
continue to decline, globally, an estimated 
3.4 million children under the age of 15 are 
still living with HIV. Approximately 90% of 
these children live in Africa. One of the 
barriers preventing scale-up of treatment is 
the lack of affordable medicines that are 
acceptable for use by children. ViiV 
Healthcare is therefore prioritising research 
to improve the diagnosis, treatment and 
care of infants and children living with HIV. 
In addition to ViiV Healthcare’s ongoing 
work to develop new formulations of the 
current portfolio for children, ViiV 
Healthcare is supporting 18 collaborative 
research trials investigating prevention of 
mother-to-child HIV transmission and 
paediatric treatment strategies. In addition, 
ViiV Healthcare supports diverse research 
initiatives through its £10 million Paediatric 
Innovation Seed Fund. 
Improving access to HIV treatment
 Commitment
Through ViiV Healthcare, continue to increase access 
to our medicines and care for adults and children living 
with HIV around the world. We will help World Health 
Organization (WHO) and UNAIDS achieve their goal 
of reaching 15 million people globally with antiretroviral 
treatment by 2015.
Over 16 million HIV-positive people in 
low- and middle-income countries lack 
access to antiretroviral (ARV) therapy.6 ViiV 
Healthcare aims to play its part to meet this 
challenge by improving access to medicines 
for all those who need treatment. 
ViiV Healthcare’s access policy applies to 
all Middle Income Countries, Low Income 
Countries, Least Developed Countries and 
all sub-Saharan African countries. Nearly 
75% of HIV-positive people live in low-
income, least developed and sub-Saharan 
African countries, where ViiV Healthcare 
offers royalty-free voluntary licences and 
not-for-profit pricing. ViiV Healthcare has  
16 royalty-free voluntary licence agreements 
with generic manufacturing companies, 
located in several countries, which enables 
them to produce and sell low-cost versions 
of GSK’s entire ARV portfolio to public 
sector and donor agency programmes.  
A voluntary licence agreement to 
manufacture Tivicay (dolutegravir) for Low 
Income Countries, Least Developed 
Countries and sub-Saharan Africa was 
signed in late 2013.
ViiV Healthcare, a global specialist HIV company established by GSK and Pfizer 
in 2009, and joined by Shionogi in 2012, is dedicated to tackling HIV – 
researching new treatments, improving access to medicines, and working with 
communities to combat stigma and discrimination.
5 Source http://www.unaids.org/en/resources/campaigns/
globalreport2013/factsheet/
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In middle income countries, ViiV Healthcare 
adopts a flexible pricing policy that varies 
according to GDP and the burden of the 
HIV epidemic in individual countries. 
Another key approach is creating 
partnerships to manufacture our medicines 
locally, which brings down the cost and 
builds skills in the local economy. An 
example of this strategy in action is the 
commercialisation of maraviroc in India 
through our partner Emcure, launched in 
December 2013. 
In the USA, where nearly 1.1 million people 
live with the HIV infection,7 ViiV Healthcare 
helps uninsured people access our 
medicines through our Patient Assistance 
Program. In addition, the Patient Savings 
Card Program helps all eligible patients 
save on out-of-pocket costs for the ViiV 
Healthcare medication they have been 
prescribed. For Tivicay (dolutegravir),  
the total potential amount of savings was 
increased from $200 to $400 per month.
Improving access to medicine for Children 
with HIV/AIDS through the patent pool
In February 2013, ViiV Healthcare extended 
its commitment to supporting children living 
with HIV through an agreement with the 
Medicines Patent Pool (MPP), the UNITAID-
backed public health mechanism. This 
significant development granted MPP a 
voluntary licence for paediatric formulations 
of the antiretroviral medicine, abacavir, in 
118 countries where 98% of HIV positive 
children live.
Supporting communities affected by HIV 
Zero new infections; zero AIDS-related 
deaths; zero discrimination: the three 
primary goals of UNAIDS’ Getting to Zero 
campaign involves a multidimensional 
strategy to address the HIV/AIDS 
pandemic. ViiV Healthcare is contributing  
to these goals through its support of, and 
partnership with, community-based 
organisations that strengthen education, 
build support services and local healthcare 
capacity, and reduce stigma and 
discrimination towards people living with 
HIV/AIDS. 
Making an impact in prevention of  
mother-to-child transmission of HIV
As part of our commitment to help children 
living with HIV, the Positive Action for 
Children Fund (PACF) supports 150 
organisations across 30 countries to deliver 
prevention of mother-to-child transmission 
of HIV. Since March 2010, the PACF has 
committed £19.5 million, with services 
reaching more than 1,280,300 women, 
children and families affected by HIV. In 
2013, the programme focused on creating 
opportunities to support capacity building 
among the groups who receive or apply for 
our grants. For example, we have set up 
PACF Online (www.pacfonline.com), an 
online community that includes regular 
training webinars so that groups can share 
experiences and learn from each other. 
Positive Action Southern Initiative reaches vulnerable communities living with HIV 
in the US
The Southwest Louisiana AIDS Council, 
one of the original grantees of the Positive 
Action Southern Initiative, provides 
support and educational services for newly 
diagnosed and out of care people living 
with HIV in rural Lake Charles, Louisiana. 
In addition, the Council’s initiatives improve 
treatment and adherence services in the 
region, resulting in better health outcomes. 
Over a two-year period, 96% of individuals 
enrolled in the Council’s initiatives were 
linked to care and treatment, and the 
number of people with an undetectable 
level of HIV in their blood rose from 37% 
to 56%, reducing the risk of illness for 
those living with HIV and the risk of 
transmission to a partner. 
Eighteen months after enrolment, average 
CD4 counts – which indicate the strength of 
the immune system – increased from 322 to 
460, and average levels of HIV in the blood 
of participants decreased by 82%. 
“We are encouraged by these findings, 
which show that our model for linking, 
engaging and retaining underserved 
populations with HIV into stable medical 
care are working,” said Angela Hursey 
from the Council. “Not only are we seeing 
improved linkage and retention rates, but 
we’re seeing measurable evidence that 
linkage to care and treatment adherence 
leads to better health outcomes, including 
higher rates of undetectable viral loads 
among people with HIV.”
HIV/AIDS
continued
A powerful example of how one of our 
smaller PACF grants (£18,000) makes a 
real difference is with the group Life 
Concern in Malawi, which identified a 
significant issue, that men often do not get 
involved in, or provide support to encourage 
the uptake of Prevention of Mother to Child 
Transmission services. The group tripled the 
number of men attending clinic visits with 
their partners, and reached more than 
13,000 people (half men, half women) 
through community awareness campaigns.
In 2013, over £1 million in grants were 
awarded to support organisations through 
ViiV Healthcare’s global Positive Action 
programme, which has supported the 
communities most vulnerable to HIV 
diseases for over 22 years. Positive Action 
focuses funding on capacity building for 
organisations that help to improve access  
to care for key populations in countries 
where individuals are facing threats of 
stigma and discrimination. 
7 Source http://www.cdc.gov/hiv/statistics/basics/
ataglance.html
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GSK supports the development of healthcare 
infrastructure and contributes to scientific 
education, as well as assisting humanitarian 
relief efforts. To maximise the impact of our 
support, we select programmes that are 
designed to be sustainable for the long term, 
partner with local and global organisations, 
and encourage our employees to participate 
in volunteering through our Pulse and Orange 
Day programmes (see pages 54 and 56).
Product and financial donations
In 2013, our global community investment 
totalled £221 million ($347 million), compared 
with £206 million ($330 million) in 2012.
We donated medicines valued at  
£146 million (at cost), including 763 million 
albendazole tablets to fight lymphatic 
filariasis and soil-transmitted helminths  
in 2013 (see page 26).8 
Product donations worth £3.8 million were 
delivered to our partners AmeriCares, Direct 
Relief, IMA World Health, MAP International 
and Project HOPE for humanitarian aid.  
These partners distributed donated medicines 
to 87 countries in 2013, including supplies  
of antibiotics and basic medicines to those 
affected by conflicts and natural disasters.  
For example, the earthquake in Pakistan,  
the Oklahoma tornado, and wildfires in the 
USA. GSK also responded to the typhoon  
in the Philippines by providing £1.1 million 
(US$1.8 million) of donated medicines, a 
cash donation of £178,000 (US$279,000) 
as well as local staff volunteering to support 
affected communities.
Health and well-being  
in our communities
We continue to work on our PHASE 
(Personal Hygiene and Sanitation Education) 
programme in Brazil, our work with Roma 
communities in Eastern Europe to improve 
health education, and a number of initiatives 
aimed at improving maternal and child 
health through our partnership with Save 
the Children. 
Our Patient Assistance Programs, which 
help underprivileged families in the USA 
access essential healthcare, accounted  
for 51% of our total giving in 2013 (see 
page 48). In line with our commitment to 
reinvest 20% of the profits we generate in 
Least Developed Countries, we invested 
£5.1 million in 2013 (£15 million since 
2009) in training frontline community health 
workers in rural areas (see page 23). 
8 GSK values product donations at cost of goods as we 
believe this is a truer reflection of the cost to GSK than  
the wholesale acquisition cost (the value cost reported  
to wholesalers) which is used as standard in the Pharma 
industry for valuing product donations. The total value  
of production donations in 2013, based on wholesale 
acquisition cost, was £512 million.
We are committed to improving the health and well-being of communities 
worldwide by funding and supporting local programmes which can make  
a real difference. 
Total giving by type in 2013 (%)
  Cash
  Product and in-kind
  Time 
  Management
24
8
66
2
Programmes supported by financial giving in 2013 (%)
  Health and well-being
  Education
  Other 
16
5828
Our giving (£ million)
2011 2012 2013
Cash 57 54 54
Product and in-kind 127 131 146
Time 3 3 4
Management 17 18 17
Total 204 206 221
Health and economic empowerment  
for women in Latin America
Our three-year partnership with women’s 
development organisation, Pro Mujer, 
aims to empower 470,000 women in 
Latin America to lift themselves out of 
poverty and give their families access to 
basic healthcare, often for the first time. 
By giving women access to financial 
services, education and small repayment 
loans to start their own businesses, Pro 
Mujer helps them improve their livelihoods, 
while contributing to a fund to pay for 
health screenings and medical services 
for their families. Health screenings by  
Pro Mujer’s team of trained healthcare 
professionals encourage positive health 
behaviours and support early detection 
and prevention of chronic diseases.
Since it began in 2012, the programme 
has already reached more than 277,000 
women and touched the lives of more 
than 1.1 million families in Argentina, 
Bolivia, Mexico, Nicaragua and Peru.
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Health and well-being  
in our communities
continued
GSK Impact Awards live up to their  
name in the UK and USA
GSK’s annual IMPACT Awards have 
channelled more than £8 million over  
the past 17 years to over 450 charities 
that are improving health in the UK and 
the USA. 
We are working to increase the impact of 
the awards through, for example, the GSK 
IMPACT Awards Network and training 
programme in the UK offers leadership 
development and essential skill-learning 
opportunities. The Network’s national 
summit in 2013 brought together 36 past 
winners to share the impact they have 
been able to make with the £30,000 cash 
prize from GSK. 
In the USA, we expanded the scope of 
the GSK IMPACT Awards to recognise 
non-profits that address pressing 
community factors – such as safety, 
access to healthy foods and recreational 
spaces, and the support of families and 
social networks – which contribute to 
health and wellness. We also established 
GSK IMPACT Grants, a new programme 
that will support the collective impact of 
several non-profit partners working 
together to improve the health of 
disadvantaged young people in the Metro 
Denver, Colorado and Greater St. Louis, 
Missouri communities. 
Loving life: Arts therapy and 
psychosocial support for cancer 
patients in Lithuania
Loving Life, an innovative three-year 
programme across five cities in Lithuania, 
is extending access to healthcare beyond 
traditional medicine to include 
psychological support and arts therapy 
for cancer patients and their families, 
increasing their quality of life. 
In Lithuania, the healthcare system is 
focused exclusively on traditional 
medicine and emotional support for 
newly diagnosed cancer patients is 
limited. Following a GSK survey that 
highlighted social integration and 
psychological support as unmet needs 
for cancer patients, we developed the 
programme in collaboration with the 
Centre for Oncopsychology and 
Communications, a local NGO. 
GSK provides funding and practical 
support for the implementation and 
expansion of the programme, which has 
supported over 300 patients living with 
cancer. To stimulate the development of 
this type of support in Lithuania, the 
Centre is developing a new course on 
psychosocial oncology in partnership 
with the University of Health Sciences, 
Lithuania, and GSK is supporting an 
international conference for NGOs 
working in this area, planned for 2014. 
Nurturing Talent in South Asia
Now in its 11th year, the Horlicks Wizkids 
programme has become South Asia’s 
largest interschool competition, with over 
40 literary, art, creative and cultural events 
for students of ages 5-18 years. 
Reaching out to more than six million 
students across 30 cities – in Bangladesh, 
India, Nepal, Pakistan, Sri Lanka and UAE 
– the programme encourages individual 
and team performance across streams like 
literature, theatre, music, quizzing, oratory 
skills, culinary skills, creative writing, IQ 
tests, art and design – subjects that do 
not traditionally receive much focus from 
schools in the region. 
Students are also recognised for their 
involvement in community projects. In 
2013, these ranged from tutoring children 
from an underprivileged fishing community 
to raising the profile of an orphanage. The 
winners are announced during a five-day 
event that includes physical training, 
personal development, overall grooming, 
communication workshops, community 
service, team building activities and 
leadership skill development. The four 
winners – the Horlicks WizTeam of the 
year – are given the opportunity to 
participate in an international student 
exchange programme. 
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Our  
behaviour
For GSK, how we do things is just as 
important as what we do. Our values-based 
culture is designed to ensure we put patients 
and customers first.
In focus
Andrew is a senior scientist who has 
worked at GSK for seven years and 
works in Biopharm Research and 
Development at our Stevenage site,  
in the UK. Like all our employees, 
Andrew uses our values and our Code 
of Conduct as a guide for decision-
making and knows that we encourage 
employees to speak up when they  
have concerns.
 Read more on page 36
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Our behaviour  
Overview
In our efforts to meet global healthcare 
challenges while ensuring the sustainability 
of our business, we navigate a wide range 
of complex ethical issues associated with 
every stage of the development and delivery 
of our products – from research through  
to manufacturing and supply, to sales  
and marketing. 
Our four core values – transparency, 
respect for people, integrity, and patient-
focus – guide us in everything we do.  
And our people, our partners and our 
suppliers are expected to adhere to the 
strict codes of ethical conduct that  
support these values. 
Over the last six years we have evolved our 
business model to better meet society’s 
expectations. And we are leading the 
industry in many areas – from increasing  
the transparency of clinical research  
to transforming the way we incentivise  
our sales teams and engage with  
healthcare professions. 
Recent allegations of fraudulent behaviour  
in China have underlined the importance  
of our efforts. We are prepared to take 
decisive action and change the way we 
operate if we are failing to meet the 
expectations of our stakeholders. 
External perspective 
“ GSK was the first pharmaceutical 
company to join the AllTrials 
campaign in February 2013 saying 
the company owes it to the 
thousands of people who have taken 
part in clinical trials to make the 
data they have generated available 
for scrutiny. Many organisations 
representing patients, doctors and 
regulators have applauded GSK’s 
decision, and we are looking to GSK to 
develop the strong leadership on 
clinical trial reporting that is 
urgently needed across the industry”. 
Síle Lane, 
The AllTrials campaign
Working with healthcare professionals
Began a process to end direct payments to 
healthcare professionals for speaking 
engagements or attendance at medical 
conferences by 2016.
 See page 43
2013 at a glance
Our values and principles
All employees must uphold our Code of 
Conduct. In addition, over 65,000 designated 
managers completed our annual Ethical 
Leadership Certification to certify their 
awareness, understanding and compliance 
with GSK’s values and policies.
65,000
 See page 36
Internal perspective 
“ Our commitment to transparency 
enables the broader scientific 
community to examine data more 
closely to conduct further research 
that can help advance medical 
science or improve patient care.  
We also have a responsibility to 
ensure that the vital contribution 
made by people who participate  
in our trials is used to help further 
scientific understanding”. 
James Shannon, 
Chief Medical Officer, GSK
Sales and marketing
Extended our ‘Patient First’ programme in our 
US business to base sales team incentives on 
scientific knowledge and behaviours that 
support ethical, patient-focused business 
practices, instead of sales volumes.
 See page 44 
Research practices
To facilitate further research and progress 
medical science and patient care we 
launched an online request system where 
external researchers can access the detailed 
anonymised patient-level data from our clinical 
trials. We also became the first company to 
publish clinical study reports – formal reports 
on the design, methods and results of our trials.
 See page 40
Our values and principles
Systematically assessed GSK’s human rights 
impacts, and developed plans relating to our 
supply chain and embedding global 
standards at the country level.
 See page 39
Manufacturing and supply chain
Began rolling out an anti-counterfeiting 
programme that will provide unique  
serial numbers on 200 packaging lines 
across 25 manufacturing sites over the  
next four years.
200
 See page 46
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Putting patients first  
in sales and marketing
We constantly challenge 
ourselves on how we can 
better meet the expectations 
of society. In 2013, we 
reinforced our commitment 
to putting patients first by 
announcing fundamental 
changes to our sales and 
marketing practices, and the 
way we interact with 
healthcare professionals.
Instead of individual sales 
targets, we will now 
incentivise our sales and 
marketing teams who detail 
our products to prescribers 
to ensure that the interests 
of patients come first. Our 
new compensation scheme 
will reward sales and 
marketing professionals for 
how well they use their 
technical knowledge to 
improve patient care and 
GSK’s overall business 
performance. It is built on 
our experience in the USA, 
which has shown that such 
an approach pays off 
through improved customer 
satisfaction (see page 44). 
We are also changing our 
relationship with healthcare 
professionals (HCPs). We 
work with HCPs in a number 
of ways, including on research 
that they conduct on our 
behalf and by soliciting their 
expertise on GSK products or 
therapy areas.
In 2014, we began a two-
year process to end the 
practice of paying HCPs to 
speak on our behalf, about 
our products or disease 
areas, to audiences who 
prescribe or can influence 
prescribing. This move is 
designed to provide patients 
with greater confidence that 
whenever they talk to a 
doctor, nurse or other 
prescriber, there is no 
perception of a conflict of 
interest. We remain 
committed to continue our 
support to HCPs, and these 
changes will help us do  
so with transparency  
(see page 43).
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Making sure our people behave ethically  
is critical to our reputation as a  
responsible business and can impact  
our commercial success.
Our 99,000-plus employees around the 
world use our Code of Conduct as a unified 
guide to the ‘GSK Spirit’ – a company 
culture that inspires a sense of individual 
responsibility and collective purpose. The 
Code was revised in 2013 with simplified 
language and increased emphasis on our 
Values and Speak Up programme. 
The Code has been translated into 27 
languages and provides a practical working 
guide for employees on how to apply GSK 
Values and Behaviours. It is supported by 
an online Values Resource Centre that 
provides tools and information to aid 
decision-making.
We require suppliers and other business 
partners to comply with our high standards 
and expectations for ethical conduct,  
as set out in our Third Party Code of 
Conduct. Employees and third parties can 
report any concerns or violations of our 
Codes anonymously through our robust 
‘Speak Up’ programme.
Our values  
and principles
Our values
We put our values at the heart of every 
decision we make. These values are to:
 • Operate with transparency
 • Demonstrate respect for people
 • Act with integrity
 • Remain patient-focused
Living our values
In 2013, we focused on further integrating  
a values-based culture across the company. 
We clarified expectations for employees 
and leaders, simplified the more detailed 
policies that underpin the Code of Conduct 
and promoted our Speak Up whistleblowing 
mechanism to encourage employees to 
report violations. 
During 2013, we reviewed and enhanced 
28 corporate policies to ensure the policies 
that support our Code of Conduct are 
written in a way that employees find clear, 
concise and accessible. The aim is to 
improve understanding of, and therefore 
enable greater compliance with, them. 
We have aligned our performance and reward 
systems with our values and introduced a new 
performance system in 2014 that formally 
evaluates employees on both ‘what’ they need to 
do and ‘how’ they do it. Also for our most senior 
people we dis-incentivise unethical working 
practices using a ‘clawback’ mechanism that 
allows us to recover performance related pay. 
(see Our People, page 59).
Our annual business ethics certification 
programme, Ethical Leadership Certification, 
requires designated managers to certify their 
understanding of, and compliance with GSK’s 
values, policies and their responsibilities to 
lead and support an ethical work environment. 
Failure to complete the certification by the 
specified deadline triggers a disciplinary  
follow-up from human resources. 
Bribery and corruption
GSK’s zero tolerance approach to bribery 
and corruption is detailed in our Preventing 
Corrupt Practices policy, which applies to 
everyone at GSK as well as third parties 
who act on behalf of the company. Our 
anti-bribery and corruption programme 
includes online and face-to-face training 
targeted at employees working in high-risk 
roles. We conduct regular audits to support 
the bribery and corruption programme, and 
our performance is reviewed monthly by an 
oversight committee. Suspected breaches 
of our anti-corruption policies can be 
reported anonymously without fear of 
retaliation through whistleblowing channels 
(see page 38). 
No matter where we operate in the world, in our interactions with patients, 
prescribers, payers and governments, we must always live our values. 
In this context we are concerned and 
disappointed by allegations of fraudulent 
behaviour in our China business. We are 
taking this matter extremely seriously and are 
cooperating fully with the Chinese authorities.
We have taken a number of actions, 
including also commissioning an 
independent report from international legal 
firm Ropes and Gray, who have extensive 
experience in anti-corruption and 
international risk.
GSK is committed to learning any lessons 
required as a result of the Chinese 
investigation and will take any steps 
necessary at its outcome. We remain fully 
committed to China, supporting the 
Government’s healthcare reforms and to 
supplying our products to patients.
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Medical governance
Our medical governance framework ensures 
we always apply good medical science, 
integrity and ethics to the discovery, 
development and marketing of GSK 
products. Overall responsibility for medical 
governance sits with our Chief Medical 
Officer, the most senior physician at  
GSK, who is supported by the Medical 
Governance Executive Committee.  
We require our external partners to adhere  
to the same or similar medical governance 
standards as GSK.
Scientific engagement
Our scientific engagement policy provides  
a set of global principles and standards that 
guide us in distinguishing non-promotional 
scientific dialogue with external stakeholders 
from promotional activity to support 
approved products. For example, with the 
exception of public health campaigns 
conducted in partnership with global public 
organisations, we wait until a product is 
granted marketing authorisation, by regional 
or national regulatory agencies, before 
sponsoring or supporting any related 
non-product or general disease area 
education activities. 
These standards, which we have adopted 
voluntarily, set us apart from our peers, as 
we have chosen to go beyond what is 
required by codes of practice and legislation 
to demonstrate our commitment to integrity 
and transparency.
Our values  
and principles
continued
Employee compliance with our scientific 
engagement policy is monitored as part of 
our global risk management and compliance 
framework, as well as through GSK’s 
Corporate Integrity Agreement in the USA. 
In 2013, we conducted 24 reviews – 
including nine that focused on our 
publication process and how we engage 
with healthcare practitioners – to enhance 
our processes and procedures, and ensure 
that our interactions with physicians are 
appropriate and transparent. 
Based on our principles for scientific 
engagement, GSK has been encouraging  
a shift in emphasis from branded, 
commercial spaces to more scientific 
booths at medical conferences, such as  
the European Respiratory Society (ERS) 
conference in 2013.
Our scientific engagement area at the event 
used interactive media to demonstrate our 
heritage, leadership and commitment to 
tackle respiratory diseases, and was staffed 
by senior GSK medical staff, including 
heads of medicine from several countries 
and scientific teams from across the 
business. We first trialled this approach at 
the ERS conference in 2012, and were very 
pleased to note that others have followed.
GSK takes action following misrepresentation  
of data in published research paper
In 2013, we became aware of allegations of 
misrepresentation of data in a research 
paper written by Shanghai-based GSK 
scientists and published in Nature Medicine 
in 20109. The published study was 
laboratory research only and did not involve 
giving an investigational drug to any 
individuals.
The integrity of our research is critical to our 
work. In June 2013, we concluded an 
investigation of the published study and, 
regretfully, established that certain data were 
misrepresented. We shared our conclusion 
with Nature Medicine and recommended  
a retraction. The paper has been retracted  
by Nature Medicine. As a precautionary 
measure, an early clinical study in which 
healthy volunteers were receiving an 
investigational drug targeting the same 
signalling pathway was also stopped.
We are committed to the highest ethical  
and scientific standards, so that regulators, 
physicians and patients can have 
confidence in the research we carry out. 
Following this investigation, GSK took 
appropriate action. Five R&D employees 
who were among the named authors of the 
publication have left the company. We also 
established a broader scientific data review 
team, overseen by an independent chair 
from outside GSK. 
The team found no evidence that patient 
safety had been compromised and no reason 
to stop or suspend any clinical research.  
The team’s recommendations are being fully 
implemented and will be embedded as 
standard practice. 
9 “Crucial role of interleukin-7 in T helper type 17 
survival and expansion in autoimmune disease,” 
published in Nature Medicine, 2010, 16: 191-197
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Our values  
and principles
continued
Compliance
Our Global Ethics and Compliance team 
provides tools, oversight and guidance to 
improve compliance with external 
regulations and internal policies. The team 
works in partnership with the business to 
promote decision-making that is based on 
values and compliance. 
In March 2013, we refreshed our employee 
campaign to raise awareness of GSK’s 
whistleblowing programme. It encourages 
and enables employees and third parties  
to report unethical or illegal conduct under 
GSK’s Code of Conduct, other GSK 
policies or external legal standards. 
Concerns can be raised through multiple 
communication channels, including 
telephone hotlines and an online form 
available in 38 languages. Line managers 
and representatives from Global Ethics  
and Compliance group, Human Resources 
and Legal are also available to listen to,  
or address concerns. We provide local 
communicators with a toolkit of materials, 
available in 28 languages, to encourage 
people to report concerns. 
Addressing misconduct
We are committed to transparency and 
report annually on how we have addressed 
misconduct within our business. In 2013, 
more than 1,800 contacts (1,600 in 2012) 
were made through our ethics and 
compliance channels – a mixture of 
allegations of misconduct and requests  
for information or guidance. 
In 2013:
 • There were 3,128 instances of employee 
discipline for policy violations (2,919  
in 2012).
 • Of these, 375 employees were dismissed 
or agreed to leave the company voluntarily 
(312 in 2012).
 • Other disciplinary actions included 2,753 
documented warnings (2,607 in 2012).
 • 161 of the policy violations related to 
violations of sales and marketing  
policies (123 in 2012). These resulted  
in 48 dismissals or separations and  
113 documented warnings. 
Types of policy violation in 2013 (%)
  Attendance, payroll
  Good manufacturing or distribution practice
  Code of Conduct
  Falsification of Documents
  Marketing and promotional activities
  Travel and Expense
  Local Work Regulations
  Other
55.4
7.0
7.5
5.4
3.7
3.0
5.7
12.3
As in 2012, the majority of employee 
discipline in 2013 was due to our continued 
focus on ‘Attendance and payroll category’ 
violations (1,641 in 2013 and 1,456 in 
2012). These attendance issues are mainly 
reported from our manufacturing business 
where we have implemented tighter controls 
to ensure we maintain and build on our 
strong track record of compliance. Other 
policy violations are thought to have been 
reported from our whistleblowing 
programme that raises awareness and 
encourages employees to report unethical 
or illegal conduct.
Employees who remain with the company 
following a policy violation receive retraining 
and increased monitoring or support. In 
some cases retraining is extended to an 
employee’s colleagues to prevent them from 
making similar mistakes.
Breaches of external codes
GSK was found to be in breach of external 
industry or government promotional codes 
36 times in 2013 compared with 25 in 
2012. We investigate every breach of an 
external code and take steps to prevent a 
reoccurrence, which may include retraining 
or other corrective action, including 
disciplinary action. 
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Human rights
 Commitment
Address the UN Guiding Principles on Business and 
Human Rights across our own operations and our 
supplier relationships.
GSK is a signatory to the UN Global 
Compact, a voluntary global standard on 
human rights, labour, the environment and 
anti-corruption. We support the UN Guiding 
Principles on Business and Human Rights 
and are committed to upholding the UN 
Universal Declaration of Human Rights,  
the OECD Guidelines for Multinational 
Enterprises and the core labour standards set 
out by the International Labour Organization. 
In 2013, as part of our support for the UN 
Guiding Principles, we worked with BSR,  
a non-profit external consultancy with 
expertise in business and human rights,  
to undertake a systematic assessment to 
identify GSK’s human rights impacts. Based 
on this assessment, we prioritised seven 
areas to further examine GSK’s policies and 
process, and their potential to positively or 
negatively impact human rights. These are: 
access to healthcare; global warming impact 
of propellants used in some inhalers; clinical 
trial standards; employment practices; 
patient safety; product counterfeiting;  
and use of third party suppliers.
As a result, we are focusing on better 
understanding human rights risks in GSK’s 
supply chain and how we can address 
these, as well as further embedding global 
standards on diversity, equality and 
inclusion at a country level. We have also 
updated our human rights statement based 
on the findings of our assessment. 
Activities in embargoed countries
Some stakeholders have concerns about 
how businesses operate in countries 
targeted by sanctions laws, such as Cuba, 
North Korea, Iran, Sudan and Syria.  
We share the UN’s belief that people  
should not be denied access to medicines 
because of the regime operating in their 
country. We aim to supply medicines and 
vaccines in all countries that need and  
wish to purchase them, including essential 
medicines in sanctioned countries, in 
compliance with applicable sanctions and 
export controls. We also comply with the 
disclosure requirements of the Iran Threat 
Reduction and Syria Human Rights Act  
of 2012.
Privacy and data security
As a global organisation, GSK collects, 
uses, and maintains a vast amount of 
personal information on our employees, 
people who participate in our research,  
and the healthcare professionals with whom 
we partner. We are committed to protecting 
this data, and require all employees and 
suppliers to comply with our global privacy 
principles, which ensure that all personal 
data are collected, used, processed, 
transferred and stored appropriately, 
securely, and in line with legal requirements. 
In June 2013, the UK Information 
Commissioner’s Office approved GSK’s 
Binding Corporate Rules (BCRs), a set  
of legally binding global policies, based  
on European Union laws, that ensure 
compliance with cross-border transfer 
requirements for research and employee 
personal information. BCRs make it 
possible to transfer personal data 
internationally between GSK entities without 
individual privacy agreements in every 
European Union country. However, data 
transfers under the BCRs also need  
to be authorised by each European country, 
and in 2014 GSK will continue progressing 
the BCR national authorisations from  
each country.
To increase our focus on information security, 
GSK established an Office of the Chief 
Information Security Officer to provide 
strategy, direction and oversight, while building 
GSK’s global information security capabilities. 
Our values  
and principles
continued
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Research  
practices
Clinical research
Research is essential to create the next 
generation of medicines to combat unmet 
medical needs and improve existing treatments. 
We conduct clinical trials on patients and 
healthy volunteers to evaluate the safety and 
efficacy of new medicines or develop innovative 
applications of known treatments.
We conduct trials in accordance with  
the International Conference on 
Harmonisation’s Good Clinical Practice 
guidelines. All trial protocols are reviewed 
by an independent ethics committee – 
made up of members of the public, medical 
professionals and scientists – which has  
the power to reject or stop a clinical trial.
Employees must complete training on Good 
Clinical Practice (GCP) before undertaking 
any roles related to GSK-sponsored clinical 
research. In 2013, employees completed 
44,685 GCP-related courses either online 
or in person. To confirm that the conduct  
of trials is in line with our standards, we 
conduct audits of our trial sites and of 
contract organisations that carry out trials 
on our behalf. 
In 2013, we conducted 323 clinical quality 
assurance assessments to confirm that  
the conduct of trials reflects our 
standards, including:
 • 254 audits of investigator sites 
conducting GSK-sponsored trials.
 • 20 audits of GSK processes.
We ensure that our research practices meet the highest ethical standards and 
make patient safety our priority at all stages, wherever we operate. 
 • 34 audits of contract research 
organisations that carry out clinical  
trials on our behalf.
 • 13 audits of GSK local operating 
companies involved in clinical  
trial activities.
 • 2 reviews of New Drug Application (NDA) 
Annual Reports.10
In addition, we conducted 51 investigations 
of suspected irregularities and took corrective 
action where appropriate. Independent 
regulatory authorities also performed 112 
inspections of GSK sites and the investigators 
we used to conduct clinical trials.
Transparency of clinical research
 Commitment
Be as transparent as possible with our clinical trial 
data, including publishing clinical study reports (without 
patient-level data) for all outcome trials of medicines 
conducted by GSK and, within an appropriate process, 
making available to researchers access to anonymised 
patient level data to further scientific enquiry.
Sharing the results of our research is vital to 
GSK as it helps to ensure that the important 
contribution made by people participating in 
trials is used to maximum effect in furthering 
scientific knowledge and understanding.  
In 2013, we built on our longstanding 
commitment to clinical trial transparency by 
being the first company to introduce a new 
system that enables researchers to access 
11 Nature online news article
Providing access to trial data to benefit medical science and patient care
In 2013, GSK became the first company  
to launch an online system enabling 
external researchers to request access  
to the detailed data that sit behind its 
clinical trial results. 
Described as a ‘sea change in clinical 
science’,11 this commitment enables 
researchers to examine data more closely  
to conduct further research that can help 
advance medical science or improve patient 
care. External researchers can submit 
research proposals and request access to 
anonymised patient level data from all studies 
started from 2013 once the medicine has 
been approved by regulators or terminated 
from development. We will regularly update 
this list to include all global studies since 
2000. By the end of 2013, approximately 
450 studies were made available. 
Researchers are also able to ask about the 
availability of data from other studies.
Researchers requesting access to the 
data must show how they will use it to 
further research and commit to publishing 
their findings, with an independent panel 
of experts reviewing proposals to ensure 
the proposed research is appropriate. 
The GSK system was launched as a first 
step and we are working with others in 
industry, and the public and charitable 
sector, to encourage the development  
of a broader, independent system where 
data from studies conducted by multiple 
organisations are made available for further 
research. In January 2014, we took an 
important step on this path and transferred 
to a new multi-sponsor request site, 
clinicalstudydatarequest.com, which 
includes studies from multiple organisations.
10 New Drug Application reports are submitted to the US 
Food and Drug Administration to provide an update on the 
status of each study completed or in progress.
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GSK’s Global Safety Board, chaired by  
our Chief Medical Officer and composed  
of senior physicians and scientists,  
makes decisions on product safety issues.  
Its remit is to ensure that safety is a key 
focus for our research teams and to review 
benefit/risk evaluations of GSK products  
in development and on the market.  
We also have an internal risk advisory  
panel to encourage sharing of information 
and best practices within the company.
Pharmacovigilance 
Pharmacovigilance relates to the detection, 
monitoring, assessment, understanding and 
prevention of adverse effects or any other 
drug related problems.12 GSK collaborates 
with industry peers, regulators, healthcare 
providers, patients and other interested 
parties to continually enhance the science 
of pharmacovigilance, and improve 
communication about our medicines.  
As part of our efforts to improve the 
pharmocovigilance process, our research 
teams perform benefit/risk evaluations 
through the life cycle of all medicines, and 
the results are presented to our Global 
Safety Board. In 2013, we created a new 
team to enhance our pharmacovigilance 
operating model.
12 As defined by the World Health Organization
Animal research
 Commitment
Rigorously challenge the need for animal studies and 
work to minimise the impact on animal welfare, by 
investing in the development of alternative studies and 
sharing animal-based data.
We recognise that animal research is a 
subject of ethical concern. We use 
alternatives to animals whenever we can 
and we aim to carry out studies with the 
fewest animals possible. However, animal 
studies remain a vital part of our research 
as, in many cases, this is the only way to 
demonstrate the effects of a potential new 
medicine in a living body before it is tested 
in humans. Regulations require us to test 
the safety of all new medicines on animals 
before they are evaluated in clinical trials. 
Where we need to use animals in our 
research, we are committed to acting 
ethically, and providing for their health and 
well-being. Our Office of Animal Welfare, 
Ethics and Strategy – led by our Chief of 
Veterinary Medicine – develops policies and 
oversees the humane and responsible use 
of animals across GSK. In 2013, we created 
a new system to establish global quality 
standards for training. This will facilitate 
sharing of best practices for improving 
animal welfare.
Research  
practices
continued
detailed anonymised patient-level data from 
trials (see case study) and expanding the 
information made publicly available on our 
clinical study register.
The register, which receives on average 
over 14,000 visits each month, now 
includes over 5,400 summaries of trial 
results, which are posted regardless of 
whether the outcomes might be considered 
to be positive or negative. In 2013, we 
expanded this to include Clinical Study 
Reports (CSRs) – formal study reports on 
the design, methods and results of clinical 
trials which form the basis of submissions  
to regulatory agencies. 
GSK was the first company to publish 
CSRs and these are available, with personal 
information removed, once the trial has been 
published and the medicines have been 
approved or terminated from development. 
We are committed to publishing CSRs  
for all current trials and for all approved 
medicines dating back to the formation  
of GSK in 2000, starting with the most 
commonly prescribed medicines. We also 
support the AllTrials campaign, which calls 
for full reporting of methods and results  
of all trials. 
Clinical trials in developing countries 
As more clinical trials take place in 
developing countries, legitimate concerns 
have been raised about running trials in 
countries where health services may not  
be as well developed. All GSK-sponsored 
clinical trials are conducted according to 
the same fundamental ethical principles, 
regardless of where they take place.
We only conduct clinical trials in countries 
where the medicines are likely to be suitable 
for the wider community. GSK does not 
conduct clinical trials of investigational 
medicines in a country if it is known at the 
outset that there is no intent to pursue 
registration to make the medicine available 
for use in that country. 
Patient safety
 Commitment
Continue to ensure the interests and safety of patients 
and consumers are of paramount importance in the way 
we design and undertake our clinical trials, our product 
quality assurance and our monitoring and reporting of 
adverse events in ongoing product usage.
Patient safety is a fundamental priority at 
GSK. All medicines have potential risks  
as well as benefits, and it is critical that  
we identify, evaluate and minimise safety 
concerns to ensure the overall benefits  
of a medicine outweigh any risks.
Our robust policies and governance 
framework help us detect and act on any 
side effects that may be associated with our 
medicines. We also apply computerised 
statistical tools to analyse safety information 
by, for example, identifying any unexpected 
adverse events (side effects) being reported 
on a disproportionate basis. We are 
committed to continually evaluate and 
communicate transparently with patients, 
prescribers, payers and regulators about  
the benefits and risks of our medicines.
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Research  
practices
continued
Studies conducted by external contractors 
on our behalf are subject to the same high 
standards as those carried out within  
GSK facilities. Over the past five years,  
our animal quality assurance group has 
assessed the care and welfare programmes 
of more than 600 contractor and supplier 
organisations. The vast majority met our 
standards on animal welfare or implemented 
our recommendations for improvement.  
In cases where contractors fail to adopt our 
recommendations or show no commitment 
to continuous improvement following a site 
visit, we stop working with them.
The 3Rs
Our approach to animal research is based 
on the 3Rs:
 • Replacing animal research with other 
methods where possible: Scientists in 
our safety pharmacology group, for 
example, have developed a test that uses 
heart tissue developed from adult human 
stem cells (iPSC) to measure the effect of 
compounds on the electrical activity of the 
heart. This test allows us to identify and 
discard compounds with a potential to 
induce fatal arrhythmias in patients early 
in development. It replaces the animals 
tests traditionally used to identify this 
liability.  
Performance in 2013
In 2013, the number of animals used in our 
research declined by 10% and was 33% lower 
than in 2000, despite the two main drivers of 
animal use (R&D investment and vaccine 
sales) increasing over the same period. 
 • Reducing the number of animals used 
in research: We have reduced the 
number of animals in genetic toxicology 
testing of pharmaceutical ingredients by 
75%, by supporting the redevelopment of 
international guidelines that now enable 
us to integrate this testing into rodent 
studies that are already being conducted 
on other aspects of safety. This type of 
integrated study helps to reduce animal 
use and improve scientific data. 
 • Refining techniques to minimise pain  
and distress and improve the welfare of 
animals: Every species has certain defining 
behaviours. Understanding and encouraging 
these ‘behavioural standards’ helps us 
promote the welfare of each species 
during research studies. In 2013, we 
established a set of behaviour standards 
for mice – including nest building, 
exploration and exercise, the opportunity 
to interact with or hide from others, and  
the opportunity to gnaw – and we are  
now working to do so for other species. 
We publish our results in scientific journals 
and engage with other scientists and 
regulatory authorities to influence broader 
industry standards, share best practices 
and learn from others. In 2013, we 
sponsored experimental design workshops, 
where over 300 GSK animal researchers in 
the UK and USA considered how we could 
reduce the number of animals used in 
research by changing the way we design 
our experiments.
Most animals in our research – including 
research carried out by contractors – are 
mice. Non-rodents account for less than  
2% of the number of animals used.  
Less than 0.3% of the animals we use  
are non-human primates.
Species used in GSK animal research 2013 (%)
  Mouse
  Rabbit
  Rat
  Guinea pig
  Other
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Figures are normalised to 2000, the first year of data after the formation 
of GlaxoSmithKline. Data includes animal research conducted by external 
contractors on our behalf, data unavailable for 2000 and 2001.
Percentage change in animal use 
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%
0
100
200
300
GSK Corporate Responsibility Report 2013  43
Note to SB. Please keep coloured gradient on the 
buttons for both normal and rollover actions please.
Working with healthcare 
professionals
 Commitment
Continue to drive a values-based approach to sales and 
marketing practices across the world, with the interests 
of consumers and patients at its core.
Payments to HCPs
At the end of 2013, we announced a 
two-year process that will change how we 
work with HCPs – becoming the first in the 
sector to move towards ending the practice 
of paying doctors to speak on our behalf 
and providing direct financial support for 
individuals to attend medical conferences. 
Starting in 2014, we will phase out the 
practice of paying HCPs to speak on our 
behalf, about our products or disease areas, 
to audiences who can prescribe or influence 
prescribing. We will work to implement 
these changes effectively in line with local 
laws and regulations across our global 
business by the start of 2016.
We still have an important role to play in 
supporting education for HCPs and in 
providing accurate information about our 
medicines to help them make the best 
treatment decision for their patients. We will 
strengthen our dedicated medical and 
scientific capability to appropriately engage 
with HCPs and improve our multi-channel 
capabilities, including use of digital 
technologies, to provide appropriate 
information on products and disease areas 
conveniently to HCPs. We will also support 
fair, balanced and objective medical 
education for HCPs through provision of 
independent educational grants.
We will continue to offer appropriate fees  
to HCPs providing services for GSK-
sponsored clinical research, advisory 
activities and market research. These 
activities are essential to provide GSK with 
insights on specific diseases, identification 
of symptoms and diagnosis, application of 
clinical trial data or medication dosage and 
administration, and on how to effectively 
and appropriately communicate the benefits 
and risks of its medicines to help meet 
patient needs.
New measures announced in 2013 will transform the way we work with 
healthcare professionals.
These changes are designed to modernise 
our relationship with healthcare professionals 
and bring greater clarity and confidence that 
whenever we talk to a doctor, nurse or other 
prescriber, it is patients’ interests that always 
come first. We understand that while we have 
an important role to play in providing doctors 
with information about our medicines, we are 
expected to do so clearly, transparently and 
without any perception of conflict of interest.
Transparency
GSK is committed to publishing the payments 
we do make to HCPs and HCOs. We already 
do so in several countries including Australia, 
France, Netherlands, Portugal, Slovakia, 
Japan, the UK and the USA, in line with locally 
agreed government or industry association 
standards. GSK will continue to disclose the 
payments we make for clinical research 
advisory activities and market research in 
these countries. We will continue to support 
and work towards transparency in other 
countries as industry associations or 
governments establish specific guidelines for 
disclosure, for example, through the EFPIA 
code on payments. 
We also continue to work towards 
publishing global figures at an aggregate 
level for the payments to HCPs that will 
continue, such as advisory activities and 
clinical research. 
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Putting the patient first
Is it possible for a pharmaceutical 
company to improve sales by asking its 
sales teams to stop focusing on how much 
they sell, and start focusing on how they 
sell it? We believe it is. 
Our sales representatives have lots of 
stories about how our ‘Patient First’ 
philosophy has changed their conversations 
with customers, and helped establish trust 
in the company. And customer satisfaction 
surveys have shown that we have indeed 
outperformed both our best competitor, and 
the competitor average, on delivering value 
to our customers. 
By incentivising our sales teams to be 
more knowledgeable than ever before,  
we have raised the bar for GSK and  
the industry.
“We listen to the customers, figure out 
how we can address their needs, and then 
we bring in the right GSK resources to 
help improve patient care,” says Jacqueline 
Carsanaro, VP of our Medical Centre 
Sales team who serve hospitals and 
clinics. High satisfaction ratings from 
customers increased by 6% in 2013, as  
a result of the team’s exceptional work  
to deliver customer-focused solutions.
Sales and  
marketing
Our mandate as a pharmaceutical company is to put the needs of patients and 
customers first. We are putting this focus on the patient, one of our core values, 
at the heart of our sales and marketing approach. 
Experiences in the last two years in the  
USA suggest that this more patient-focused 
approach has significantly improved both 
customer interactions and satisfaction rates 
with GSK’s US pharmaceutical business.
Direct-to-consumer marketing of 
prescription medicines
We advertise our prescription medicines 
directly to consumers in New Zealand and 
the USA. Direct-to-consumer (DTC) 
advertising of prescription medicines is not 
permitted in other markets.
All DTC advertising in the USA is governed 
by our DTC Communications policy, based 
on the PhRMA Guiding Principles:  
Direct to Consumer Advertisements about 
Prescription Medicines. All our DTC 
advertising in the USA is reviewed by legal, 
regulatory or medical specialists and new 
DTC television advertisements are 
submitted to the US Food and Drug 
Administration (FDA) for review and 
comment prior to broadcast. Again, in 2013, 
our US Pharmaceutical business did not 
receive any Notice of Violation or Warning 
Letters from the FDA for advertising or 
promotion of products. 
 Commitment
Continue to drive a values-based approach to sales and 
marketing practices across the world, with the interests 
of consumers and patients at its core.
Our global Code of Practice for Promotion 
and Customer Interactions ensures that 
GSK’s scientific engagement with external 
communities and the marketing of our 
products are driven by our values. The code 
applies to all sales and marketing employees 
as well as third parties acting on our behalf. 
It requires all promotions to be accurate, 
and all promotional activity to be clearly 
identified as such. 
GSK led the industry as the first 
pharmaceutical company to decouple reward 
for our US sales representatives from the 
number of prescriptions issued, focusing 
instead on demonstration of our values  
and focus on the patient (see case study).
In 2014, we will begin to roll out this 
approach on a global basis and implement  
a new global compensation programme  
that will have no individual sales targets. 
Instead, GSK’s sales professionals who 
work directly with prescribing healthcare 
professionals will be evaluated and 
rewarded for their technical knowledge, the 
quality of the service they deliver to support 
improved patient care and the overall 
performance of GSK’s business. This new 
compensation system is being rolled out in 
a phased approach across EMAP, Japan 
and Europe, with the intent that all countries 
GSK operates in within these areas will 
move to this approach by January 2015. 
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Manufacturing 
and supply
Efficient and responsible manufacturing and supply is critical to enable  
us to get high-quality products to patients and consumers in the right place  
at the right time. 
of zero accidents, zero defects and zero 
waste, and we are significantly expanding 
our dedicated quality teams around the 
world to reinforce our commitment to deliver 
high-quality products to patients and 
consumers. Across our manufacturing 
network we invested around £40 million  
in 2013 to reduce environmental impacts. 
Many of these improvements are bringing 
additional business benefits by, for example, 
improving efficiency and increasing 
manufacturing capacity. 
We are also working on sustainability 
programmes with our suppliers. In 2013,  
we asked more than 500 of our largest 
materials suppliers in our highest spend 
categories to disclose their sustainability 
footprint (carbon, water, waste and energy 
use) to identify priority areas for 
improvement across the supply chain. 
Supplier standards
Our Third Party Code of Conduct commits 
our network of approved external suppliers 
and business partners to uphold GSK’s 
values. It sets out standards on ethical 
conduct, anti-bribery, fair labour (including 
protection of human rights), environment, 
health and safety management, and quality 
control. Suspected breaches can be 
reported through our Speak Up programme, 
which is open to third parties (see page 36).
Risks to the supply chain are integrated  
into our overall risk management and 
compliance process.
Our audit teams around the world manage 
and regularly assess the quality 
performance of over 6,000 suppliers of 
materials, active pharmaceutical ingredients 
and finished products. More than 100 key 
suppliers have been assessed using the 
GMS Quality Risk Model, specifically 
created for this purpose. We also conduct 
audits of suppliers specifically on ethical, 
environmental, health and safety (EHS), 
governance and risk management. We 
assess all our suppliers on first selection 
and subsequently, also audit on high risk 
areas. On completion of every audit, we 
agree an improvement plan with suppliers  
to address any areas of concern and verify 
these plans are implemented satisfactorily. 
Where significant gaps are identified, we 
may suspend or terminate our work with  
a supplier, or decide not to work with a 
potential new supplier. 
We have increased resources to provide 
more extensive EHS risk-based auditing 
across the supply base, including external 
suppliers and third party distributors. In 
2013, we conducted 32 internal EHS audits 
involving site visits to supplier facilities. We 
also commissioned a specialist insurance 
company to review risks to supply. GSK is 
also a member of the Pharmaceutical Supply 
Chain Initiative (PSCI), through which we 
collaborate with other pharmaceutical 
companies to audit suppliers on their human 
rights and labour practices as well as their 
EHS performance. In 2013, PSCI audited  
six suppliers relevant to the GSK supply 
chain. 
 Commitment
Continue to ensure the interests and safety of patients 
and consumers are of paramount importance in the way 
we design and undertake our clinical trials, our product 
quality assurance and our monitoring and reporting of 
adverse events in ongoing product usage.
A holistic approach
Each year we produce four billion packs  
of medicine and consumer healthcare 
products and 900 million doses of vaccines, 
and supply these to 170 countries. Our 
suppliers are integral to this process, and 
we expect them to uphold the same high 
standards we set for ourselves. 
Each year we spend around £9 billion  
on goods and services with 1,000 
manufacturers accounting for 80% of  
our spend. The ingredients and materials  
we buy feed into our network of 86 GSK 
manufacturing sites in 36 countries.  
Around 10% of our external spend is with 
suppliers who provide us with finished or 
part-finished products. 
We are moving to an ‘end-to-end’ supply 
chain model for our pharmaceutical, vaccine 
and consumer healthcare products that will 
standardise and improve our controls 
across our entire supply chain and 
manufacturing operations – from procuring 
raw materials, through quality controls, to 
packaging, and the transport and logistics 
involved in delivering products to our 
customers. As part of this transition, across 
our network of pharmaceutical and 
consumer healthcare manufacturing sites, 
we are driving progress towards our vision 
As part of our work to assess and manage 
GSK’s impacts on human rights (see 
page 39), we are working to standardise  
our approach to procurement across 
geographies and business units, and  
to simplify our existing controls to more 
effectively identify and manage human  
rights risks in our supply chain. 
Supplier EHS audits 2009-2013 
(existing and potential suppliers) 
2013 2012 2011 2010 2009
Americas 2 3 4 5 11
Europe 5 0 7 5 13
Asia 26 10 38 29 46
Africa 0 0 0 0 0
Total number 
of audits 32* 13 49 39 70
Number and types of supplier audited on EHS in  
2013 (existing and potential suppliers) 
Type of supplier Americas Europe Asia Total
Primary (raw materials, 
intermediates and 
pharmaceutical ingredients) 0 2 17 19
Contract manufacturing 
(pharmaceutical 
formulations) 1 3 0 4
Consumer Healthcare 1 0 9 10
* Each supplier audit is counted as a single audit, even 
where multiple sites/locations are included
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Supplier diversity
Diversity within our workforce and among 
our suppliers supports the continuous 
innovation that our business is built on 
exposing us to new perspectives and fresh 
ideas. Sourcing from under-represented 
groups, such as small businesses, women 
and minorities, also supports economic 
development and is a regulatory requirement 
in the USA. In 2013, 12% of our total US 
expenditure was with diverse small 
businesses, a 2% increase from 2012.
We engage with a global network of diverse 
suppliers by participating in relevant 
conferences and through initiatives such  
as the US National Minority Supplier 
Development Council’s Global Link initiative 
and Minority Supplier Diversity UK (of which 
GSK is a board member), an organisation 
that develops links between global 
businesses and ethnic minority businesses. 
Payment terms
We greatly value the relationships we have 
with our many suppliers and understand the 
pressures on cash flow and financing faced 
by smaller companies. Following a change 
to our standard payment terms for suppliers 
in the UK and USA in 2012, we offered  
to review these payment terms for smaller 
suppliers identified as micro, small and 
medium size enterprises in Europe or diverse 
suppliers in the USA. We also offer a range 
of supply chain finance options to both our 
UK and US suppliers.
Several companies have taken up these 
opportunities already and we are planning 
increased communications, as well as a 
dedicated small business hotline, to make 
more of our smaller suppliers aware of the 
support available.
Manufacturing 
and supply
continued
Anti-counterfeiting 
With no global study on the issue, it is 
difficult to quantify the prevalence of 
counterfeit drugs. But there is little doubt 
that the problem is widespread, and poses 
a serious threat to patient and consumer 
health, as well as a business threat to GSK 
and other pharmaceutical companies.
Counterfeit drugs can range from precise 
replicas of the original product to products 
with no legitimate active ingredients. They 
are not supported by any appropriate quality 
control, testing or monitoring, and may 
include impurities, such as particulates or 
micro-organisms. For patients consuming 
these counterfeits, the risks range from lack 
of treatment or protection, to actual harm 
caused by the product.
Our comprehensive global anti-counterfeiting 
strategy combines the use of technology, 
analysis, investigations, appropriate legal 
enforcement action, and interactions with  
law enforcement and customs. Counterfeits 
of GSK products are discovered through 
consumer and patient complaints, 
investigations, and raids conducted by law 
enforcement and regulatory agencies as  
well as investigators acting on behalf of GSK. 
Our analysis has shown that the most 
counterfeited GSK products include our 
Sensodyne and Aquafresh toothpastes, and 
medicines such as Panadol, Dolex, 
Augmentin and Ventolin. 
We have introduced a range of anti-
counterfeiting measures such as product 
codes that can be used by consumers in Africa 
to verify authenticity via a simple text message. 
In China, where the largest volumes of 
counterfeits are manufactured, we include  
a unique serial number on each product 
package of all products on the Essential 
Drug List, to enable electronic monitoring for 
the purpose of patient safety. We are looking 
to extend this to additional products in a 
programme running over the next four years.
We work closely with law enforcement and 
regulatory agencies to combat counterfeiters. 
During 2013, there were significant seizures 
as a result of such cooperation. In China, for 
example, authorities conducted raids at six 
counterfeiting factories which resulted in  
19 convictions for counterfeiting of a variety 
of medicines, including Contac NT, a cold 
treatment, and Fenbid, a pain reliever. In 
Pakistan, three counterfeiters were arrested 
and a large quantity of counterfeit Ventolin 
Syrup (used for treating asthma) was seized 
during a raid by the Pakistan Provincial  
Drug Authorities.
There has been an increase in the number of 
reported counterfeit incidents in 2013 when 
compared with previous years, which can be 
accounted for by an increase in successful 
raid actions in Pakistan, and seizures and 
discoveries of counterfeit Grandpa,  
a headache powder, in South Africa.
GSK anti-counterfeiting activity
2013 2012 2011 2010 2009 2008 2007 2006
Number of reported 
cases of counterfeit 494 354 378 367 259 289 429 248
Number of raids 307 208 148 96 94 94 71 57
Number of arrests 272 124 181 132 129 84 127 94
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Public policy and 
patient advocacy
We contribute to the debate on global health challenges and other issues  
by advocating for a policy environment that protects the interest of patients 
around the world, while supporting our business.
 • Calling on G8 governments to 
acknowledge the potential for greater 
information exchange and data 
transparency among tax authorities  
in demonstrating the effectiveness  
of national and international tax rules. 
 • Working with US policymakers on the 
implementation of the Affordable Care Act 
to support the provision of medicines and 
vaccines through the new federal and 
state-run Health Insurance Marketplaces, 
and the Medicaid insurance programmes 
for low-income Americans. Additionally, 
we launched a new collaborative platform, 
Healthy Communities for a Healthy 
America, to identify and advocate for 
solutions that promote collaboration, 
improve access to high quality healthcare, 
and advance innovation. This includes the 
‘patient-centred medical homes’ and 
comprehensive medication management 
coordinated care models to improve the 
quality of care for patients, and reduce 
overall healthcare costs.
 • Partnering with the US Department of 
Health and Human Services, the 
Biomedical Advanced Research and 
Development Authority, and Texas A&M 
University, to open an influenza vaccines 
manufacturing facility in an unprecedented 
public health collaboration to ensure a 
rapid national vaccine response in the 
event of an influenza pandemic. 
 • Partnering with European governments to 
help reduce the impact of fiscal austerity 
measures on continued patient access  
to life-saving GSK medicines.
 • Working with governments to increase 
coordination, simplify pharmaceutical 
registration and improve the registration 
processes in China, Russia, Taiwan and 
Ukraine, to address the challenge of 
regional disparity in access to medicines. 
Trade association membership
GSK is a member of many trade and industry 
associations that primarily represent 
pharmaceutical, consumer product and 
vaccine businesses at the national, regional 
and international levels. Membership in 
these groups can support the efficiency  
and effectiveness of our public policy work. 
See our website for a full list.
Political contributions
We do not make corporate political 
contributions. 
Employee PACs
Some of our US employees choose to make 
personal political contributions through the 
GSK employee Political Action Committee 
(PAC), which allows eligible employees to 
provide financial support to political groups, 
in accordance with the Federal Election 
Campaign Act. In 2013, the GSK employees’ 
PAC contributed $484,810 with 60%  
to Republican candidates and 40% to 
Democratic candidates running for state  
and federal offices.
Lobbying expenditure
In 2013, costs associated with lobbying  
of EU institutions were in the range of 
€600,000 to €650,000 as outlined in the 
European Transparency Register. This figure 
includes running the Brussels advocacy 
office, salaries, external events, travel and 
accommodation, consulting costs and 
educational materials. It also takes into 
account the proportion of employee time 
spent on representing GSK’s interests to 
EU institutions. It excludes trade association 
membership fees.
In the USA, we spent $3,720,000 on federal 
lobbying activities in 2013 (see the US federal 
lobbying register). This includes the costs  
of salaries and benefits for all employees 
registered to lobby the US Government,  
use of lobbying consultants, support for 
lobbying contacts such as planning activities 
and research, running the GSK Washington 
DC government affairs office, support staff, 
and the portion of trade association fees 
associated with federal lobbying.
 Commitment
Demonstrate that all GSK interactions with patient 
advocacy groups and political stakeholders are 
conducted appropriately, ethically and transparently.
We are committed to ensuring that all our 
interactions with political stakeholders and 
patient advocacy groups are conducted 
appropriately, ethically and transparently.  
In 2012 we reviewed and published the 
criteria we use to work with public policy 
groups. In 2013, we assessed our 
memberships against these renewed criteria 
and as a result we withdrew from the 
American Legislative Exchange Council 
(ALEC). We remain committed to working 
with public policy groups aligned to our 
values and priorities. We have also agreed 
new Standard Operating Procedures that 
govern our work with public policy groups 
and we will train employees on these in 2014.
Key public policy engagements during  
2013 included:
 • Supporting immunisation programmes 
around the world, such as our partnership 
with GAVI Alliance, working with partners 
such as the Innovative Medicines Initiative 
to address related R&D, manufacturing 
and access challenges, and exploring new 
financing mechanisms for vaccination.
 • Working with governments and other 
stakeholders, primarily from Europe and 
the USA, to address the growing threat  
of antimicrobial resistance (see page 18)  
by encouraging greater investment in 
R&D, and supporting activities that 
promote appropriate use of antibacterials.
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Public policy and 
patient advocacy
continued
Patient advocacy
We engage with patient groups – non-profit 
organisations founded by patients, care-givers, 
family members and health professionals –  
to help improve our understanding of patient 
needs and illnesses. Patient groups engage 
with healthcare providers, governments, the 
media and patients to promote improved 
treatment and healthcare services. They also 
campaign on issues that affect patients’ and 
care-givers’ lives. Some carry out research into 
the causes of, and potential treatments for 
specific conditions. 
Our relationship with patient groups  
guides our R&D and helps to ensure that 
patient opinions are heard (see page 17).  
We recognise that some stakeholders want 
to understand the nature of our support for 
patient groups. We publish information 
online on all our work with patient groups in 
Europe, Asia Pacific and Emerging Markets, 
as well as information on our support for 
patient groups working globally, including 
details of the funding received. We publish 
information online on all our work (including 
funding details) with patient groups in 
Europe, US, Canada, Australia, Asia Pacific 
and Emerging Markets.
We provide funding to patient groups in  
the form of unrestricted grants to support 
the day-to-day running of the organisation, 
corporate partners fees and defined 
projects. Our support also includes the 
development of educational materials, 
training for staff, and collaboration on 
disease awareness and prevention projects. 
For example:
 • As a member of the European Patients’ 
Academy on Therapeutic Innovation, we are 
contributing expertise, staff time and funding 
to develop in-depth training courses and 
support qualitative research to help patients 
in 12 European countries become more 
effective advocates during the research 
and development of new medicines.
 • Working with the National Coalition of 
Patients with Chronic Diseases and other 
pharmaceutical companies to organise 
the National Forum of Patient Associations 
in Romania. The activity included a 
national information campaign for patients, 
roundtables with doctors, and the launch 
of a telephone helpline for patients to  
get information on their rights and 
disease-related questions. 
 • In Iowa, USA, we are collaborating with the 
Partnership for Better Health – a network  
of healthcare providers, advocates and 
consumers dedicated to lowering the cost 
of care through prevention, access and 
innovation through collaboration. This helps 
educate policymakers and the public about 
the need to invest in preventing chronic 
diseases affecting the USA, including 
diabetes, heart disease and lung disease.
 • Through our ‘Uniting a Community’ initiative, 
which originated from the Patient Advocacy 
Leaders Summits, we focus on healthy 
ageing and cancer. 
The European Patient Advocacy Health 
Advisory Board (HAB) is made up of  
13 European patient groups and is an 
opportunity for GSK employees to gain 
patient group insight on our policies and 
initiatives. It brings the voice of the patient into 
the heart of the organisation and helps us 
understand how we can meet patient needs. 
In 2013, topics we covered included our work 
on antibiotics, adaptive licensing, clinical data 
transparency, our plans for working with 
patient groups in the Emerging Markets Asia 
Pacific region and our partnership with Save 
the Children (see page 15). 
All GSK employees and relevant third 
parties who work with patient groups must 
follow our guidelines and Standard 
Operating Procedures. For example,  
we limit the amount of funding we can 
provide to 25% of a patient group’s overall 
funding, and require that relationships with 
patient groups must never be linked to 
promotion of our products. 
Patient Advocacy Leaders Summits
Our Patient Advocacy Leaders Summits 
(PALS) have been uniting patient advocates 
for more than ten years across different 
therapeutic areas to discuss health policy, 
develop new skills and explore ways to 
expand their influence. In the USA, in 2013, 
a national PALS event in Washington, D.C. 
and six regional PALS across the country 
focused on the patient advocate’s role in 
implementing healthcare reform, the 
implications of different Health Insurance 
Marketplaces, as well as the issue of 
Medicaid expansion in the states. 
Read more online
We publish more detail online on key  
issues including:
 • GSK Anti-Bribery and Corruption 
Handbook 
 • GSK Anti-Bribery and Corruption 
Guidelines for Third Parties 
 • Cloning technologies and stem  
cell research
 • Disclosure of clinical trial information 
 • The care, welfare and treatment of animals
 • The role of transgenic animals in  
biomedical research
 • Use of Non-human Primates (NHPs)  
in the Discovery and Development  
of Medicines and Vaccines
 • Counterfeiting of healthcare products 
 • Pharmacovigilance
 • Criteria for working with public  
policy groups
 • Global Code of Practice for Promotion  
and Customer Interactions
 • Code of Conduct
 • Clinical trials in the developing world 
We also facilitated PALS in Germany, Japan 
and Romania. Since 2002, more than 7,000 
patient advocates from over 55 countries 
have participated in PALS events around 
the world.
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Our approach  
to tax
Businesses are increasingly being 
challenged to ensure they contribute through 
the tax system to the societies in which they 
operate, and to provide information on their 
tax management principles and policies.
We understand our responsibility to pay  
an appropriate amount of tax. At the same 
time we have a responsibility to our 
shareholders to be financially efficient and 
deliver a sustainable tax rate. We fully 
support efforts to ensure companies are 
appropriately transparent about how their  
tax affairs are managed.
Our contribution: we have a substantial 
business and employment presence in many 
countries around the globe and we pay  
a significant amount of tax, including 
corporation and other business taxes, as 
well as tax associated with our employees. 
For example, since the formation of GSK  
we have paid more than £24 billion in 
corporation tax globally.
In 2013, our global corporation tax charge 
on core profits was approximately  
£1.7 billion equating to a Group tax rate on 
profits of 23%. This means that the corporate 
tax due on our core profits around the world 
amounted to nearly one quarter of the total 
core profit we made during the year. Further 
details about our corporate tax charges for 
the year are set out in our Annual Report.
We pay a considerable amount of tax in the 
UK given that only 5% of Group sales are 
generated in the country. This is because a 
significant proportion of our global corporate 
functions and R&D and manufacturing 
activities are located in the UK, where we 
are currently increasing our investment. In 
addition to corporation tax on the profits 
generated, the employment and value that 
these activities create are subject to a 
number of other UK taxes, including indirect 
tax and employment taxes.
We’ve continued our programme of 
centralising Pharmaceutical intellectual 
property and product inventory ownership 
into the UK, which was started in 2012. The 
change to our IP ownership structure is 
made possible by the introduction of new 
‘patent box’ tax rules by the UK Government 
which came into force in 2013, making the 
UK a more attractive place to locate IP and 
investment. Our decision to centralise IP 
and fund more R&D from the UK means that 
over the medium term we expect to pay 
more corporation tax in the UK, as more of 
the value we generate from sales of our 
pipeline products will have been created in 
the UK and be subject to UK tax.
Relationship with tax authorities
GSK seeks to maintain open, positive 
relationships with governments and tax 
authorities worldwide and we welcome 
constructive debate on taxation policy. In 2012, 
we entered into a bilateral Advance Pricing 
Agreement with the IRS and HMRC14 and in 
2013 we have started bilateral discussions 
with Tax Authorities in a number of other 
countries with the intention of agreeing further 
Advance Pricing Agreements. These 
agreements provide long-term certainty for 
both tax authorities and for GSK over the  
tax treatment of GSK’s business.
Transparency with Tax Authorities
GSK supports calls for multinationals to 
provide greater transparency to Tax 
Authorities. During 2013 we participated  
in consultations on the proposed Country 
by Country Reporting Disclosure to Tax 
Authorities, which was announced in the 
Organisation for Economic Co-operation 
and Development’s (OECD) Base Erosion 
and Profit Shifting Action Plan in July. 
International tax framework
As a multinational business we believe we 
should contribute to the debate regarding 
global tax policy, and in particular the 
current debate on whether the existing 
international tax law framework, which is set 
by the OECD, is fit for purposes in today’s 
environment. GSK supports the work that 
the OECD has commissioned, supported 
by the G8, in its Base Erosion and Profit 
Shifting paper, and is committed to 
providing relevant business input. 
Transfer pricing15
In line with current OECD guidelines we 
base our transfer pricing policy on the arm’s 
length principle and support our transfer 
prices with economic analysis and reports. 
The worldwide nature of our operations 
means that our R&D and manufacturing 
operations are centred in a number of key 
locations. A consequence of this is that our 
cross-border supply routes, necessary to 
ensure supplies of medicines into numerous 
end-markets, can be complex.
Tax Havens 
We do not engage in artificial tax 
arrangements – those without business  
or commercial substance – and our policy  
is to use locations only where we have 
substantial business presence. We have a 
substantial local business presence in the 
vast majority of the territories where we 
operate whether through business offices, 
sales force, manufacturing, R&D facilities  
or local distribution of our products, all of 
which contribute to economic development 
and create shared value for the region and 
our business.
Internal processes
We have robust internal policies, processes, 
training and compliance programmes  
to ensure we have alignment across our 
business and meet our tax obligations.  
Our Audit and Risk Committee, and the 
Board, are responsible for approving our  
tax strategy and management.
14 This is an agreement between a tax payer and a tax 
authority on an appropriate transfer pricing methodology 
for certain transactions over a fixed period of time.
15 An underlying principle of transfer pricing is that even 
though two companies are within the same group,  
they have to act as if they were independent enterprises. 
This means that companies must be appropriately 
rewarded for the assets they employ, and the risks they 
assume, when entering into intra-group transactions,  
to ensure profits generated are taxed in the countries 
where the value arises. An appropriate reward is 
considered to be the reward which would be obtained from 
a third party. This is known as the ‘arm’s length principle’.
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In focus
Alicia is an electrical engineering 
graduate on one of GSK’s specialist 
graduate schemes. Future talent is 
essential to business success and  
we run several schemes to support 
talented employees, like Alicia, in their 
early careers.
 Read more on page 53
Our  
people
Our people are essential to our 
success. We focus on building their 
individual capabilities, and aim to 
support and empower them to be  
the best they can be.
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Internal perspective 
“ When I look at myself now and 
compare it to before I attended 
Energy for Performance, I realise  
I am a totally different person. I am 
a better leader, husband and father. 
The way I look at it is – you have to 
take care of your own health first 
and be a role model for others before 
they will look up to you as a leader, 
be willing to listen and want to 
follow what you have to say.”
Richard Lewis
Immunology & Rare Diseases, GSK 
Internal perspective 
“ We have designed the new 
Performance System to connect 
individual performance with reward 
and align our collective efforts to 
deliver our strategy. At the heart  
of the system are individual and 
leadership expectations which  
guide what we do and how we do it, 
aligned to our values.”
Claire Thomas
SVP Human Resources, GSK 
Our people 
Overview
By creating strong leaders, offering 
individual development opportunities and 
rewarding our people based on how they 
deliver as well as what they achieve, we are 
motivating our employees to excel and put 
our values at the heart of every decision 
they make. We want them to feel proud of 
the work they do, the company they work  
for and the difference they make.
For GSK, living our mission starts from within, 
by improving the health and well-being of our 
employees. We are helping people build their 
energy levels, resilience and productivity,  
and we are introducing unrivalled preventive 
healthcare benefits for employees and their 
families worldwide.
As an inclusive employer, we want to ensure 
all of our people feel valued, thrive as 
individuals and are inspired to work together 
to help us achieve our mission, whatever 
their background.
2013 at a glance Talent and leadership development Reached over 6,500 leaders in 30 countries 
through our coaching programmes to 
strengthen leadership capabilities.
 See page 53
6,500
Talent and leadership development 
Increased the number of employees each 
year completing voluntary assignments with 
Non-Government Organisations or non-profit 
organisations through PULSE to 99 – up from 
94 in 2012. 
 See page 54
Inclusion and diversity
Increased the proportion of women in 
management to 41%, up from 40% in 2012. 
 See page 55
41%
Inclusion and diversity
The graduation of our first Project Search 
cohort and subsequent recruitment of the 
next group of students.
 See page 55
Health, safety, and well-being
Reduced injury and illness rates by 12%  
from 2012.
 See page 57
12%
Health, safety, and well-being
Equipped 48,300 employees with the tools  
to cope with workload stress through energy 
and resilience training since 2008.
 See page 58
48,300
Performance, reward and recognition
Began the roll out of preventive healthcare 
benefits through our Partnership for 
Prevention programme, which will be available 
to employees and their families worldwide  
by 2018.
 See page 59
Performance, reward and recognition
Launched the GSK Expectations as part of 
our new Performance System to better link 
employee reward with our values.
 See page 59
GSK’s Partnership for 
Prevention (P4P) programme 
is setting the standard in 
employee healthcare. 
In 2012 we piloted the 
programme in Ecuador, 
Ghana, Nigeria and 
Romania. By 2018, P4P will 
offer all benefits-eligible 
employees and their families 
access to up to 40 preventive 
health services – from 
vaccinations to cancer 
screenings – at low or no 
cost. No other multinational 
company is doing this on the 
same scale. 
No matter what job they do,  
or where they work, we want 
all our employees to have 
access to the healthcare 
they need to be fit and 
healthy. By providing access 
to preventive healthcare we 
are reinforcing our efforts 
to maintain a motivated, 
engaged and resilient 
workforce, and giving our 
employees the opportunity 
to improve and protect their 
health. 
These services are of even 
greater need for those 
working in countries where 
preventive healthcare may  
be unavailable or access  
is limited. 
Setting the standard in 
employee healthcare
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Graduate to senior leader in  
just four years with ESPRIT
Dipal joined GSK through our post 
graduate programme in 2009 and, just 
four years later, she has moved into her 
new role as European Marketing Director. 
Completing the ESPRIT MBA 
programme helped her achieve this. 
The four-year programme enabled her to 
gain a broad range of experience working 
in our pharmaceutical business in 
Australia, our Vaccines business in 
Thailand and in the Vaccines Centre of 
Excellence in Belgium. This fast-tracked 
her learning and development, and gave 
her the skills, knowledge and confidence 
to take on her new role as a senior leader. 
Managers and leaders
We provide our managers with the skills to 
engage their teams and motivate individuals 
to perform at their best through our 
leadership programmes, which aim to 
develop future leaders around the world.
In 2013, over 3,500 leaders completed our 
Leading Delivery programme which helps 
middle-level managers translate the strategic 
ambition of our business into meaningful 
action. We also enrolled 144 leaders onto 
Leading Business, which is designed to 
develop the capabilities of those managing  
a business function. For people who are  
new to management positions, we launched 
Management Essentials, which teaches  
core management skills. 
Coaching is one of the key ways we help 
people build their skills and strengthen 
leadership capabilities. We made this a global 
focus for GSK in 2013, through programmes 
such as Fundamentals of Leadership, which 
provides training for leaders and managers, 
and Coaching for Effective Leaders. Since 
2010, over 450 leaders have been trained  
as Job Plus coaches and over 250 of our 
high potential executives received coaching 
from Executive Coaches. In total we have 
reached over 6,500 leaders through our 
coaching programmes.
Talent and leadership 
development
We attract and retain the most talented people by investing in training  
and development that is tailored to individuals’ needs, and builds on  
employees’ strengths. 
Early careers
We offer a wide range of opportunities 
including internships, industrial placements, 
apprenticeships and graduate schemes for 
entry level students. These programmes help 
us develop the skills our business requires in 
the future. Our intake of graduates onto 
development programmes around the world 
continued to rise in 2013, up from 303 in 
2012 to 334 in 2013, making progress 
towards our global target to recruit 450 
graduates a year by 2015 (see chart).  
In the UK, 58 apprentices joined GSK in 
2013, and we have committed to recruiting 
140 apprentices over the next two years. 
300
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Graduate recruitment globally
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Target
We want the most talented, high-potential 
employees to become the next leaders at 
GSK. Our programmes aim to identify and 
accelerate the progression of our strongest 
talent through, for example, our flagship 
global MBA programme, ESPRIT. In 2013, 
85 ESPRIT participants completed a series 
of rotations across 22 countries in finance, 
R&D, medical and commercial units – 
enabling them to build their skills and 
knowledge in different markets and regions 
(see case study). 
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Talent and leadership 
development
continued
Development through community involvement
 Commitment
Extend volunteering opportunities to bring about 
positive change to communities and global health while 
providing individual development.
Our PULSE Volunteer Partnership 
programme gives employees the 
opportunity to work full-time for three or  
six months with a non-profit organisation or 
charity, to help address global healthcare 
challenges while developing their leadership 
skills. In 2013, 99 employees volunteered 
with 47 organisations, including Save  
the Children, as part of our new global 
partnership with the charity (see page 15).
Employees who completed PULSE 
assignments in 2012 were found to be 21% 
more likely to change roles and 41% less 
likely to leave GSK (compared to the overall 
employee population in the same countries). 
In 2013, surveys conducted with our 
partners indicated that 83% of non-profit 
organisations are doing something 
differently even six months after the PULSE 
volunteers have left their assignments.  
Find out more about PULSE volunteering  
on our website and see page 56 for more  
on volunteering at GSK. 
“ The PULSE programme has made us a 
more capable organisation – stronger, 
faster, and smarter. GSK employees 
can know that they are helping to save 
or greatly improve the lives of people 
around the world.”
Ross Comstock
IT Director, Santa Barbara US (an NGO working 
with PULSE volunteers since 2009)
“ I swapped my job as Director 
Marketing in France to work with 
CARE International in Bangladesh to 
develop a communication strategy for 
CARE and GSK’s 20% reinvestment 
initiative to help reduce maternal and 
child mortality in remote parts of Asia. 
I feel that my biggest achievement was 
to develop the staff capacity to 
implement communication activities 
after my departure. Having seen the 
impact of our 20% reinvestment work 
in the least developed countries, I feel 
really proud of my work at GSK.”
Isabelle
GSK France
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Project Search improves young 
people’s employability
In 2013, 12 students aged between  
18 and 24 – all with learning disabilities 
– completed work experience at GSK,  
to help them transition from education  
to work, as part of our support for  
Project Search.
One-to-one support from GSK 
employees who volunteered as mentors 
helped the students build their skills as 
they completed three ten-week rotations 
in a variety of roles including reception, 
IT, procurement, hospitality and security. 
Three of the interns have since secured 
part-time jobs working in facilities 
management and retail, and one has 
been taken on full time by a local Council. 
“I am overwhelmed by how much the 
students have grown in confidence and 
ability in such a short time,” says Lorna, 
Project Search Tutor at GSK. “And the 
students, with their positivity and 
commitment to work, have become a real 
inspiration to many of our employees.” 
Inclusion and 
diversity 
We aim to create an inclusive workplace to attract and retain the most talented 
people from all backgrounds and cultures. 
 Commitment
Continue to promote inclusion and diversity globally  
at GSK.
Gender diversity
GSK’s focus is to enable gender diversity  
in management and senior roles. In 2013,  
we have introduced targeted individual  
and group coaching and sponsorship for 
emerging diverse talent. In 2014, we will 
invite employees to join dialogue sessions 
to discuss and address hidden barriers that 
could hinder gender diversity. 
In 2013, the percentage of women in 
management continued to rise (see chart). 
Women represent 21% of our Corporate 
Executive Team and we have exceeded our 
goal to achieve at least 25% female board 
representation by 2013, with five female 
non-executive directors making up 33%  
of the Board. GSK ranked joint third in the 
2013 Female FTSE100 Board Report,  
a study of women’s representation on the 
boards of the UK’s top companies. 
Disability
We want to make sure that people with 
disabilities have access to career 
opportunities at GSK, bringing valuable 
talent and expertise to our business. 
Disability is a global focus for GSK and we 
are establishing a Global Disability Council 
to agree priority areas, set objectives and 
monitor our progress.
We maintain our long-standing relationship 
with disability organisations such as 
SERMES in Spain and the Business 
Disability Forum in the UK. Through our 
participation in the Project Search initiative, 
we are also helping young people with 
learning disabilities make the transition  
from education to work (see case study).
Cultural and ethnic diversity
To promote cultural diversity, in 2013,  
we piloted a new online resource to help 
develop employees’ awareness of cultural 
differences and build the skills needed to 
interact effectively with colleagues around 
the world. The application will be launched 
globally in 2014.
We value the broad spectrum of experiences 
employees from different parts of the world 
can bring to our business. The people we 
employ in our Emerging Markets, Asia Pacific 
and Japan, represent 43% of our total 
workforce. Six nationalities are represented  
on the Corporate Executive Team and Board.
We monitor and benchmark the proportion 
of ethnic minorities in our workforce at a 
local country level against industry averages 
and the national population in countries 
such as the UK and USA (which we report 
locally), and engage with groups 
representing diverse communities. 
Women in management positions (%)
2009 2010 2011 2012 2013
SVP, VP 25 25 26 27 28 
Director 36 37 38 39 40
Manager 42 42 42 43 44
Total 38 38 39 40 41
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Orange United Employee Engagement 
In 2013, for the first time we asked all our 
employees from 115 countries to work 
together to support a single cause.  
We set them the ambitious goal to raise 
£1 million for Save the Children as part 
of our global partnership with the charity 
(see page 15). And we are delighted to  
see how enthusiastically our people have 
risen to the challenge. From marathon 
exercise sessions of Zumbathons and 
dodgeball tournaments, to book and bake 
sales, fundraising activities during our 
Orange Week alone raised almost 
£337,000, making a massive contribution 
to the target.
Engaging our 
people
Engaging our employees in our mission and strategy gives them a clear sense  
of purpose, and enables them to understand how their actions contribute to the 
success of the business. 
Our CEO and members of the Corporate 
Executive Team (CET) deliver live broadcasts 
and messages to keep employees updated 
about the company’s progress towards its 
strategy and commitments. We encourage 
employees to have regular interaction with 
leaders and provide our leaders with the 
resources they need to respond effectively. 
More than 80% of senior leaders reporting  
to the CET have received communication 
training to help them engage more effectively 
with their teams. 
Listening and responding to our employees
We engage with our people formally and 
informally to understand their views about 
working at GSK and how we can improve 
their experience. 
More than 36,000 employees are using our 
new social networking tool to ask questions  
or raise issues, promoting dialogue with 
colleagues around the world at all levels of the 
company. We have also enhanced our intranet 
to encourage more interaction and internal 
dialogue by, for example, enabling employees 
to post comments on news features. 
We frequently ask all employees to participate 
in a formal survey to understand how we are 
doing as an employer. We appreciate them 
taking the time to complete this survey and 
responding to their feedback is a priority. 
Since the last full survey in 2012, individual 
business units have developed action plans 
to address several issues identified as key 
areas for improvement, such as training 
leaders to be better coaches (see page 53), 
supporting employees through change and 
better recognising individuals’ contributions 
(see page 59). 
In 2013, we introduced regular interim 
surveys for individual business units and 
functions, covering around 36,000 
employees during the year. Results showed 
that most businesses had made significant 
improvements in team leader effectiveness, 
a priority area for improvement based on the 
2012 survey results.
Our approach to restructuring
In 2013, we implemented the second phase 
of a major change programme that was 
announced in 2012. The programme 
focuses on encouraging more integrated, 
collaborative and efficient ways of working 
across our businesses, advancing 
technology and reducing costs. We are 
aware of the effect restructuring can have 
on employees and aim to achieve our 
organisational and financial goals without 
eliminating positions or by redeploying 
employees where possible. If jobs are lost 
as a result of changes to the business, we 
consult with employees and their 
representatives, and offer compensation 
and other support such as outplacement, in 
line with local requirements and employment 
legislation. Our Employee Assistance 
Programme and resilience training provide 
additional support (see page 58).
Volunteering
As part of our efforts to engage and motivate 
our people, we encourage them to get involved 
in local projects to support their communities 
through our Orange Day volunteer programme, 
which entitles employees to one paid day a 
year for volunteering. In 2013, we launched 
a major fundraising initiative, challenging 
employees around the world to work together 
to raise £1 million for Save the Children  
(see case study). 
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Health, safety 
and well-being
 Commitment
Continue to create a working environment that inspires 
people to grow and perform in a healthy and resilient way.
First and foremost, we have a responsibility 
to ensure no physical harm comes to our 
people while they are at work, and safety is a 
fundamental part of our corporate culture. 
But we recognise that employees’ resilience 
can also be affected by a wide variety of 
factors, from workload to stress in their 
personal lives. Our efforts to promote 
employee well-being focus on giving our 
people the support they need to build their 
energy levels and cope with stress.
We are also going one step further than any 
other multinational employer by committing to 
provide comprehensive preventive healthcare 
benefits to all our employees and their families 
worldwide through our Partnership for 
Prevention programme (see performance, 
reward and recognition, page 59). 
Embedding a culture of zero harm 
To achieve our goal of zero harm to 
employees, we focus on preventing 
incidents before they occur and targeting 
training and awareness activities on key risks 
such as safe driving and use of machinery. 
In 2013, we achieved a 12% reduction in injury 
and illness rate compared with 2012. We also 
worked to increase reporting of near-miss 
incidents to help us address specific safety 
issues before an incident occurs and share this 
knowledge across the business to help prevent 
more serious incidents elsewhere. As a result, 
in 2013, we reported 131,924 near-miss 
incidents – an increase of 98% since 2012.
Our move to a global model for health and 
safety management will facilitate sharing  
of risk profiles and best practices between 
sites, while retaining a focus on health  
and safety at site level. We have also 
expanded our network of health and safety 
coordinators who make sure our safety 
programmes are on track. 
We had two serious incidents in 2013:  
two employees received minor burns in  
a fire in Irvine, UK; and a maintenance 
worker in Verona, Italy, suffered a partial 
finger amputation during a check on 
machinery which required the safety  
guard to be removed. 
Targeting specific safety risks
In many countries, driving represents one of 
the biggest safety risks to our employees. 
Following a pilot in 2012, we launched a driver 
safety training programme in 11 countries in 
2013. More than 2,300 employees have 
completed the training and it is having a 
significant impact. GSK Australia, for instance, 
has experienced a 25% reduction in  
business-related driving incidents in the first 
year of implementing the programme. In 2014, 
we will deliver this training in three further 
emerging markets through tablets and smart 
phones. Employees can also invite a family 
member to do the training free of charge, 
helping to extend safety to their home life. 
To improve safety for employees working  
in manufacturing, we have continued  
to implement risk reduction initiatives.  
This included upgrading the protective 
guards that stop manufacturing employees 
getting close to machinery when in 
operation, and reviewing respiratory 
protective equipment to reduce exposure  
to harmful airborne powders. 
In 2013, we also continued to improve 
process safety across our manufacturing 
and R&D operations to prevent serious 
events such as fires, explosions and 
releases of hazardous substances. Working 
with the University of Sheffield in the UK, 
we are developing a four-day open access 
training course on process safety covering 
fire and explosion risk, and prevention 
strategies specifically for the pharmaceutical 
and consumer healthcare industries.  
The course will form part of the University’s 
Masters of Science in Process Safety and 
Loss Prevention.
Leading causes of reportable injury and illnesses (%) 
Slips/trips/falls
Ergonomic
Machinery
Motor vehicle accidents
Contact with sharp objects
Burns thermal/chemical
Other
24.0
23.5
11.4
6.9
5.6
18.2
11.9
As a progressive healthcare company, helping our employees stay healthy, 
resilient and productive is a priority and brings our mission to life for our people.
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Read more online
We publish more detail online on key  
issues including:
 • Hazardous chemical management 
 • GSK and REACH
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Health and safety data summary
2010 2011 2012 2013
Hours worked (million) 207.9 204.0** 204.2** 185.7***
Fatalities 1 2 2 0
Calendar days lost 10,824 10,114** 9,370** 6,875
Number of injuries and illnesses with lost time 508** 429** 404** 349***
Lost-time injury and illness rate* 0.24 0.21 0.20 0.19
Calendar days lost rate* 5.21 4.84 4.59 3.71
Reportable injury and illness rate* 0.41 0.36 0.33 0.29
Number of near-miss incidents † 7,034 29,309 66,514 131,934
* Per 100,000 hours worked
** Data has been restated where actual data is now available to replace estimated data that was reported previously
*** In 2013, this excludes data from a number of Commercial Operations business units. 
† Near-miss incidents were reported globally from 2012. Data from 2010 and 2011 relates to results of a pilot project from  
Global Manufacturing and Supply
+ Data is assured by BV, see page 70
Energised and resilient employees
We believe levels of energy are a good 
indicator of how people feel and perform. 
By supporting employees to manage and 
increase their energy levels, we are helping 
them cope better with workloads and  
stress within and outside the workplace. 
Our Energy for Performance (E4P) 
programme includes personal and  
team-based workshops and training 
courses that help employees remain 
focused, energised and productive. 
The objective is to enable employees to lead 
healthier and happier lives at work and at 
home. Participants agree that it works:  
80% said their performance at work had 
improved after completing E4P training. 
By the end of 2013, a total of 44,500 
employees in 55 countries had participated 
in energy and resilience training since it  
was introduced in 2008 and it is having a 
significant impact (see quote). The results  
of our research on the impact of E4P have 
been published in a peer-reviewed journal. 
In 2013, we introduced Renew and Refuel 
and Energy Coaching programmes to our 
Energy and Resilience portfolio, and 
launched several new courses, including: 
 • Time for a Moment – an online course that 
encourages employees to find time to take 
short breaks in their working day to 
increase concentration and focus.
 • Energising You! – an educational initiative 
that provides advice on how to boost 
energy by eating regular, healthy meals.
 • Managing for Resilience – a one-day 
workshop that teaches leaders how to 
build their teams’ skills and confidence, 
and reduce stress that can lead to  
mental illness. 
We have also scaled-up our Employee 
Assistance Programme (EAP) – enabling 
employees worldwide to access practical 
advice, information and counselling through 
a confidential helpline and website. 
Impact of Energy and Resilience training (2008-2013)
Type of 
training
Total number  
of employees 
Countries Impact 
Energy for 
Performance 
(E4P)
8,300 35 90% reported increases in energy  
12 months after the programme
More likely to make improvements in their 
lifestyle, especially diet, and report they  
are in excellent health
Resilience 
(personal)
4,000 16 Improvement in recovery and energy 
Resilience 
(team-based)
36,000 55 Significant reduction in perceived 
workplace pressures and better able  
to cope 
Health, safety 
and well-being
continued
“ Before the introduction of P4P,  
there wasn’t wide awareness of the 
importance of vaccines and other 
medical check-ups – for example  
I did not know that there was a 
vaccine that can help protect against 
cervical cancer. The general health 
screenings have also made me realise 
that I need to be cautious about my 
glucose and cholesterol levels and 
make certain lifestyle changes 
immediately. If the P4P service did  
not exist, I may not have taken such 
health issues into consideration.  
And even if I had, I might not have 
been able to afford the treatment.”
Rhoda 
An employee in Ghana 
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Performance, reward  
and recognition 
Putting our values at the heart of 
performance and reward
In 2014, we are introducing a new 
performance system to ensure our 
employees understand what is expected of 
them and help them set clear objectives that 
will help deliver our strategy. This will create 
a clear link between our values and how our 
employees are rewarded, with GSK 
Expectations clearly outlining the way we 
expect employees to work and deliver our 
strategy. We have also introduced a new 
five-point rating scale to enable us to 
provide clearer feedback on employee 
performance and help differentiate our  
best performers. 
The performance system includes a new 
global bonus structure where 60% of an 
employee’s bonus will be aligned to the 
achievement of their individual objectives 
and 40% will be based on business area 
results. This greater emphasis on individual 
performance will help employees 
understand how they personally contribute 
to the delivery of our strategy and living our 
values, and how this links to their reward. 
We are also introducing a new 
compensation system for our sales teams 
that rewards patient-focused behaviours, 
rather than the amount of sales (see  
page 44). For our most senior people, we  
disincentivise unethical working practices 
using a ‘clawback’ mechanism that allows 
us to recover performance-related pay.  
See our Annual Report for more on 
Executive pay.
For GSK, how people achieve results is just as important as what they achieve. 
Incentivising behaviour that is consistent with our values is a priority in the 
way we evaluate, recognise and reward performance. 
Extending preventive healthcare benefits 
to all employees
We are putting our values into practice by 
introducing competitive benefits packages, 
including preventive healthcare benefits for 
employees and their families that are unmatched 
by any other multinational company. 
Our ground-breaking Partnership for 
Prevention (P4P) programme offers all 
benefits-eligible employees, and their family 
members, access to up to 40 preventive 
health services at little or no cost. To date, 
over 5,200 employees and family members 
in 11 countries including Ecuador, Ghana, 
Nigeria, Romania and the Middle East, are 
receiving P4P benefits. We plan to 
implement P4P globally by 2018. As part  
of the pilot we ran in 2012, we also focused 
on encouraging employees to do more 
exercise and improve their diet, and have 
since developed a global physical fitness 
programme which will be launched in  
2014. For more on P4P, see case study  
on page 52. 
Pensions and other benefits
Other benefits and total reward packages 
vary from country to country, but are always 
designed to be attractive and competitive  
in each local market. These include shares 
and savings plans, health benefits and 
pensions (see our Annual Report). 
Recognising our exceptional scientists
Our business is founded on innovation 
and we want our scientists to know we 
value the important contribution they 
make. Our Exceptional Science Award 
Programme offers rewards of company 
shares to scientists who have made an 
outstanding contribution to the discovery 
and development of new medicines –  
but who are not eligible for annual share 
grants. The programme is designed to 
emphasise how scientific research and 
development is linked to the success of 
our business. We awarded 616 grants  
in 2013, and a total of 1,792 since 2011.
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Our  
planet
We are working hard to reduce our 
environmental footprint, even as we grow 
our business to extend the benefits of GSK 
products to more patients and customers 
around the world.
In this section
Our planet overview  61
Taking a scientific approach  
to sustainability 62 
Carbon  63
Water  65
Waste  66
Managing other impacts 67
Engagement 68
Data to summary 69
Summary of assurance statement 70
In focus
Adina is a pharmacy manager in London 
at one of the pharmacies where GSK is 
running our Complete the Cycle inhaler 
recycling scheme. Complete the Cycle 
encourages patients to return their old 
inhalers to a participating pharmacy so 
they can be recycled, helping reduce 
waste and carbon emissions.
 Read more on page 66
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Engagement 
Reviewed carbon, 
water and waste data 
from over 216 suppliers 
to better understand 
environmental impacts 
in our supply chain.
 See page 68
2013 at a glance
Our planet 
Overview
We are committed to managing and 
reducing the environmental impacts of our 
operations and our products across their 
life-cycle. Our stakeholders expect us to, 
and the long-term success of our business 
depends on it. To ensure we can continue 
to deliver high quality products to patients 
and consumers in the future, we must 
protect the natural resources we need to 
make them today.
These resources are already becoming 
scarcer and more expensive, and the effects 
of climate change and water scarcity could 
threaten some of the improvements in global 
health our medicines, vaccines and 
consumer products are helping to deliver.
We have set ambitious goals to reduce 
carbon, water and waste across our value 
chain – from the sourcing of raw materials 
and the impacts of our own labs and 
factories, to the use and disposal of our 
products by patients and consumers.  
By using resources more efficiently, and 
collaborating with others to tackle these 
challenges, we can reduce costs and 
enhance competitiveness.
“ We are focused on reducing 
emissions, energy and water use 
throughout our supply chain, which 
both benefits the environment and 
also reduces waste and cost, so that 
we can reinvest savings in 
innovation and improving access  
to our medicines.”
Roger Connor
President, Global Manufacturing and Supply, 
GSK
External perspective
“ I applaud GSK’s approach to 
minimising their environmental 
footprint. They are the first 
company worldwide to announce 
that all new respiratory drugs will 
only be launched in dry powder 
formulations, which have less than 
10% of the global warming 
potential than HFA inhalers. 
However, GSK must maintain 
momentum if they are to reach 
their ambitious carbon targets.” 
Ashley Woodcock OBE
Consultant Respiratory Physician, University 
Hospital of South Manchester  
Shared in Nobel Peace Prize with IPCC  
and Al Gore
Internal perspective
Carbon 
Our Scope 1 and 2 carbon emissions  
from our operations grew slightly in 2013, 
although they remain 7% lower than our  
2010 baseline. 
 See page 64
Carbon 
Our Scope 3 emissions (excluding raw materials) 
increased by 1.5% in 2013 across the value chain 
due to strong sales of HFA propellant-based 
inhalers, and have increased by 11% since 2010.
 See page 64
Water 
Used 2% less water in our  
operations during 2013. 
Mapped water use across our value chain 
– production of raw materials accounts for  
an estimated 84% of our total water footprint  
and our own operations represent just 1%.
 See page 65
Water 
Became the first company to be awarded 
global certification to the Carbon Trust’s  
Water Standard in recognition of  
our year-on-year reductions  
in operational water use globally.
 See page 65
Waste 
Generated 11% more waste than in 2012 due 
to business growth, but achieved 6%  
reduction compared to 2010.
 See page 66
Waste 
Achieved zero waste to landfill at 37 sites.
 See page 66
 2%
REDUCING WATER
YEAR ON YEAR
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The sourcing of raw materials 
and the complex, energy-
intensive chemical processes 
involved in transforming them 
into our products accounts for 
around half of our value chain 
carbon footprint.
Over the last five years, 
we have been using 
innovative technology to 
reduce environmental 
impacts associated with 
manufacturing active 
pharmaceutical ingredients 
– the substances in our 
drugs that treat or prevent 
illness. Following trials in 
Jurong, Singapore, teams at 
the eight facilities where we 
produce active ingredients 
are implementing holistic 
improvement plans which 
are bringing significant 
environmental benefits and 
cost reductions.
Infrastructure investments 
included installing a 
biogas plant at Irvine, 
UK, a combined heat and 
power facility in Worthing, 
UK, and a photo oxidation 
system for waste treatment 
in Singapore. Our site in 
Cork, Ireland, where we 
are now bio-treating waste 
and recovering the energy 
produced, achieved zero 
waste to landfill for the third 
year running in 2013, and has 
cut water use by 57% and 
carbon emissions by 41% 
since 2008.
We are also making changes 
to the chemical processes 
themselves. For example, we 
are investing in a new process 
at our facility in Quality Road, 
Singapore, which uses 
enzymes in the manufacturing 
of amoxicillin (one of the most 
widely prescribed antibiotics 
in the world). This innovative 
process will significantly 
cut our carbon emissions 
by reducing cooling 
requirements, as well as 
producing less organic waste.
Many of the improvements 
we are making take time to 
implement. But across all 
eight sites, we have already 
cut energy use by 4%, CO2 
emissions by 12%, water use 
by 10% and waste to landfill 
by 82% since 2010.
Taking a scientific 
approach to 
sustainability
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Carbon  We have set ambitious targets to achieve a carbon neutral value chain by 2050. 
We are reducing operational carbon emissions, and engaging with suppliers  
and consumers to cut emissions associated with sourcing raw materials  
and using our products.
Understanding our 2013 value chain carbon footprint 
Logistics
We aim to minimise carbon emissions  
from transporting our products to  
customers by using sea freight rather  
than air and by redesigning packaging  
to make transportation more efficient.
Raw materials
We are working with suppliers to reduce 
the impacts associated with sourcing raw 
materials, as well as exploring ways to use 
resources more efficiently in our products.
GSK’s operations
We are investing in technology, efficiency 
measures and renewable energy to reduce 
carbon emissions from energy use in our 
operations. We also generate carbon emissions 
during the production of propellant-based 
inhalers and from employee travel.
40% 14% 1% 44% 1%
Use of our products
Some of our products, particularly 
propellant-based inhalers, generate  
carbon emissions during use by  
patients and consumers.
Disposal
We have established an inhaler 
recycling programme and engage with 
patients to reduce emissions associated 
with disposal of our products. 
Energy Use of metered  
dose inhalers
HFA and process 
emissions
Use of other 
products
Business travel
Sales force
1.3m
tonnes CO2e per annum
5.3m
tonnes CO2e per annum
15m
tonnes CO2e per annum
Total emissions
0.25m
tonnes CO2e per annum
1.0m*
tonnes CO2e per annum
0.1m
tonnes CO2e per annum
0.2m
tonnes CO2e per annum
0.2m
tonnes CO2e per annum
0.2m*
tonnes CO2e per annum
5.6m*
tonnes CO2e per annum
1.8m
tonnes CO2e per annum
6.3m
tonnes CO2e per annum
* This is an estimate
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Scope 1 & 2 GHG Emissions
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Scope 3 GHG Emissions
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  Product logistics
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  Propellant emissions during use of inhalers
  Use of other products
  Disposal of products
Carbon 
continued
Performance in 2013
 Commitment
Reduce our overall carbon footprint by 25% by 2020 
(vs. 2010) and have a carbon neutral value chain  
by 2050.
In 2013, our Scope 1 and 2 emissions,  
those in our operational boundaries, were 
1.83 million tonnes CO2e, a slight increase of 
0.6% compared to 2012, but a 7% reduction 
since 2010. The investments we made in 
2013 will start to deliver further carbon 
emission reductions in 2014 (see chart). 
In 2013, our Scope 3 emissions, such as 
those associated with logistics, business 
travel and patients’ use of our HFA propellant-
based inhalers, increased by 1.5% compared 
to 2012 – an overall increase of 11% since 
2010 (see chart). Tackling our Scope 3 
emissions continues to be a challenge, 
especially as our product sales continue to 
increase. In particular, we are looking at 
long-term options to reduce our carbon 
emissions related to Ventolin whilst still 
meeting patient needs and preferences.
Product impacts
We are using carbon footprint analyses of 
our top 35 products to identify where we 
can make the most effective reductions  
from emissions associated with our  
products – from sourcing raw materials,  
to manufacturing, to use and disposal.  
For example, in 2013 we reduced the 
amount of propellant (HFA134a, a powerful 
greenhouse gas) used to purge aerosol cans 
of air before they are filled with Ventolin.
Operational impacts
Reducing energy use, and the carbon 
emissions associated with generating 
energy that we purchase, is an important 
focus of our programme to cut 
environmental impacts. We are investing  
in energy-efficient technologies and 
increasing our use of renewable energy.  
For example, at our facility in Irvine, UK,  
we are introducing a series of alternative 
energy sources, including a £3.7 million 
wind turbine and an anaerobic digester  
that will use waste from the site to generate 
energy. The combined heat and power plant 
we installed in 2010 is already reducing the 
cost of producing our antibiotics at the site  
by £650,000 annually.
Our vaccines site in Tuas, Singapore, has 
installed a trigeneration plant which uses 
waste energy generated in the production  
of electricity for heating and cooling. This 
has improved energy efficiency by 15-20%, 
and saved around £1 million a year. In 2013, 
the site’s achievements were recognised by 
the Singapore Energy Efficiency National 
Partnership Awards in the Best Practice 
category. By improving efficiency, these 
measures have prevented the site’s total 
energy consumption from rising even as 
production volumes increased.
We continue to identify opportunities for 
profitable energy and carbon emissions 
reductions at all our sites around the world. 
In 2013, for example, we increased the 
amount of biomass used as a fuel, replacing 
coal at two sites in India.
External recognition and partnerships
In 2013, our achievements in cutting carbon 
emissions across our value chain were 
recognised by the CDP, a not-for-profit 
organisation providing a global framework  
to measure companies’ impacts on the 
environment. GSK was the only healthcare 
company listed in the Global 500 climate 
change report 2013, to be ranked in the 
CDP Performance Leadership Index, and 
the CDP Disclosure Leadership Index for 
both our performance and the quality of our 
reporting. Our 2013 CDP submission is 
publicly available on the CDP website.
During the year we also received the 
Carbon Trust’s Best in Continuing Carbon 
Reduction award for year-on-year 
reductions in emissions associated with  
our operations. This followed our global 
certification to the Carbon Trust Standard  
in 2012, which we will renew in 2014. 
We continue to work with the Association of 
the British Pharmaceutical Industry and the 
UK National Health Service Sustainable 
Development Unit. Following the 
development of carbon footprinting 
guidelines for the pharmaceutical sector in 
2012, together we launched a tool to help 
companies calculate the carbon footprint  
of tablet medicines that are distributed in 
blister packs. 
GSK is also a member of the UN Caring for 
Climate programme, an initiative that is 
increasing businesses’ role in addressing 
climate change.
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Water 
 Commitment
By 2020, reduce our water impact across the value 
chain by 20% (vs. 2010).
Mapping our water footprint across  
our value chain
We use more than 15 million cubic metres 
of water a year in our operations – research 
laboratories, manufacturing facilities and 
offices. But this accounts for just 1% of our 
total water footprint. The remaining 99% of 
our footprint relates to water used in the  
rest of our value chain (see chart). To 
reduce our overall water impact, we need  
to explore ways to reduce our suppliers’ and 
consumers’ water use too.
Working with external experts to gain a better 
understanding of our water footprint and 
where our biggest impacts are, we estimated 
the total water footprint associated with our 
products was 1,540 million m3. The production 
of raw materials used to make our products 
account for the vast majority of our footprint, 
and the second biggest contributor is 
consumer use of our products (see chart).
This initial high-level assessment helped  
us determine where we need to more 
accurately investigate water consumption in 
our value chain – including water use in the 
agricultural supply chains for the milk, malt, 
wheat and glucose that goes into some of 
our products, and water in the use of our 
toothpaste by consumers. We are also 
starting to understand where in the world 
our water use has a high impact on the 
environment and communities. 
To reduce the overall water impact associated with our products, we are working 
to reduce suppliers’ and consumers’ water use, as well as targeting reductions in 
our own operations.
This analysis will help us develop effective 
programmes to meet our 2020 commitment 
to cut water impact by 20% across our 
value chain. For example, we have already 
begun efforts to address consumer water 
use by using our toothpaste brands to 
launch ‘Turn off the Tap’ campaigns in Italy 
and Puerto Rico, which encourages people 
to use less water when brushing their teeth.
Reducing water use in our operations
In 2013, we achieved a further 2% reduction 
in water consumption in our operations, 
keeping us on track to meet our 2015 target 
to cut operational water use by 20% (from 
the 2010 baseline).
Each year, we conduct a high-level 
assessment of water use in our global 
operations, using the World Business 
Council for Sustainable Development’s 
Global Water Tool to help us identify where 
we can save water and respond to potential 
water risks. Four countries – Belgium, India, 
the UK and the USA – account for 70%  
of our total water use. We also use the 
WBCSD tool and information on local 
watersheds to identify operations in areas  
of water scarcity.
We have developed a systematic approach 
to find opportunities to save water at sites 
with high volume use, where consumption is 
increasing and in areas where water is scarce. 
We rolled out improvement programmes  
in Pakistan and Kenya in 2012, followed  
by the UK and India in 2013, and we are 
starting to see results. For example, our 
Horlicks manufacturing plant in Slough,  
UK – which was our second biggest 
consumer of water – has reduced water 
use by 56% since 2010.
External recognition and partnerships
We are working with NGOs to develop a 
long-term strategy that will address issues 
of water scarcity, water quality, and 
regulatory risk and help reduce potential 
impacts on communities. This builds on  
the commitments we made in the UN CEO 
Water Mandate, an initiative that helps 
companies develop and implement 
sustainable water practices which GSK 
signed in 2009.
In 2013, GSK became the first company to 
be awarded global certification to the Carbon 
Trust’s Water Standard in recognition of our 
year-on-year reductions in water use, and the 
way we manage and measure water across 
our global operations. We also respond to the 
CDP Water Disclosure Project each year and 
our latest submission is publicly available on 
the CDP website.Estimated Value Chain Water Footprint*
  Water used to produce raw materials 
  Water used to generate purchased energy
  Water used in our operations
  Water used by consumers and patients using our products
Net water consumption in our operations
2010 2011 2012 2013 2015 
Target
Million cubic metres 18.7 17.4 16.1 15.7 14.9
Estimated Value Chain Water Footprint*
  Water used to produce raw materials 
  Water used to generate purchased energy
  Water used in our operations
  Water used by consumers and patients using our products
* Based on an analysis of 2010 data and latest version conversion factors
84%
2%
1%
13%
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Breathing life into old inhalers
Around 63% of the 73 million inhalers 
used in the UK every year go in the  
rubbish bin; most end up going to landfill.
GSK’s inhaler recycling programme, 
Complete the Cycle, encourages patients 
to return their old inhalers to participating 
pharmacies, which are then sent back to 
us to be recycled. Not only does this 
reduce waste sent to landfill, it also 
prevents the remaining propellant in used 
inhalers being released as greenhouse 
gases, as we collect it when crushing the 
cans to recover the aluminium.
Now established in the UK and in 31 cities 
in the USA, the programme has also been 
set up in several other markets including 
Australia, Chile, the Czech Republic  
and Hungary.
Waste 
 Commitment
By 2020, reduce our operational waste by 50%  
(vs. 2010).
In 2013, we generated 11% more waste 
than in 2012 as a result of business growth. 
During the year we sent only 6% of our total 
waste to landfill and 37 of our sites have 
now achieved zero waste to landfill – up 
from 34 in 2012. By 2020, we aim to halve 
our operational waste compared to 2010 
and and have zero waste to landfill.
We recognise that as our business continues 
to grow we need to continue our efforts to 
reduce waste that our sites generate. We 
have identified which sites are responsible  
for generating the majority of our waste and  
in 2014 we will have an increased focus on 
developing and implementing improvements 
at 4 high impact manufacturing sites in 
addition to our established programme to 
reduce waste.
Efforts to cut waste to landfill include 
reusing refrigerated packaging from 
shipping vaccines as an insulation material 
for the construction industry, which saves 
64 tonnes of waste a year that we previously 
paid to send to landfill. At our sites in 
Barnard Castle and Montrose, UK, we have 
set up centralised points of collection for 
waste and are using smaller bins that are 
more frequently emptied to encourage 
employees to use them more regularly.
Our goal is to halve operational waste by 2020. We are doing this by adopting 
four simple steps to eliminate, reuse, recycle and generate energy from waste – 
in that order of priority.
Operational waste
2010 2011 2012 2013 2015 
Target
2020 
commitment
Total waste generated 
(thousand tonnes)*
178 170 151 167 133 89
Waste to landfill  
(thousand tonnes)
17.5 13.5 10.0 10.5 12.9 0
*  In 2013, we changed the way we report on waste and no longer include solvent waste that is recycled and reused on site as 
part of the total waste generated.
Read more online
We publish more detail online on key  
issues including:
 • Climate change
 • Hazardous chemical management 
 • Genetically modified micro organisms and 
Environment, Health and Safety (EHS) 
 • GSK and REACH
 • GSK and the convention on  
biological diversity
 • GSK public policy on nanotechnology 
 • Ozone depletion and metered-dose 
inhalers for asthma
 • Pharmaceuticals in environment 
 • The impact of climate change on health
 • Use of ozone depleting substances in 
ancillary plant and equipment
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Managing  
other impacts 
We manage a range of other important issues to reduce our overall 
environmental impact, in addition to our priority focus areas of carbon,  
water and waste.
our medicines – and to encourage the  
use of lower-impact alternatives.
We are also investing in research into 
sustainable chemistry. In 2013, construction 
of a carbon neutral sustainable chemistry 
laboratory began as part of a £12 million 
collaboration with the University of 
Nottingham in the UK. We also pledged 
£400,000 each year until 2024 to establish 
a Centre of Excellence for Sustainable 
Chemistry in São Paulo, Brazil, to advance 
and share knowledge on the subject 
between researchers in Brazil and the UK. 
In Singapore, we are funding research into 
green and sustainable manufacturing as 
part of our partnership with the Singapore 
Economic Development Board.
Pharmaceuticals in the environment
Pharmaceuticals are not always completely 
absorbed or broken down by the body,  
and residues can find their way into the 
environment when excreted – or if unused 
medicines are disposed of by consumers. 
We take this issue seriously and assess the 
environmental risk associated with patients’ 
use of our products to help ensure that 
predicted concentrations do not exceed 
safe levels. We also conduct and support 
research in this area. For example, we have 
funded two students at the University of 
York and the University of Cambridge to 
study the impacts of pharmaceuticals in the 
environment as part of their PhD research. 
Our policy statement on Pharmaceuticals  
in the Environment is available online.
Biodiversity
GSK is not directly involved in bioprospecting 
– the process of discovering new products 
that come from biological resources, such 
as plants or animals. But we do source a 
number of compounds which are derived 
from biological resources. We take 
responsibility for ensuring these have been 
obtained legitimately and are used in the way 
they are intended. We also support efforts  
to conserve biological diversity, such as the 
Convention on Biological Diversity, the Bonn 
Guidelines and the Nagoya Protocol.
Packaging
We are also working to reduce the 
environmental impact of our packaging and 
aim to source 90% of wood fibre material 
used for paper packaging from responsible 
sources by 2020. In 2013, we repeated  
our survey of suppliers of carton board 
packaging, corrugated packaging and 
leaflet paper and use this information  
to help us in our purchasing decisions.
Refrigerants
We have reduced our inventory of 
chlorofluorocarbon (CFC) refrigerants, 
which deplete the ozone layer, to below 
reportable levels. This inventory will be 
eliminated within the next five years as 
remaining equipment containing CFCs 
becomes obsolete.
Environmental remediation
We take responsibility for removing pollution 
and contaminants from soil, surface and 
ground water at facilities we have used 
previously, and at the disposal sites of waste 
management companies we have used.  
In 2013, we spent $5 million on remediation 
work, compared with US$3.8 million in 
2012. We have sole or part responsibility  
for 28 remediation sites globally.
Compliance and fines
In 2013, we received three environmental 
fines totalling £2,110. These fines were for 
late submission of a report about the fuel  
oil purchased at our sites in Pennsylvania, 
USA; improper labelling of an empty road 
tanker leaving our site in Cork, Ireland; and 
a discharge of waste that was above the 
effluent limit in Tianjin, China.
Internal audits
We audit our operations to make sure 
environmental risks and impacts are 
identified and managed effectively. Sites are 
selected for audits based on knowledge of 
the business, modelling of risk indicators 
and trends from previous audit findings.  
The environmental, health and safety (EHS) 
audits are conducted by a team of certified 
ISO 14001 Environmental Management lead 
auditors. In 2013, the team audited 27 sites 
across different business units around the 
world. The site audits included a review of 
environmental management systems. In 
addition we audited our approach and 
governance processes around our 
progression towards our 2020 commitments 
on carbon, water and waste. For information 
on audits of our suppliers, (see page 45).
Sustainable supply lines
 Commitment
Build sustainable supply lines for our Nutrition portfolio 
and work with local farmers to improve their agricultural 
practices, improve their yields, their competitiveness 
and their livelihoods.
In 2013, we began working with a dairy supplier 
in India to develop a secure supply of locally 
produced whey protein (from milk) to make 
Horlicks. This will benefit the supplier by 
improving agricultural practices and help us 
reduce our environmental footprint. We are now 
sourcing 60% of whey protein from the local 
supplier in India and we aim to increase the 
amount of locally produced whey protein we 
use to 85% by 2016. Within our product range, 
Horlicks is the second largest source of carbon 
emissions and milk-based products account  
for more than half of its carbon footprint. 
Green chemistry
We apply the principles of green chemistry 
when producing many of our medicines to 
help us reduce or eliminate hazardous 
chemicals from the drug development and 
discovery process. See GSK’s position 
statement on Hazardous Chemicals 
Management for more information.
Our Green Chemistry Performance Unit 
(CPU), established in 2012, researches 
ways to replace hazardous or unsustainable 
chemicals with lower impact alternatives.  
In 2013, we published a specialist guide  
that helps our scientists understand the 
environmental impact of different  
reagents – chemicals used to produce  
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Engagement
Employees
Using a range of tools, including online 
social networks, we build our employees’ 
understanding of environmental issues  
and the ways they can help address these 
collaboratively. Our global network of 
sustainability advocates within GSK, help  
to raise awareness among their colleagues 
about the changes they could make at work 
and at home to reduce environmental 
impacts. We recognise teams who have 
made a particularly valuable contribution  
to environmental sustainability through our 
annual CEO’s Environment, Health, Safety 
and Sustainability Awards (see case study).
Suppliers
In 2013, we started systematically gathering 
data from our suppliers on their carbon 
emissions, water use and waste, building on 
our engagement with 32 suppliers in 2012. 
Using Ecodesk, a publicly accessible 
database, we asked over 550 suppliers to 
submit their data to help us better understand 
and map our suppliers’ sustainability 
performance. By the end of 2013, 261 of  
the suppliers we contacted had completed  
an Ecodesk profile.
We are using this data to prioritise our 
efforts to reduce suppliers’ environmental 
impacts. For example, we met with Granules, 
the company that supplies the active 
ingredient we use in Panadol. Together, we 
identified opportunities to reduce energy 
use by 16% and have set up a collaborative 
programme to realise these savings.
We cannot meet our ambitious commitments without engaging our employees 
and partners across our value chain, and working with others in our industry  
to address global environmental challenges.
Industry
We also communicate GSK’s sustainability 
message and share our experiences 
externally. In 2013, for example, our Head  
of Environmental Sustainability was a guest 
speaker at Cleanmed Europe and CDP’s 
FTSE 350 Climate Change Report launch. 
Participating in Cleanmed Europe gave us an 
opportunity to engage with 500 healthcare 
and pharmaceutical professionals – and 
gather useful feedback on our performance.
Employees recognised for discovering new process that cuts carbon and costs
In 2013, our CEO’s Environment, Health, 
Safety and Sustainability Awards 
recognised an exceptional team of 
biologists and chemists working across 
our R&D and manufacturing units. Working 
collaboratively, the team discovered and 
developed a new way to manufacture a 
chemical that we use in clinical trials for  
a treatment for Fabry disease – a rare 
genetic metabolic condition. Using 
synthetic biochemistry, the new process 
not only reduces manufacturing costs, but 
also cuts CO2e emissions by around 80%.
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Data  
summary
2010 2011 2012 2013 
% vs 
2010
2015 
target
Scope 1 and 2 emissions (’000 tonnes CO2e)
Gas and other fuel 570 572 530 533 -6%
Electricity and steam 964 881 804 796 -17%
Propellant emissions during manufacture of inhalers 214 223 244 254 19%
Sales force travel 165 169 167 177 7%
Other emissions 62 72 77 73 18%
Total 1,975 1,917 1,822 1,833 -7%
Scope 3 emissions (’000 tonnes CO2e)
Purchased materials* 5,600 5,600 5,600 5,600 0%
Product logistics 169 200 203 202 20%
Business travel by air 96 97 98 93 -3%
Propellant emissions during use of inhalers 4,647 4,760 5,198 5,302 14%
Use of other products* 1,000 1,000 1,000 1,000 0%
Disposal of products* 200 200 200 200 0%
Total 11,712 11,857 12,299 12,398 6%
Total scope 1 and 2 emissions (’000 tonnes CO2e) 13,687 13,774 14,121 14,230 4% -10%
Water (million m3)
Water use in our operations 18.7 17.4 16.1 15.7 -16% -20%
Waste (’000 tonne)
Waste generated** 178 170 151 168 -6% -25%
Waste to landfill 17.2 13.1 10.1 10.5 -39% -25%
Mass efficiency %***
Weighted average of new processes in calendar year 1.5% 2.8% 2.3% 1.0% 2.5%
* Estimated data (not verified by Bureau Veritas)
**  Waste generated no longer includes solvent waste that is recycled on site and reused in processes
*** Mass efficiency is a measure of the amount of raw materials required to make a new active pharmaceutical ingredient, and weighted to account for the scale of manufacture. In 2013, one low volume process was transferred to manufacturing, leading to 
the lower efficiency figure. We remain on track to achieve our 2015 target of 2.5%, which is an average of performance over five years. We will no longer report mass efficiency because it covers the chemistry stages registered for regulatory purposes, 
not the complete manufacturing process. We now have an established carbon footprint reduction strategy with a 25% reduction target by 2020 (not verified by BV).
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Summary of assurance 
statement
Basis of reporting and  
external assurance
Energy and CO2e emissions data are 
collected from all 72 of our pharmaceuticals 
and consumer healthcare manufacturing 
sites, 16 vaccines sites, 21 pharmaceuticals 
and consumer healthcare R&D sites, the UK 
headquarters building and over 60 offices 
and distribution centres. Water and 
hazardous and non-hazardous waste data are 
collected from all our manufacturing vaccines 
operations, and R&D locations. Based on our 
materiality assessment, we do not collect 
non-hazardous waste and wastewater data 
from offices. Volatile organic compound 
(VOCs) are reported only from sites that 
manufacture pharmaceuticals or contain R&D 
pilot plants. We use the Greenhouse Gas 
Protocol for all of our calculations of  
CO2e emissions from energy use, propellants 
and refrigerants.
We use CO2e country factors for electricity 
published by the International Energy 
Agency in 2013.
Sites were selected for review from all of the 
GSK businesses. Site specific audits were 
conducted at four sites where data was 
verified back to source. There was special 
focus on sites that had been top contributors 
to environmental emissions the previous 
year, sites that had not been previously 
visited in prior years, and sites that had 
difficulty submitting data in a timely manner.
Bureau Veritas’ Summary  
independent assurance statement
Bureau Veritas UK Limited has been 
engaged by GSK plc to provide 
independent assurance of the Environment, 
Health and Safety (EHS) performance data 
for 2013 that has been prepared by GSK 
plc. The objective of Bureau Veritas’ work  
is to express an opinion on the accuracy 
and reliability of the EHS data and to 
provide a summary of findings. 
The full assurance statement can be found 
online that includes details of the scope of 
work, methodology, findings and 
recommendations for improvement.
Summary of Scope and Methodology 
Assessment of performance data 
contained within the EHS Data Table and 
associated data management processes: 
this involved detailed review of the integrity 
of selected datasets and aggregation and 
checking processes at a corporate level, 
as well as sampling data back to source  
at four GSK sites. The sites were chosen 
to represent the facilities with significant 
environmental impact, GSK operations  
and geographical spread.
Interviews with senior EHS staff to 
understand GSK’s objectives and approach 
to data management. 
Opinion and Recommendations
As a result of the verification conducted  
as per the scope of work, it is Bureau 
Veritas’ opinion that GSK’s 2013 EHS  
performance data: 
 • provide a fair summary of EHS-related 
activities and performance; and
 • contain performance metrics and 
information that are based on established 
collection and collation processes, and 
are deemed to be free from significant 
error, omission or bias. 
The data evidenced at site level was seen  
to be based on well-established and 
implemented data management processes 
and underlying systems. 
There are certain areas that could lead to 
further refinement, such as: more complete 
inclusion of EHS data from the Commercial 
Operations business units; and more formal 
definition and structure to the quality control 
process for following up anomalies detected 
in consolidated EHS data. Further detail 
may be seen in the full assurance statement.
Statement of independence, impartiality  
and competence 
Bureau Veritas is an independent professional 
services company that specialises in quality, 
environmental, health, safety and social 
accountability, with over 180 years history. 
The assurance team has extensive 
experience in environmental, social, ethical, 
and health and safety information, systems 
and processes.
Bureau Veritas’ Code of Ethics ensures  
that staff avoid conflict of interest and 
maintain high ethical standards in their 
business activities. 
GSK’s response to assurance
We are pleased with Bureau Vertitas’ findings 
on GSK’s established processes in managing 
Environment, Health and Safety data. We are 
committed to continue improving, with the 
ultimate goal of providing the most accurate 
EHS data to the public on our website. In 
2014, we will continue to work toward 
improving our data accuracy with an emphasis 
on incorporating the recommendations 
provided by Bureau Veritas. The data in the 
Corporate Responsibility Report can be used 
by sites to improve their management of their 
environmental, health, and safety programmes. 
In 2014, we will continue working with all sites 
to improve their data submission, including 
providing comments for the explanation of 
trends in a complete and timely fashion.
Read GSK’s full response to assurance here.
London, February 2014
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Governance and 
engagement 
Governance
We have a robust governance structure  
in place to evaluate our policies and 
programmes, and ensure the approach we 
take on corporate responsibility issues is 
appropriate. Our board-level Corporate 
Responsibility Committee (CRC) has  
overall responsibility and sits within  
a clear organisational structure that  
ensures accountability (see graphic).
 • Corporate Executive Team (CET):  
Headed by our Sir Andrew Witty,  
the CET is responsible for managing  
the business and overseeing internal 
policies and programmes. 
 • Corporate Responsibility Committee 
(CRC): Headed by our Chairman, Sir 
Christopher Gent, and including CET 
members, this Board-level committee 
provides high-level guidance and 
oversight on our approach, and reviews 
our performance and progress against  
our commitments (see page 9). It meets  
at least four times a year and reports  
its findings to the Board annually. 
 • Audit and Risk Committee: The board-
level committee focuses on the key 
business risk areas for GSK, including 
non-financial and reputational risks.  
It is supported by our Risk Oversight  
and Compliance Council (ROCC).
Our commitment to good governance and transparent reporting reflects our core 
values. To help us prioritise the issues we focus on, we engage with a wide range 
of stakeholders to understand what matters most to them.
Board
(Chairman, 3 Executive Directors and  
11 independent Non-Executive Directors)
Audit and Risk  
Committee
Remuneration
Committee
Nominations
Committee
Corporate Responsibility 
Committee
Finance  
Committee
Corporate Administration  
and Transactions 
Committee
Chief Executive
Officer
Corporate Executive  
Team
Audit & Assurance
Our Audit & Assurance department conducts 
independent assessments of the adequacy 
and effectiveness of GSK’s management of 
significant risk areas – including aspects of 
our performance as a responsible business. 
Outcomes are reported to the Audit and Risk 
Committee, in line with an agreed Assurance 
Plan. This includes assessing, on a sample 
basis, the processes and controls in place to 
comply with laws, regulations and company 
standards throughout GSK. 
The audit team recommends strategies for 
improvement and GSK managers develop 
action plans to address the causes of 
non-compliance and gaps in internal 
controls. Audit & Assurance tracks these 
plans through to completion and reports 
results to senior management and the  
Audit and Risk Committee.
Read more about assurance, internal audit 
and risk management in the Governance 
section of our Annual Report.
See our Annual Report for a summary of the 2013 CRC Report, including topics covered 
in CRC meetings, such as employee compensation and human rights, and further details 
on corporate governance.
Our governance structure and systems
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Governance and  
engagement 
continued
Stakeholder engagement
Regular dialogue with stakeholders enables 
us to understand how our business may 
affect – or be affected – by them. Their 
feedback helps us to identify and prioritise 
important issues and develop responses 
that are in the best interests of society, as 
well as our shareholders. 
We engage with a wide range of 
stakeholders through: day-to-day 
interactions with customers; engagement 
with governments and patient advocacy 
groups (see page 47); regular dialogue with 
employees (see page 56), suppliers, 
partners (see page 17) and investors. 
In 2013, we also sought feedback on our 
corporate responsibility performance and 
reporting through formal engagement 
exercises, including, a survey of more than 
260 stakeholders worldwide, a series of 
face-to-face interviews and two roundtable 
discussions with 20 opinion formers in the 
UK and the USA. 
This engagement found that, although our 
focus on access to healthcare is considered 
appropriate and our performance in this 
area strong, we should further highlight our 
partnerships, strive for greater transparency 
in the way we do business, be clearer about 
the business case for our corporate 
responsibility activities, and show how we 
plan to meet and measure progress against 
our commitments. We have used this 
feedback to strengthen our communications 
and reporting in 2013.
“ GSK is recognised as a market leader 
in its access to medicines. We ask the 
pharmaceutical sector to focus on 
making access about something 
commercial, embedded in the business 
and economically scalable, and GSK 
have gone further than most on this.”
Vicki Bakhshi
F&C Asset Management
“ I would like to see GSK develop more 
context around economic development 
and the linkages to your business. 
There are other ways you’re 
contributing, such as building 
capacity, R&D and training staff in 
developing countries.”
Mark Little
BSR 
Material issues
In 2013, we conducted a formal materiality 
assessment to prioritise the issues that  
are most important to our business and  
our stakeholders. 
We used the findings of stakeholder 
engagement we have conducted over the 
last two years to assess the importance  
of specific issues to different groups of 
stakeholders, as well as looking at how 
important each issue is to our business – 
our values, our strategy and our products. 
The resulting ‘matrix’ of issues is shown 
below. We will use this to inform our approach 
to reporting and help us prioritise our efforts 
in relation to responsible business.
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Materiality Analysis Output
Importance to business success
B oi diversity Security of supply
Health, safety and well-being
Human Rights (labour) Talent, attraction and rewardEthical supplier standards
Water use
Privacy and data securityWaste and recycling
Training and development
Anti-counterfeitingAnimal research
Community investment Diversity and inclusion 
Tax and economic 
contribution
Energy use and climate change
Product safety and qualityLobbying and advocacy practices
Intellectual property rights
Responsible sales and marketing 
Clinical trials conduct
Product innovation
TransparencyEthical conduct
Access to healthcare
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About our reporting
We report our performance annually in this 
report as part of our commitment to being 
open and transparent about our business 
activities. Responsible business is also 
covered in our Annual Report.
Data coverage
Data in this report relates to GSK’s global 
operations in the calendar year 2013, 
except where otherwise stated. Data in the 
environment and health and safety sections 
has been independently verified by Bureau 
Veritas. Brand names appearing in italics 
throughout this report are trademarks 
owned by and/or licensed to GSK or 
associated companies.
Reporting standards
Our index against the Global Reporting 
Initiative guidelines shows which elements  
are covered in the report. As a signatory to the 
UN Global Compact, we publish an annual 
Communication on Progress to demonstrate 
how we uphold its ten principles.
Your feedback counts
We welcome your feedback on our 
responsible business performance  
and reporting. Please contact us at  
csr.contact@gsk.com. You can also request 
receive regular updates on our progress.
About this report
